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SUMMARY
Rheumatoid arthritis (RA) is an inflammatory, autoimmune condition, the pathogenesis 
of which is unclear. The disease is characterised by an infiltration of inflammatory cells 
into the synovium and subsequent release of factors such as cytokines, which have the 
capacity to both trigger events leading to destruction of the joint architecture, and also 
mediate the perpetuation of the inflammatory process, for example by modulating the 
expression of adhesion molecules, thus suggesting a crucial role for the immune 
system. Females are known to have a heightened immune response compared to males, 
and also an increased susceptibility to autoimmune disorders, including RA, the onset 
and severity of which can be modulated by periods of endogenous hormonal changes, 
indicating a possible association with the sex hormones.
The aim of this Ph.D. was to investigate the effect of sex hormones on the immune 
system in vitro, using peripheral blood mononuclear cells (PBMC) from RA patients 
and from normal, healthy controls. Various parameters were assessed, including 
cytokine production and integrin expression, with particular reference to changes in 
immune function thought to occur in RA.
Oestrogen and testosterone had no effect on the release of interleukin-6 (11^6) or 
tumour necrosis factor (TNF) from control PBMC. In addition, oestrogen had no effect 
on interleukin-lp (IL-lp), IL-6, TNF-a, transforming growth factor-p (TGF-p) or 
prolactin mRNA expression, using either control or rheumatoid cells. PBMC 
proliferation was also unaffected by oestrogen and testosterone, whereas the same 
concentration range of oestrogen induced significant proliferation of an oestrogen- 
dependent cell line, ZR-75. The morphology of ZR-75 cells was altered by culturing in 
the absence of oestrogen, which correlated with a downregulation of the integrin 
subunit, a6. However, incubation of control or rheumatoid PBMC with and without 
oestrogen did not alter their pattern of integrin subunit expression.
Oestrogen receptor (ER) protein and mRNA were readily detectable in the ZR-75 cell 
line, whereas the receptor protein was undetectable in all other cell types, including 
PBMC, and the mRNA was present in only very low amounts. The expression of p29 
antigen, an ER related protein, was demonstrated in all cell types studied, including 
PBMC, synovial fibroblasts and rheumatoid synovial tissue. This data suggests that the 
sex hormones, oestrogen and testosterone are ineffective in in vitro assays of immune 
function, when studying control or rheumatoid PBMC, which may be a result of 
constitutively low receptor levels.
CHAPTER ONE 
INTRODUCTION
1.1  AN OVERVIEW OF RHEUMATOID ARTHRITIS, THE IMMUNE 
SYSTEM AND SEX HORMONES
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which is associated 
with destruction of the articular cartilage, in conjunction with bone and soft tissue. In 
RA, the synovial membrane becomes hypertrophied as a result of the infiltration of 
cells, mainly lymphocytes and monocytes, and the local proliferation of synovial 
fibroblasts. Neovascularisation also occurs, leading to the formation of a pannus which 
grows over and erodes the surface of the cartilage and subchondral bone. Susceptibility 
to the disease appears to be linked to the class II MHC alleles HLA-DR4 and -DR1. 
However, the actual trigger for disease onset remains a hypothetical issue and other 
factors are likely to modulate the severity.
The infiltration of the synovial tissue with cells which have the capacity to elicit an 
inflammatory response indicates that this process is central to the pathogenesis of RA 
In the normal situation, inflammatory reactions are controlled, with factors released 
concomitantly to both upregulate and downregulate cell responses. The release of 
interleukin-1 (IL-1) from accessory cells activates T cells which release cytokines such 
as interleukin-2 (IL-2) and interferon-y (IFN-y). IFN-y has the capacity to activate 
monocytes and macrophages to release further IL-1 and other monokines such as 
tumour necrosis factor-a (TNF-a). Hence, a cascade of inflammatory mediators is 
generated. However, in a disease such as RA, there is a failure to contain the 
inflammatory response and a chronic, destructive scenario arises. Within the 
rheumatoid joint, T cells appear in a pseudo-activated state, displaying an upregulation 
of certain activation markers on their cell surface, whilst the production of 11^2 and 
IFN-y and the expression of IL-2 receptors are downregulated. It is thought that 
macrophages, synoviocytes and chondrocytes are the main effector cells, with the 
capacity to produce an array of cytokines, growth factors and degradative enzymes, all 
of which are detectable in significant amounts within the RA synovial membrane and 
fluid. The factors released are potentially responsible for both the destruction seen 
within the joint and also reparative processes which occur in parallel.
The mechanism of cellular infiltration into the RA synovial membrane is thought to be 
via adhesion molecules, including the integrin family, the expression of which is 
modulated by the inflammatory process. Systemic and local release of cytokines 
following the initiation of an inflammatory response is likely to upregulate ligands, 
such as ICAM-1, ELAM-1 and VCAM-1 on endothelial cells, and their respective 
receptors on the surface of circulating cells, thus leading to an increase in cellular
adhesiveness. Trans-endothelial migration and the perpetuation of cells within the joint 
is also thought to be mediated by integrins, with the latter occurring as a result of 
binding to connective tissue components and cell-cell interactions.
The presence of cells such as T cells and monocytes within the synovial tissue and the 
detection of mediators released by these cells which have the potential to both trigger 
the destructive processes occurring in RA and participate in the upregulation and 
perpetuation of the inflammatory response, for example by increasing expression of 
adhesion molecules, indicates that the immune system is crucial to the development and 
progression of RA. Research into causes of, and potential therapy for, the disease have 
therefore centred around immune function. A relationship between gender, sex 
hormones and the immune system has been recognised for many years. Females have a 
heightened humoral and cell-mediated immune response compared to males, a greater 
resistance to infections, increased tumour rejection capacity and a relative resistance to 
tolerance. In addition, women are more likely to develop autoimmune diseases than are 
men. In RA, the female:male ratio is approximately 3.5:1 with disease onset occurring 
predominantly at the time of the menopause. Pregnancy often results in a clinical 
remission although exacerbation is seen in as many cases postpartum. Thus, prima 
facie, there would seem to be an association between the immune system, 
autoimmunity and sex hormones.
In the case of systemic lupus erythematosus (SLE), an autoimmune condition 
characterised by anti-dsDNA and other antibody formation, inflammation and damage 
to the kidneys and central nervous system, women, especially those of child-bearing 
age, are approximately ten times more likely to develop the disease. In addition, other 
autoimmune conditions including scleroderma, autoimmune diabetes mellitus and 
Sjogren's syndrome also affect predominantly the female sex. Other arthritides, 
including osteoarthritis (OA), and bone disorders, such as osteoporosis (OP), also 
seem to be hormonally linked. OA occurs predominantly in females around the time of 
the menopause and has been related to a period of hormonal imbalance, rather than 
being due to simple 'wear and tear' as originally thought (reviewed by Spector & 
Campion, 1989). Osteoporotic fractures are seen in 1:2 females but in only 1:40 men, 
with an increase in the incidence from the seventh decade onwards. OP has been linked 
to the loss of ovarian function and its onset is effectively delayed by the administration 
of female sex hormones (reviewed by Hillard & Stevenson, 1991; Lindsay, 1991).
The role of the immune system in RA and the potential association with sex hormones 
has resulted in an increasing interest in the role of these hormones in immune function.
Many of the initial investigations were centred around the effect of natural fluctuations 
in endogenous hormone levels, and the effect of altering these levels, such as during 
pregnancy, at the time of the menopause and with the use of oral contraceptives, in 
relation to disease onset and activity. With the explosion of knowledge into the many 
aspects of immunity in recent years, studies have become geared to a role for sex 
hormones in specific aspects of the immune system which may in turn explain their role 
in RA. However, pharmacological doses of the hormones are often employed in studies 
of cell function in vitro, and one may question the relevance of this to the in vivo 
situation.
The following review of the literature will begin by discussing the clinical and 
epidemiological studies of sex hormones and the part they play in the pathogenesis of 
RA, after a brief introduction into the production and metabolism of the sex hormones 
and their receptors. Secondly, functional studies of sex hormones and the immune 
system will be addressed, including the role of specific immune cell types, cytokines 
released and adhesion molecules, in relation to the pathogenesis of RA as described 
above. Comparisons are made between RA and SLE, as the hormones often appear to 
have differing effects in these autoimmune diseases, which may be useful when trying 
to unravel the complexities of sex hormones and the immune system.
1 .2  SEX HORMONES AND THEIR RECEPTORS
1.2.1 Production and Metabolism
Sex hormones are derived from cholesterol, with testosterone and oestradiol being the 
major biologically active species (reviewed by Siiteri, 1979; Spector, 1989). The 
various routes of hormone production and metabolism are summarised in Figure 1.1.
In men, testosterone is mainly derived from the testes (approximately 80%), with the 
remainder originating from the adrenal glands. Testosterone is metabolised to 
dihydrotestosterone (DHT) and to oestradiol, with a combination of all three hormones 
being responsible for its biological effects. Oestradiol is formed from testosterone, as 
described above, and also from the conversion of androstendione to oestrone. In 
females, 30-40% of the total testosterone produced is from the peripheral conversion of 
serum androstenedione, approximately 25% is from the ovaries, with the remainder 
originating from the adrenals.
CHOLESTEROL (LDL)
Pregnenolone ►  17-Hydroxypregnenolone-►Dehydroepiandrosterone ►  Dehydroepiandrosterone sulphatei i i
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\  / 
\ I
\ I
/  '  I
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Figure 1.1 Primary routes of biosynthesis and metabolism of the major sex steroids. (Spector, 1989).
The majority of circulating oestradiol in females derives from the follicle destined to 
ovulate. Extra-glandular formation of oestrogen from circulating androgens is a 
principal source of oestrogen, not only in males, but also in postmenopausal women. 
The amount formed depends on the precursor availability and metabolic factors such as 
obesity and hepatic disease. During pregnancy up to 50% of dehydroepiandrosterone 
sulphate (DHEAS) is converted to oestradiol in the placenta which helps to maintain 
high levels of this hormone.
The secretion of testosterone is controlled by luteinising hormone (LH) produced by the 
pituitary, which in turn is under the control of luteinising hormone-releasing hormone 
(LHRH) and factors such as circulating testosterone levels. Oestrogen secretion is 
controlled by follicle-stimulating hormone (FSH) and also by positive and negative 
feedback mechanisms relating to plasma levels. As LHRH can stimulate the release of 
FSH as well as LH, and a separate follicle-stimulating hormone releasing-hormone has 
yet to be defined, LHRH is sometimes referred to as gonadotropin-releasing hormone 
(GnRH).
Steroid hormones in the blood are reversibly bound to albumin and other proteins, 
including corticosteroid binding globulin (CBG) and sex hormone binding globulin 
(SHBG), a glycoprotein of molecular weight 94 kD. The binding to albumin is weak 
and non-specific, whereas binding to CBG and SHBG is of much higher affinity and is 
specific. CBG binds cortisol and progesterone and SHBG binds androgens and 
oestrogens with affinity: DHT > testosterone > oestradiol. The binding capacity of 
SHBG is twice as great in females and oestrogens are able to stimulate, and androgens 
suppress, SHBG synthesis. The result of this is that only approximately 2-3% of the 
total steroid in serum occurs in a free form, available for target cell receptors. However, 
the relevance of SHBG in sex hormone physiology is still unclear.
1.2.2 Receptors
To assess the sensitivity of a given cell type or tissue to the effects of sex hormones it is 
essential to first ascertain whether or not specific receptors are present. The 
development of radioactively labelled ligands enabled specific binding sites to be 
detected. Subsequent to this, isolation of cDNA for the receptors has identified a family 
of related genes which bind ligands of great diversity, including the adrenal steroids, 
sex steroids and vitamin D3 (reviewed by Green & Chambon, 1986; Evans, 1988). The 
initial cloning of the human glucocorticoid receptor (GR) demonstrated an incredible
similarity to the viral oncogene erbA (Hollenberg et al, 1985). This relationship was 
confirmed for other receptors including that for oestrogen (ER) (Green et al, 1986). In 
addition, the erbA proto-oncogene product was identified as the thyroid hormone 
receptor (Weinberger et al., 1986). Thus, the steroid and thyroid hormone receptor 
superfamily was defined, and is continuing to expand as more gene products are 
identified. Two such products are ER-related genes 1 and 2 (ERR1 and ERR2), the 
ligands for which are as yet unknown, hence the term 'orphan receptors' is used 
(Giguere et al., 1988).
ER was identified within rat uterus, associated with the nuclear and cytosolic 
components (Toft & Gorski, 1966). This led to the design of a two-step model for 
oestrogen action within the cell, whereby cytoplasmic ER, upon binding oestrogen, 
could translocate to the nucleus and activate specific genes (Jensen et al, 1968). 
However, the subsequent development of immunocytochemical techniques allowed 
receptors to be studied in situ, which demonstrated that the unoccupied ER resided in 
the nucleus, and that the previously shown cytosolic form was in fact due to disruption 
techniques employed during experimental procedures (King & Greene, 1984). Thus, a 
new model was formulated in which the unoccupied form of the ER resided in the 
nucleus, loosely associated with certain genomic elements, and subsequent hormone 
binding resulted in a stronger association with these elements and hence the initiation of 
transcription (Greene & Press, 1986). This model was also confirmed for other 
members of the steroid and thyroid hormone receptor family. However, some 
receptors, such as that for glucocorticoid, are cytoplasmic in nature. This is thought to 
be due the presence of nuclear localisation domains within the GR which are inactive in 
the absence of ligand. In the case of ER the nuclear localisation signal is constitutively 
active (Picard et a l, 1990a).
Functional domains
The comparison of sequences for the sex steroid receptors along with mutation 
experiments have revealed that functional domains exist, with each domain being 
responsible for a specific step in receptor activation. Figure 1.2 demonstrates the 
functional domains of the ER. Kumar et al. (1986; 1987) constructed a series of human 
ER deletion mutants using site-directed mutagenesis, and transfected these into HeLa 
cells, which do not express ER constitutively. They confirmed that the highly 
conserved regions C and E were responsible for DNA- and ligand-binding, 
respectively. In addition, they proposed that region D, whose length and composition
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Figure 1.2 Functional domains of the oestrogen receptor.
did not affect receptor functioning, could act as a hinge between regions C and E, and 
region A/B may be necessary for effective transcription in some oestrogen-responsive 
genes. The mechanism of hormone-regulated gene expression has been widely 
reviewed (Beato, 1989; Rories & Spelsberg, 1989; Gibson et al, 1990; Parker, 1990; 
Wahli & Martinez, 1991; King, 1992).
The DNA-binding domain was found to be cysteine-rich and thus able to form two 
'fingered' structures, Cl and CII, coordinated by a zinc ion. These zinc fingers thus 
had the potential to interact with the DNA helix of a specific region of the genome, 
known as a hormone responsive element (HRE). Receptor species are thought to be the 
same in different tissues, therefore it is the difference between these nuclear binding 
sites which is likely to determine a tissue-specific response of a given hormone. The 
first, N-terminal, finger was shown to be responsible for specific DNA sequence 
recognition, with the second likely to be involved in non-specific DNA binding and 
hence stabilisation of the complex (Green et a l, 1988). In particular, it is the three 
amino acids on the C-terminal side of Cl which confer sequence specificity (Mader et 
al., 1989). Thus, binding of hormone-receptor complexes, the trans-acting proteins, to 
cis-acting HRE sites on the DNA, via region C, culminates in transcriptional regulation 
of hormone-responsive genes.
The sequences of specific HREs have now been defined. Klein-Hitpass et al. (1988) 
found that the 13 bp oestrogen responsive element (ERE) of the Xenopus vitellogenin 
A2 gene differed from that of the Al and the chicken vitellogenin II genes by only three 
central positions, and hence they derived the consensus ERE: GGTCANNNTGACC. 
An ERE has since been demonstrated in human genomic DNA (Inoue et al., 1991) and 
EREs have also been reported in the 5' flanking region of both the human GnRH gene 
(Radovick et al., 1991) and the rat prolactin gene (Maurer & Notides, 1987), and 
within the rabbit progesterone receptor (PR) gene (Savouret et al., 1991). The 
similarity between the sequences of the ERE and responsive elements for other 
hormones, such as glucocorticoid and progesterone, means that substitution of just one 
or two base pairs can be sufficient to convert one response element to another (Klock et 
al., 1987). Interestingly, a protein capable of binding region II of the mouse MHC 
class I regulatory element (H-2RIIBP) showed homology with the DNA-binding 
domains of hormone receptors and was found to bind to an ERE (Hamada et al.,
1989). There is also the potential for 'cross-talk' whereby heterodimers are formed 
between two subunits not normally associated, leading to an inhibition of a response 
through a specific enhancer sequence (reviewed by King, 1992). A complex network
of interactions arises due to the conservation of both the structure of DNA-binding 
domains and also homology of responsive elements (reviewed by Beato et al, 1989).
Sequencing of the HREs of the steroid hormone receptors revealed them to be 
palindromic elements containing 5-6 bp in each half of the palindrome, separated by 
3 bp (see Klock et a l , 1987). It was speculated therefore, that the hormone-receptor 
complex would bind as a dimer. Indeed, it was found that the activated receptor, with 
bound ligand, formed a homodimer via noncovalent interactions between the two C and 
the two E regions, with the two C regions held together such that they could recognise 
and bind the HRE simultaneously (Kumar & Chambon, 1988). The necessity of a 
ligand-binding domain for receptor dimerisation and DNA-interaction is somewhat 
controversial, with some reports stating that hormone-binding is essential for the 
formation of stable dimers (Kumar & Chambon, 1988) and effective gene transcription 
(Kumar et al, 1987; Webster et al, 1988), whereas others have reported that ER was 
able to bind an ERE in the presence or absence of oestrogen, dependent on Mg2+ 
concentrations and temperature (Brown & Sharp, 1990), as a monomer or a dimer 
(Medici e ta l , 1991).
One possible explanation for the contradictory literature is the association of the 
receptor with a heat shock protein of 90 kD (hsp90). Hsp90 is a non-DNA, non-steroid 
binding phosphoprotein which has been identified as a component of non-transformed 
8S receptors of steroid hormones including progesterone, oestrogen, androgen and 
glucocorticoid receptors (Catelli et a l , 1985). In addition, the production of certain heat 
shock proteins, such as the 90 and 108 kD types, is dependent on sex hormones, and 
their production is increased following acute or chronic stimulation with oestrogen 
and/or progesterone (Ramachandran et al, 1988). Following studies with the GR, it 
was hypothesised that the free hormone-binding domain complexes with hsp90, thus 
preventing DNA-binding, with the binding of ligand subsequently relieving this 
inhibition (Denis et a l , 1988; Picard et al., 1988). This was further supported by the 
observation that deletion of the hormone-binding domain of ER inhibited interaction 
with hsp90 (Green, 1990). Picard et al (1990b) demonstrated that reduced levels of 
hsp90 inhibited GR transcriptional activity. However, Kumar et al. (1987) found that 
by removing the hormone-binding domain of the ER, thus inhibiting association with 
both ligand and hsp90, weak binding to the ERE could still occur. The interaction 
between the ER and hsp90 was shown to require sequences N-terminal to the ligand- 
binding domain, as well as region E itself (see figure 1.2) (Schlatter et al., 1992).
Thus, in studies utilising a receptor which is already dissociated from hsp90, it may be 
expected that DNA-binding would occur in the absence of hormone.
In general, it would seem that the presence of hormone is essential for gene regulation. 
It has been suggested that DNA and oestrogen may act together to transform the ER 
into the correct conformation for transcriptional activation, as DNA-binding altered the 
dissociation of oestrogen from the receptor complex (Fritsch et al., 1992). A similar 
theory of conformational change, this time by folding of the ERE into a structure which 
could be bound more tightly, was proposed by Lannigan & Notides (1989). Synergism 
between two ERE with individually low enhancer activities, resulting in a complex with 
high oestrogen inducibility has also been reported (Klein-Hitpass et al., 1988). The 
synergism was most efficient with ERE in close proximity, and was hypothesised to 
occur as a result of short range DNA conformational changes. Thus, it may not be the 
sequence of the HRE alone which confers specificity, but also the three dimensional 
configuration of the DNA. The ER also requires phosphorylation for effective 
activation, and conversely, dephosphorylation for inactivation. This was initially 
thought to occur on tyrosine residues, but more recently it is the serine residues which 
have been shown to be the primary target (Denton et al., 1992), suggesting a role for 
protein kinase C (PKC) which is a serine-threonine kinase. It was proposed that 
phosphorylation would increase the affinity of the receptor for DNA sequences and 
therefore prolong the life of the ER/ERE complex.
Oestrogen is known to activate transcription by means of two intra-receptor sequences, 
TAF-1, in the A/B region, and TAF-2, in the E/F region, as well as via the standard 
transcription-activation function of the DNA-binding domain (Tora et al., 1989).
TAF-1 is constitutively active whereas TAF-2 requires oestrogen-binding. It is thought 
that the anti-oestrogen, tamoxifen, acts as a partial agonist by the promotion of the 
DNA-binding of an ER in which TAF-1 is active and TAF-2 is not (reviewed by 
Green, 1990). In contrast, the full antagonist, ICI 164,384, binds the receptor and 
induces a conformational change such that the complex can bind to the ERE, but fails to 
promote subsequent transcriptional events (Sabbah etal., 1991).
Steroids can regulate gene expression at a transcriptional level or post-transcriptionally, 
by affecting events such as mRNA processing and stabilisation, protein synthesis, 
processing and secretion. As well as activating genes by binding to enhancer sequences 
on the DNA, hormone receptors can mediate repression by binding silencers. This may 
occur by the attachment to a different HRE, or in a competitive nature by binding to an 
overlapping DNA sequence. Alternatively, a region other than the DNA-binding site 
may be involved (reviewed by Beato, 1989). Steroid induction of transcription requires 
numerous protein factors in addition to the primary requirement for an interaction of the 
active receptor complex with its HRE.
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Figure 1.3 represents a possible mechanism for gene transcription (reviewed by Rories 
& Spelsberg, 1989). Initially, the activated steroid receptor complex (R) binds to an 
acceptor site (A), which then becomes associated with the nuclear matrix (NM), or 
binds an acceptor site which is already linked to the nuclear matrix. This then enables 
the DNA-binding domain of the receptor to interact with an HRE which may occur at 
some distance from the acceptor site, and other transcription factors, denoted TF1 and 
TF2, are then able to bind, with DNA folding occurring to bring the enhancer and 
promoter sites into closer proximity. Finally, the protein-DNA complex thus formed is 
recognised by RNA polymerase II, additional transcription factors bind and gene 
transcription ensues. The complex remains in contact with the nuclear matrix as this 
contains the hormone responsive genes.
1 .3  THE INFLUENCE OF SEX HORMONES IN RHEUMATOID 
ARTHRITIS
1 .3 .1  Abnormalities in Sex Hormone Metabolism
Various clinical and epidemiological studies have been carried out in search of a link 
between aberrant sex hormone metabolism or natural hormonal fluctuations and 
autoimmunity. The results of studies of hormone levels in female patients have been 
variable. Reductions in oestrone, DHEAS and testosterone levels have been recorded in 
postmenopausal women, possibly as a result of corticosteroid therapy (Sambrook et 
al., 1988), whereas a further study reported increases in testosterone, androstenedione 
and DHEAS postmenopausally (Cutolo et al., 1986). An increase in cortisol levels in 
both pre- and postmenopausal patients has also been observed, possibly as a result of 
the stress and pain incurred (Spector et al., 1987). Thus, there is a great deal of 
conflicting evidence for hormonal abnormalities in female RA sufferers.
The consistent finding however, is of low testosterone levels in male RA patients. 
Studies which formed this conclusion measured either serum total (ie. bound and 
unbound) testosterone (Cutolo et al., 1988), or both total and free (ie. unbound) levels 
(Gordon et al., 1988; Spector et al., 1988; Swinden et al., 1990). Free, unbound 
testosterone is believed to be the principal active androgen and is therefore a more 
reliable indicator of androgen status than total serum testosterone alone. Gordon et al. 
(1988) measured testosterone levels before, during and after rheumatoid flares in ten 
male patients and concluded that this peak in disease activity was associated with 
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Figure 1.3 A model of steroid receptor action on gene transcription (Rories & 
Spelsberg, 1989). See text for details of abbreviations.
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not appear to be due to abnormalities in the hypothalamic-pituitary axis in that 
responses to LH and FSH are as expected (Cutolo et al., 1988; Gordon et al.y 1988), 
except for one study, which found no increase in LH in response to the lowered 
testosterone (Spector et al., 1988). However, the latter occurred in both the RA group 
and the OA controls, and is therefore more likely to be a result of chronic disease per 
se. A lowered response to human chorionic gonadotropin (HCG), which stimulates 
testicular testosterone production, was noted in one investigation, perhaps indicating a 
reduced testicular steroid biosynthesis pool or chronically low gonadotropin stimulation 
(Cutolo et al.y 1988).
Evidence suggests that there may also be a link between the HLA system, sex 
hormones and RA (reviewed by Spector, 1989; Cutolo & Accardo, 1991). An 
association between RA and the class II antigen DR4 is widely reported (Panayi et al.,
1978). Studies have shown a link between testosterone levels and the HLA-B locus 
(Gerencer et al., 1982), and the enzyme 21-hydroxylase, responsible for synthesis of 
both cortisol and sex steroids, has been mapped to within the class III region of 
chromosome 6, close to the B locus (New, 1985). It has been speculated that gene(s) 
within the HLA region could therefore either influence androgen metabolism directly, 
for example via 21-hydroxylase, or perhaps class I and II molecules, important in 
antigen presentation to T cells, interact with specific androgen receptors on specialised 
antigen presenting cells (APC) (reviewed by Cutolo & Accardo, 1991). In the mouse, 
several loci in the MHC control both the immune system and various aspects of sex 
differentiation, including blood testosterone and testosterone binding globulin levels 
and sensitivity to testosterone (Ivanyi et al.y 1972). Thus, in genetically susceptible 
individuals, there may by abnormal hormone metabolism which leads to, or 
exacerbates, RA. However, it may be the case that alterations in hormonal levels are a 
consequence of the disease and/or treatment rather than being the predisposing factor.
If the oestrogen/androgen story were to be taken literally then it could be concluded that 
women are protected by endogenous hormones up to the onset of the menopause when 
onset of RA is most likely to occur. In males there is an inverse relationship due to 
declining androgen levels with age. Any event which prematurely upsets the balance of 
hormones is thus likely to lead to onset of disease in susceptible individuals. However, 
as will be seen in the proceeding sections, events which cause considerable change to 
the body's natural hormonal pattern, such as pregnancy and the ingestion of oral 
contraceptives, do not have such clear-cut effects, and the endocrine-immune 
association seems to be far more complicated than anticipated (reviewed by Spector, 
1989; DaSilva & Hall, 1992).
1 .3 .2  The Menstrual Cycle and the Menopause
A recent report has shown that the average female develops her first symptoms of RA at 
the time of her menopause (McHugh, 1990). Indeed, the female:male ratio in RA 
reaches a peak at the age of 40-44 years, then declines to unity after the sixth decade of 
life (Goemaere et al., 1990). Although the effects of dramatic hormonal fluctuations at 
the time of the menopause on RA appear to be very clear cut, relatively moderate 
cyclical hormonal changes, such as those which occur during the menstrual cycle, seem 
to have less obvious effects. There have been reports of differences in disease activity 
at various stages of the cycle (Latman, 1983; Rudge etal., 1983; Grinlinton, 1988). 
Reductions in severity were recorded during the postovulatory phase, when plasma 
concentrations of progesterone and oestrogen are high (Latman, 1983), and increases in 
clinical measurements of RA disease activity were detected in the late-luteal phase 
compared to the mid-follicular phase, following these hormonal surges (Grinlinton, 
1988). However, others have failed to demonstrate any effect of the menstrual cycle on 
RA (Goldstein etal., 1987).
1 .3 .3  Oral Contraceptive Use
Data regarding the use of oral contraceptives and RA needs careful analysis due to the 
influence of a variety of parameters. First, studies are either of the cohort type, 
whereby individuals without RA are followed and examined for the later development 
of the disease, or are case-control studies in which RA patients are compared to 
controls without RA for past and present use of oral contraceptives. Secondly, the 
choice of controls for case-control studies is an important consideration, as is the date 
of the study, whether it be of the cohort or case-control type, its location and the 
collection of data following the survey. Attempts have been made to clarify the potential 
confounding issues (Esdaile, 1989).
In two cohort studies, one from the UK and one from the USA, no protection from oral 
contraceptive use was seen (Hannaford et al., 1990; Hemandez-Avila et al., 1990). The 
former group summarised the data from a large study originating from the Royal 
College of General Practitioners which began in 1968. The data available in 1978 
suggested a halving of the risk for RA in current users (Royal College of General 
Practitioners, 1978), but by 1987 the benefit seemed to have disappeared. It was 
suggested that a reduction in the incidence of RA amongst former and never users 
between 1968 and 1987, with no such trend seen with current users of oral
contraceptives, meant that the ratio between current and never users had approached 
unity. Another possible explanation is that the change from high oestrogen to low 
oestrogen oral contraceptives resulted in the loss of a protective effect.
Other studies however, have reported a protective effect of oral contraceptive use to 
date in RA (Vandenbrouke et al., 1982; Vandenbrouke et al., 1986; Hazes et al.,
1989a; Koepsell et al., 1989; Hazes et al., 1990a; Hazes et al., 1990b; Spector et al.,
1990). This includes protection with current but not past use (Koepsell et al., 1989), a 
reduction in RA but only with oral contraceptive use before the age of 35 (Spector et 
al., 1990) or greater protection in females with a family history of RA and those aged 
31-40 years at the onset of the disease (Hazes et al., 1990b). Alternatively, there may 
simply be a protective effect reported, independent of age or whether use is past or 
present. To overcome the problem of adequate control selection, Hazes et al. (1989b; 
1990a) used female siblings, either sisters also suffering from RA in multicase families, 
or unaffected sisters from sporadic case families. These results showed a protective 
effect which was much stronger in the multicase than the sporadic case families. In a 
recent review it was concluded that oral contraceptives may mitigate or postpone the 
onset of RA slightly, but that oestrogens are not able to alleviate the symptoms (see 
Section 1.3.5) (Bijlsma & van den Brink, 1992).
The data from twelve conflicting studies, incorporating four different countries, was 
analysed, and the overall trend was for a slight protective effect in case-control studies 
but no effect in cohort studies (Romieu et al., 1989). Another review of the literature 
concluded that in general, data originating from American studies failed to show a 
benefit from oral contraceptive use in RA, whereas European findings usually indicated 
considerable protection (Vandenbrouke et al., 1989). When disease course was 
followed in RA patients over a period of 6 years in relation to past or present use of 
oral contraceptives, it was concluded that use prior to disease onset was associated with 
a reduction in the severity of the condition (van Zeben et al., 1990). In their review of 
the literature, Spector and Hochberg (1989) also surmised that rather than being 
’protective', oral contraceptives may serve to prevent the progression from mild to 
severe forms of RA. This may also explain the divergence between American and 
European studies, as the majority of European investigations were hospital based, 
where patients with more severe forms of the disease are likely to be included (Hazes & 
van Zeben, 1991). However, as any protective effect seen was independent of dose, 
duration of use and the presence of DR4 (Hazes et al., 1990b), and the use of female 
sex hormones therapeutically has shown little benefit (see Section 1.3.5), this
hypothesis would also seem to be inadequate to encompass all of the complexities in 
this area.
1 .3 .4  Pregnancy
One consistent finding that links hormonal variations with changes in the immune 
system is that of a remission of RA during pregnancy (reviewed by Spector & DaSilva, 
1992). A considerable proportion of RA sufferers have been found to go into clinical 
remission during pregnancy, but an equally large number suffer a postpartum 
exacerbation of the disease (Ostensen et al., 1983; del Junco et al., 1989). This pattern 
has been shown both in classical RA and in a patient with palindromic RA (Verwilghen 
& Panayi, 1992). When attempting to uncover the cause of pregnancy-induced 
remission in RA, levels of immune complexes and rheumatoid factors were seen to 
vary during and after pregnancy in a small number of patients, with some correlation 
between levels and the clinical changes recorded (Pope et al., 1983). The levels of all 
the sex steroids increase dramatically during the third trimester, which could potentially 
act to suppress the maternal immune system. It has been proposed that progesterone is 
the essential hormone for control of immunity during pregnancy (reviewed by Stites & 
Siiteri, 1983). However, the factor(s) responsible for the postpartum flare have yet to 
be elucidated. When a group of RA sufferers were followed during and after 
pregnancy, it was found that the increased risk was highest during the first three 
months postpartum, but persisted for the subsequent nine months. This flare was 
greatest in women who had disease onset after their first pregnancy, suggesting that the 
hormonal changes which occur, or the exposure to paternal HLA antigens may be of 
influence (Silman et al., 1992). Disease activity during pregnancy has also been related 
to the similarity between maternal and foetal HLA, with an amelioration in maternal RA 
associated with a disparity in HLA class II antigens between the mother and foetus, 
especially HLA-DRB1, -DQA and -DQB (Nelson et al., 1992; Nelson et al., 1993).
Rather than pregnancy per se influencing disease progression, it has also been 
suggested that lower fertility rates (del Junco et al., 1989) or poor reproductive 
outcome (Silman et al., 1988) may be risk factors for RA. However, these 
observations have since been disputed (McHugh, 1990; Spector & Silman, 1990). In 
1992, Pritchard published a report which concluded that although pregnancy was found 
to ameliorate RA, it was also the most common identifiable event leading up to the 
onset of disease in females of childbearing age. Thus, pregnancy itself maybe a risk 
factor for the development of RA, perhaps explaining the protective effect seen with
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oral contraceptives by some groups (see Section 1.3.3). However, it has also been 
reported that nulliparity is detrimental, and that nulliparous, non-oral contraceptive 
users had a four-fold higher risk of RA compared to parous oral contraceptive users 
(Spector et al., 1990). The contradictions in the literature are reviewed by Hazes (1991) 
and Silman (1992). The influence of oral contraceptives and pregnancy is brought into 
context somewhat by the results of a survey into the incidence of RA in a group of 
nuns, and the finding that the prevalence of the disease is identical to that in the general 
population (McGill & Brougham, 1990).
The overall picture is that there is no benefit of pregnancy in the long-term, only whilst 
the immune system is compromised to prevent rejection of the foetus. Pregnancy serum 
was found to contain a substance which could stabilise lysosomal membranes (Hempel 
et al.t 1970) and interfere with polymorphonuclear leukocyte (PMNL) phagocytosis 
(Persellin & Leibfarth, 1978) and may thus account, at least in part, for the reduction in 
inflammation seen. This was observed in particular with third trimester serum, which 
correlates with the peak of disease suppression. Various factors released during 
pregnancy have the potential to modulate the inflammatory process in such a way that 
they have an ameliorating effect in RA (reviewed by Nicholas & Panayi, 1988). Such 
factors include alphafetoprotein (Lu et al., 1984) which can inhibit macrophage class II 
expression, and pregnancy-associated oc2 glycoprotein which has been reported to 
reduce human monocyte Fc receptor and HLA-DR expression (Thomson et al., 1979; 
Persellin & Rhodes, 1981). However, the immunomodulatory activities of certain 
factors are now thought to be due to contaminating species, for example HCG, which 
was found to be contaminated with uromodulin, a naturally occurring IL-1 inhibitor 
(see Section 1.8.1) (Muchmore & Decker, 1985). When pregnancy serum was 
fractionated, two regions of immunosuppressive activity were located and it was 
postulated that these exist in normal sera as inactive complexes and are activated during 
pregnancy (Davies & Browne, 1985).
1 .3 .5  Therapeutic Uses of Sex Hormones
The first female sex hormone preparations became available in the early 1960s and their 
effect on RA was subsequently investigated. Norethynodrel, a combination of 
ethinyloestradiol and progesterone resulted in some improvement in all of the six 
patients initially studied (Blais & Demers, 1962). More recently, when female patients 
were treated with ethinyloestradiol alone a certain degree of amelioration of symptoms 
was recorded (van den Brink et al., 1989), whereas with patients treated with the high-
dose oral contraceptive Lyndiol no effect was reported (Hazes et al., 1989c). The use 
of hormone replacement therapy in RA has also been found to be ineffective (Carette et 
al., 1989), whereas the treatment of peri- and postmenopausal women with non- 
contraceptive hormones prior to disease onset considerably reduced the risk of 
subsequent development of RA (Vandenbrouke et al., 1986). However, a recent review 
concluded that the use of oestrogens in RA is an ineffective form of therapy (Bijlsma & 
van den Brink, 1992). Progesterone has also been used, as an intra-articular 
administration in twelve RA patients, with potent local anti-inflammatory effects, 
possibly as a result of agonistic glucocorticoid-like effects at high steroid levels 
(Cuchacovich et al., 1988).
The testosterone deficiency recorded in a high proportion of male RA sufferers lead to 
the treatment of seven male patients with 120 mg/day testosterone undecanoate for six 
months (Cutolo et al., 1991). This resulted in an increase in total testosterone and 
DHEAS levels and a reduction in FSH and LH, which was associated with 
improvements in disease parameters and clinical status, including an increase in the 
number of CD8+ T cells and a reduction in the CD4:CD8 ratio (see Section 1.6.2). 
Therefore, although some success has been recorded with the use of oestrogens and 
androgens as therapy in RA further investigations are required before any firm 
conclusions can be made. All the hormones used to date have been synthetic and it may 
prove worthwhile to use naturally occurring hormones in the future.
1 .4  THE INFLUENCE OF SEX HORMONES IN SYSTEMIC LUPUS 
ERYTHEMATOSUS
Whereas in RA females seem most susceptible to development of the disease at the time 
of the menopause, females of child-bearing age are most susceptible to SLE. In this 
age-group the female:male ratio is 9:1. However, the ratio is considerably reduced in 
prepubertal children and after the menopause (reviewed by Lahita, 1985). There is also 
a link with Klinefelter's syndrome, in that increased oestrogenicity in males with the 
disorder leads to an heightened tendency to develop autoimmune conditions, including 
SLE and RA (Stem et al., 1977). Pregnancy has been associated with both the onset of 
the disease (Mund etal., 1963) and increases in the severity in patients with disease 
onset prior to pregnancy (Tincani et al., 1991). In addition, fluctuations in endogenous 
hormonal levels during the normal menses have also been stated to have detrimental 
effects on disease activity, with approximately 60% of patients in one study reporting 
adverse symptoms in the ten days prior to menstruation (Rose & Pillsbury, 1944). As
with RA, the use of oral contraceptives is a rather confounding issue. A worsening of 
disease symptoms was reported with oestrogen oral contraceptives, whereas pure 
progesterones did not result in an exacerbation (Jungers et al., 1982). However, in a 
later study of eighty-five female SLE patients no such association was found, although 
most of the patients included suffered only mild disease, in contrast to the Jungers 
study which consisted solely of those with severe SLE (Julkunen, 1991).
1 .4 .1  Abnormalities in Sex Hormone Metabolism
SLE has been associated with an increased 16a-hydroxylation of oestrone resulting in 
elevated levels of metabolites which are highly oestrogenic. This was found to occur in 
both male and female patients, and family data indicated that it could be an inherent 
abnormality (Lahita etal., 1982). Steroids such as cortisol and 16a-hydroxyoestrone 
which possess a stable ketol moiety are able to form stable covalent adducts with 
proteins. The reaction occurs preferentially with membrane proteins and increased 
levels of these 16a-hydroxyoestrone-protein adducts have been found on the 
membranes of red cells and lymphocytes of female SLE patients and also in pregnant 
women (Bucala et al., 1984; Bucala et al., 1985). Anti-oestrogen antibodies were 
found to correlate with levels of plasma 16a-hydroxyoestrone and with active disease 
which may contribute to the pathogenicity of SLE (Bucala et al., 1987; Counihan et al.,
1991). Interestingly, antibodies to the 16a-hydroxyoestrone-modified proteins were 
detected in 26% of SLE patients and in 25% of normal, disease-free females with a 
history of oral contraceptive use (Bucala et al., 1987; Counihan et al., 1991).
An increased oxidation of testosterone at the C-17 position has been reported in females 
with active disease, which would also have the potential to enhance levels of the female 
sex hormones (Lahita et al., 1983). Hormonal variations due to increased 16a- 
hydroxylation and oxidation at C-17 have been postulated to be important in the 
enhanced disease symptoms seen during pregnancy (reviewed by Lahita, 1992). In 
males with SLE, increased resting serum levels of oestrone, androstenedione and LH 
were detected, with concomitant reductions in testosterone, DHT and oestradiol 
(Lavalle et al., 1987). It was concluded that androstenedione to testosterone, and 
testosterone to DHT conversions were impaired, with the resulting low testosterone and 
DHT in turn stimulating LH release via the normal feedback mechanism. This supports 
the work of Lahita et al. (1982) showing the preferential accumulation of 16a- 
hydroxylation products, androstenedione and oestrone. Reduced serum oestradiol and 
increased testosterone have also been reported in a group of postmenopausal SLE
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patients (Folomeev et al., 1989). Other abnormalities in hormonal metabolism in SLE 
include progesterone deficiency (Amalich et al., 1992) and elevated prolactin levels 
(Lavalle et al., 1987). However, the general finding in SLE is of an abnormality in sex 
hormone metabolism resulting in a reduction in androgen levels and a hyperoestrogenic 
state (reviewed by Talal & Ansar Ahmed, 1987).
1 .4 .2  Therapeutic Uses of Sex Hormones
As a result of studies into abnormal hormonal metabolism in SLE, compounds with 
potent antioestrogenic and proandrogenic effects were considered as potential 
therapeutic agents. Androgens and synthetic hydroxy progesterone derivatives have 
been tried with variable results (reviewed by Asherson & Lahita, 1991). In five patients 
with Klinefelter's syndrome associated with autoimmune disease, three with Sjogren's 
syndrome and two with SLE, treatment with testosterone undecanoate resulted in a 
correction of abnormal testosterone and LH levels, as well as normalisation of CD3+ 
and CD8+ numbers, with a concomitant correction of the CD4:CD8 ratio (Bizzarro et 
al., 1987). In addition, all patients treated went into a clinical remission.
1 .5  ANIMAL MODELS OF AUTOIMMUNITY
The link between gender, sex hormones and autoimmune disease is more clearly seen 
in animal models (reviewed by Ansar Ahmed et al.y 1985a; Lahita, 1985; Holmdahl et 
al.y 1989; Ansar Ahmed & Talal, 1990). Type II collagen-induced arthritis (CIA), a 
common experimental model for arthritis in rats and mice, appears to be controlled by 
sex hormones. It has been shown, for example, that sex hormone-related phenomena 
such as pregnancy-induced remission and postpartum flare of the disease, can be 
reproduced in this animal model (Mattson et a l ., 1991). Treatment of mice with 17J3- 
oestradiol delayed the onset without affecting the incidence of CIA, whereas treatment 
after the onset reduced both the severity and duration of the disease (reviewed by 
Holmdahl et al.y 1989).
The FI hybrid mouse strain from B10Q and DBA/1 parentals (QD strain) is highly 
susceptible to CIA, with the incidence being greater in males than females, in contrast 
to human RA. Treatment with oestrogen resulted in a reduction in disease 
manifestations in both castrated and non-castrated males, whereas testosterone implants 
in normal female mice caused an exaggeration of CIA, via an inhibition of ovarian
oestrogen production (Jansson & Holmdahl, 1992). Collagen-induced T cell-mediated 
arthritis in DBA/1 mice is also readily inducible in males rather than females, and the 
male preponderance for development of CIA has been demonstrated in other mouse 
strains, with oophorectomy significantly enhancing the expression of the disease in 
females (Holmdahl et al., 1986). In contrast to the above mouse models, in Lewis rats 
CIA is readily induced in females rather than males. However, castration of female rats 
produced similar effects to castration of female mice, in that an increase the incidence of 
polyarthritis occurred, which was reversed following treatment with 17p-oestradiol 
(Larsson & Holmdahl, 1987), further supporting an important role for oestrogen in the 
protection against this model of RA.
The above results with CIA demonstrate an apparent role for oestrogen in the protection 
against the development and/or reduction in severity of the disease. However, in other 
animal models of autoimmunity androgens appear to be the significant contributory 
factor. For example, male LEW/N rats are relatively resistant to an induced form of 
polyarthritis, thought to be due to the presence of male sex hormones, with 
orchidectomy or oestrogen therapy increasing their susceptibility (Allen et al., 1983). 
MRL-lpr mice, which spontaneously develop an aggressive lupus and 
lymphoproliferative disorder, show reduced antibody levels following treatment with 
androgens (Steinberg et al., 1980). Thus, oestrogens and androgens can have opposing 
effects on different autoimmune conditions, and potentially on the same autoimmune 
condition expressed in different animal models.
Perhaps the most widely reported animal model of autoimmunity is the New Zealand 
black (NZB)/New Zealand white (NZW) FI hybrid mouse model (B/W). Females have 
an accelerated expression of lupus and Sjogren's syndrome-like diseases, compared 
with males, with high levels of circulating antibodies and immune complexes. This 
strain is considered a laboratory model for SLE and demonstrates the opposing 
hormonal effects to those seen with animal models of arthritis, in as much as 
oestrogens exaggerate and androgens ameliorate the condition. Prepubertal 
orchidectomy increased expression of the disease in males and replacement with the 
male sex hormone DHT delayed the onset (Roubinian etal., 1978). Prepubertal 
castration of females, in contrast, had no effect on disease progression. However, 
when castration of female or male mice was combined with 17p-oestradiol alone, or in 
conjunction with either DHT or progesterone, increased mortality, autoantibody 
production and immune complex nephritis was observed (Roubinian et al., 1979a). The 
increase in mortality in males was reduced following administration of progesterone 
alone, whereas danazol, a weakly androgenic preparation, was ineffective, but the anti-
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androgen, cyproterone acetate, lead to premature autoantibody production in male mice. 
DHT also increased survival of female B/W mice, even if given after the onset of 
disease, although anti-DNA antibodies were still found to be present, suggesting that 
the mode of action may be via a reduction in immune complex deposition (Roubinian et 
al.y 1979b). In addition, androgens reduced and oestrogens enhanced spontaneously- 
and immunisation-induced antibodies to ssDNA in NZB/NZB, NZB/C3H, NZB/CBA 
and NZB/DBA mice (Steinberg et al.y 1979). Young castrated male B/W mice with an 
oestrogen implant produced increased IgM antibodies to a variety of antigens, whereas 
testosterone was ineffective. Older female B/W mice receiving testosterone responded 
in the same manner as age-matched males (Brick et al.y 1985).
Evidence points to a direct effect of sex hormones on immunity. However, it is also 
possible that differences in immune reactivity between the sexes is due to an effect of 
sex chromosomes, or genetic background, rather than a direct hormonal effect. For 
example, NZB mice appear to be insensitive to the suppressive effects of testosterone, 
an effect which may be genetically mediated (Raveche et al.y 1979). In addition, not all 
mouse strains are susceptible to oestrogen-mediated suppression of CIA, therefore, 
there may be a genetic restriction to sensitivity (reviewed by Holmdahl et al.t 1989). 
Holmdahl et al. (1992) reported that the spontaneously developing arthritis in DBA/1 
mice is dependent on DBA/1 recessive genes. When FI hybrids were created between 
this strain and BXSB mice, earlier development of the disease was seen, suggesting 
that the BXSB genetic background had a permissive and contributory effect on disease 
progression. In addition, there is some evidence for a Y-chromosomal link with the 
susceptibility of male BXSB mice to develop a lupus-like syndrome (Murphy & Roths,
1979). X-linked genes may also contribute to differences in immune function observed, 
for example, experimental autoimmune thyroiditis in rats was thought to be associated 
with the X chromosome (Lillehoj et al.y 1981). To overcome this problem either 
reciprocal crosses or castrated and hormonally altered animals were studied, with the 
results indicating that although genetic influences may come into play, sex hormones 
per se seem to have an important role in controlling the immune system (Steinberg et 
al.y 1979).
Other problems encountered when studying hormonal effects in vivo include, the ability 
of testosterone to be metabolised to oestrogen, the dose of hormones used, the age of 
administration of the hormones and the differential effects on differing autoantibodies 
and various immune responses studied (Steinberg et al.y 1979). Behaviour can also 
seemingly affect disease outcome (Holmdahl et al.y 1992). Therefore, although it is
possible to overcome these considerations via careful experimental design, it is 
important to keep an open mind when interpreting the literature.
In summary, oestrogen has been shown to enhance autoantibody production in certain 
autoimmune conditions which rely on B cell hyperactivity, such as SLE, but oestrogens 
can also seemingly reduce autoimmunity mediated by T cells, for example in RA. 
However, this is likely to be a gross oversimplification of a complex balance of the 
hormones and their metabolites occurring in vivo.
1 .6  SEX HORMONES AND THE IMMUNE SYSTEM
In 1968 Terres et al. reported a quantitative difference between the immune response of 
males and females. The observations were made when studying antibody production in 
Swiss Albino mice following an antigenic challenge, when it was found that female 
mice produced 10-85 times more antibody than males. Previous observations of 
qualitatively higher immunoglobulin levels in normal female adults and children, of 
both IgM (Butterworth et al., 1967) and IgG (Lichtman et al., 1967) subtypes had been 
made. In general, it seems reasonable to conclude that females have greater immunity, 
both humoral and cell-mediated, than males, although there has been some 
disagreement on this, with Santoli et al. (1976) stating that, in humans, males have the 
stronger cell-mediated immune response.
When considering individual hormones, oestrogens, androgens and progesterone all 
seem able to modulate the cell-mediated immune system. The following Sections 
concentrate mainly on the effects of oestrogens and androgens, although progesterone 
has also been reported to have important immunosuppressive actions such as increasing 
skin graft survival (Kind & Ciaccio, 1980), reducing immune spleen cell function 
(Sekiya et al., 1975) and enhancing suppressor T cell activity in vitro (Holdstock et al.,
1982). The effects of progesterone and other sex hormones on immune function and 
autoimmunity have been widely reviewed (Stites & Siiteri, 1983; Grossman, 1984; 
Ansar Ahmed et al., 1985a; Lahita, 1985; Talal & Ansar Ahmed, 1987; Ansar Ahmed 
& Talal, 1990; Lahita, 1990; Denman, 1991). Many of the initial studies of sex 
hormone effects in the immune system related to modulation of thymus function. More 
recently, specific immune cell types have been analysed.
1 .6 .1  The Thymus
Administration of sex hormones in vivo was found to result in a change in thymic 
weight, with oestrogenic compounds causing hypertrophy and androgenic compounds 
causing atrophy (Chiodi, 1940). These findings, along with the observation that both 
oestradiol (Grossman et al., 1982) and testosterone (Grossman et al., 1983) were able 
to regulate the release of thymic serum factors, fuelled ideas that hormonal modulation 
of the immune system may occur via the thymus. Grossman et al. (1982; 1983) 
performed experiments to study the in vitro response of thymic lymphocytes to 
concanavalin-A (ConA) or phytohaemagglutinin (PHA) under the influence of specific 
thymic factors from either control, castrate, thymectomised or castrate and 
thymectomised male rats, treated with or without oestradiol or DHT. They reported that 
in cultures with castrate rat serum there was an increased response to both mitogens 
which could be reduced by using sera from oestrogen-treated animals. A heightened 
response to PHA was also seen with sera from thymectomised rats and this was lost 
when the animals had been treated with either oestradiol or DHT. No stimulation of the 
PHA response was seen in castrate, thymectomised animals. This led to the hypothesis 
that there are thymic-derived serum stimulatory and inhibitory factors, and gonadal 
stimulatory and inhibitory factors, with the latter affecting the former, and with all 
under the influence of the sex hormones.
There have also been a number of in vivo studies directed towards finding specific 
thymic-derived factor(s) which are controlled by sex hormones and which, in turn, 
affect immunity. In 1991, Erbach & Bahr measured oestrogen effects on antibody 
responses in ovariectomised adult Lewis rats which had been thymectomised or sham- 
operated. It was found that an intact thymus and oestradiol treatment were prerequisites 
for enhanced antibody production in response to a given stimulus, a response which 
could be mimicked in ovariectomised/thymectomised animals by the administration of 
oestradiol and thymosin fraction 5. Thymic epithelial cells produce a number of soluble 
factors and hormones which are involved in the development of the T cell system and 
hence in the regulation of immunity. Many of the activities were found to reside in 
thymosin fraction 5, which is a semipurified aqueous extract of calf thymus. Thus, it 
appears that potentiation of humoral immunity by oestrogen requires a constitutive 
thymic factor. As injection of immunodeficient old mice with synthetic thymosin ai, a 
28 amino acid residue peptide from thymosin extract 5, restored T-helper cell activity, 
IL-2 production and IL-2 receptor expression (Doria et al., 1992) it is tempting to 
speculate that such a factor could be crucial in the development and maintenance of a 
functional immune system.
The first reports of sex hormone receptors within the immune system were of oestrogen 
and androgen binding sites in the thymus (reviewed by Grossman, 1984). These 
observations were made using rat and mouse tissue and there was some contention as 
to whether the receptors were localised to the reticuloepithelial matrix of the thymus, or 
whether their distribution was more widespread. Recently, androgen receptors (AR) 
have been found on human thymocytes (Kovacs & Olsen, 1987), indicating that sex 
hormone receptors have various locations within the thymus. In support of a 
predominantly reticuloepithelial location for sex hormone receptors, Luster et al. (1984) 
found that it was the supernatants from thymic epithelial cultures, rather than from 
thymocytes, when incubated with oestrogen, that were compromised in terms of 
supporting mitogenic responses. However, the proceding observations provide 
overwhelming evidence for the additional presence of receptors on thymocytes.
The enzyme 20ahydroxysteroid dehydrogenase (20aSDH) is located in thymocytes, 0- 
bearing splenic lymphocytes and in bone marrow pre-T-lymphocytes (large cells), but 
not in non-lymphoid haematopoietic cells, and is therefore used as a marker for thymic, 
as well as splenic and bone marrow cells. By measuring changes in 20ocSDH activity it 
was found that when testosterone and its metabolites were administered to castrated 
mice there was an increase in the number of large cells in the bone marrow, with a 
concomitant reduction in thymic cell number. However, the residual thymic cells were 
of the more mature type, responded vigorously to PHA and ConA and possessed most 
of the 20aSDH activity (Weinstein & Berkovich, 1981; Weinstein & Isakov, 1983). It 
was suggested that changes caused by testosterone in the marrow affected the thymus 
via alteration of thymic cell subpopulations (Weinstein & Berkovich, 1981). In 
addition, oestrogen has been found to affect thymic cell populations and, as with 
testosterone, it was found that oestradiol implants in castrated B/W mice led to an 
increase in mature thymocytes. These were of the 'helper' rather than 'suppressor' 
phenotype, ie. those with Lyt 1+2- antigens on their cell surface (Novotny et al.,
1983). It was postulated that the effects of oestradiol on the thymus were both direct 
and indirect, with direct action on thymic ER, and indirectly via an alteration in bone 
marrow precursor cells. More recently oestrogen effects on a broad range of thymocyte 
subpopulations have been studied (Screpanti et al., 1991). The major consequence of 
oestradiol administration to mice was seen to be a redistribution of subsets which 
appeared to occur via a selective depletion of 'immature' and 'intermediate' thymocyte 
cell populations. The enrichment of 'mature' cell subsets which resulted could have 
been due to the loss of the less mature subsets, or could theoretically have been due to 
oestrogen driving cells towards further steps of differentiation. As IL-la mRNA levels 
were elevated in the thymus following oestrogen exposure, and IL-1 has also been
shown to alter thymocyte subset patterns (Fowlkes et al., 1987), it was hypothesised 
that oestrogen may be acting by stimulating the release of this important cytokine.
1.6.2 T Cells
Sex hormones have been reported to influence T cell responses both in vitro and in 
vivo. Various hormones, including oestradiol, progesterone, testosterone, 
diethylstilbestrol (DES), cortisol and 11-desoxycortisol (a steroid with low biological 
potency) were all able to inhibit PHA- and ConA-induced human lymphocyte 
proliferation, whether the donor was male or female (Ablin et al., 1974; Mendelsohn et 
al., 1977; Wyle & Kent, 1977). Other observations such as increased tumour survival 
in oestrogen-treated female mice compared to androgen-treated females, contrasting to 
increased tumour survival rate in androgen-treated male mice, demonstrate that 
oestrogens and androgens are able to act preferentially on female and male cells, 
respectively (Franks, 1975). When responses of human female lymphocytes to PHA- 
stimulation were studied during the menstrual, follicular and luteal phases of the 
menstrual cycle, no difference was seen (Caggiula et al., 1990), indicating that normal 
endogenous fluctuations in hormone levels do not alter this one aspect of immune 
function.
Weinstein et al. (1984) looked at lymphocyte responses in various strains of mice and 
found cells from female or testosterone-insensitive males to be more reactive in the 
mixed lymphocyte reaction (MLR). Oestrogen implants in male mice led to an increased 
responsiveness. In addition, castration of male mice enhanced and androgen treatment 
of females depressed antigen presentation, once again demonstrating the opposing 
effects of male and female sex hormones in immunity. In the MLR in rats, tamoxifen 
was seen to be inhibitory, whereas oestrogen was ineffective at physiological 
concentrations but reduced reactivity at pharmacological concentrations (Baral et al.,
1991). In a study of oestrogen and testosterone modulation of DTH and antibody 
production in a variety of normal and autoimmune mouse strains, Carlsten et al. (1989) 
concluded that the effects of both sex hormones on immune functions are genetically 
linked but that the genetic basis for hormone susceptibility is different for oestrogen and 
testosterone. It has since been suggested that the gene encoding for oestrogen-mediated 
suppression of DTH is specific for T cell-dependent inflammatory responses and is 
independent from histocompatibility products (Carlsten & Tarkowski, 1993).
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The finding that the MLR could be enhanced in both sexes by removing suppressor T 
cells (CD8+ T cells) or by the addition of a T cell growth factor (Weinstein et a l ,
1984), led to the hypothesis that oestrogen may selectively act on this T cell population. 
This observation was further supported by the findings of studies with normal and 
autoimmune mice, whereby oestrogen depressed the Lyt-2+ cell population (analogous 
to human CD8+ T cells) and testosterone enhanced or maintained levels (Ansar Ahmed 
et a l , 1985b). Binding sites for dexamethasone, oestrogen, progesterone and 
androgens were detected on human leukaemic cells (Danel et a l , 1981) and ER was 
shown to be present on human PBMC (Danel et a l , 1983). Subsequently, Cohen et al 
(1983) further purified T cells from thoracic duct lymph and found that ER were 
present on the CD8+ subpopulation, with AR being undetectable. Kovacs & Olsen
(1987) also failed to demonstrate AR on human PBMC, T cells or Jurkat cells. Stimson
(1988) provided further evidence for the presence of ER on the CD8+ T cell 
population, and found the CD4+ subset to be ER-negative. In addition, a CD8+- 
enriched spleen cell population responded to 17p-oestradiol with a dose-dependent 
increase in immunoglobulin secretion, primarily IgM, whereas CD4+-enriched spleen 
cells were unresponsive (Stimson, 1988). The theory thus proposed was that oestrogen 
acts to depress the CD8+ population of T cells, leading to an increase in B cell 
differentiation and an increased antibody production.
CD4 and CD8 molecules are members of the immunoglobulin family of adhesion 
molecules (see Section 1.7). CD8 acts as a co-receptor with the T cell receptor for class 
I MHC molecules on the surface of suppressor/cytotoxic T cells. CD4 is a co-receptor 
with the T cell receptor for class II MHC on helper/inducer T cells. Thus, both 
molecules are essential for an effective immune system (reviewed by Springer, 1990). 
Veys et al (1982) reported a reduction in CD8+ T lymphocytes in the peripheral blood 
of RA patients, whilst CD3+ and CD4+ cell numbers remained unchanged, hence the 
CD4:CD8 ratio was seen to increase. However, in paired synovial fluid samples, CD4+ 
cells were detected at lower levels and CD8+ cells were increased compared to 
peripheral blood. Emery et al (1987) utilised a different panel of monoclonal antibodies 
(mAb) which allowed a distinction to be made between helper/inducer (CD4+4B4+) 
and suppressor/inducer (CD4+2H4+) cell populations, the latter of which induce CD8+ 
cells. They reported a depletion of the CD4+2H4+ subset in blood and synovial fluid 
samples from RA patients, and an increase in the ratio of the two subsets, especially in 
synovial fluid. However, no difference in the CD4:CD8 ratios could be found. The 
group concluded that the reduced CD4:CD8 ratio reported in RA synovial fluid could be 
due to an underlying deficit in the CD4+2H4+ subset and that, when the balance
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between the two CD4+ subsets becomes significantly altered, failure to induce CD8+ 
cells may occur.
When studying CIA in rats, an anti-arthritic effect with oestrogen was seen in the 
absence of CD8+ T cells (Larsson et al., 1989). However, depletion of CD8+ T cells 
itself reduced the incidence of CIA in non-oestrogen treated, thymectomised rats, 
suggesting that this cell subset is of importance. Rather than a direct effect of oestrogen 
on CD8+ cells, an increase in the murine T-helper cell (CD4+) subset has also been 
reported with oestrogen (Novotny et al., 1983), and in ten patients treated with a daily 
dose of a CD4 mAb, six showed a clinical response (Reiter et al., 1991).
In premature ovarian failure T lymphocyte activation was enhanced, in terms of higher 
HLA-DR expression and elevated IL-2 receptor expression (Nelson, et al., 1991). In 
this condition, the relative number of CD4+ and CD8+ counts increase, but there is a 
reduction in the CD4:CD8 ratio (Pun & Ho, 1990), thought to be due to oestrogen 
deficiency (Ho, 1992). Therefore, it may be the ratio of T cell subsets which is 
important, rather than effects on individual cell types, and it has been postulated that 
cyclical changes in oestrogen release by the ovaries stimulates the immune system 
through changes in the CD4:CD8 ratio, leading to the heightened susceptibility to 
autoimmunity in females. However, as previously mentioned, the response of female 
lymphocytes to PHA was unaltered by the stage of menstrual cycle (Caggiula et al.,
1990). Although much of the literature points to a unique role for oestrogen in 
modulating T cell activity, Weinstein & Berkovich (1981) demonstrated that castration 
decreased, and testosterone-treatment increased, suppressor T cell activity in mice, and 
proposed that testosterone may also be an important contributory factor in the female 
prevalence in autoimmune disease.
1 .6 .3  B Cells
Physiological concentrations of oestrogen were found to stimulate, and testosterone 
inhibit, pokeweed mitogen (PWM)-induced B cell differentiation in vitro, using 
peripheral blood lymphocytes from various donors (Paavonen, 1981; Sthoeger et al., 
1988; Kalman et al., 1989). High concentrations of oestradiol were inhibitory 
(Paavonen, 1981). The effect was measured as an increase in IgG rather than IgM 
antibodies, and there was no difference between males and pre- or postmenopausal 
females (Weetman et al., 1981; Sthoeger et al., 1988). Antibody formation in response 
to T cell-dependent and -independent antigens in rats was increased by oestrogen and,
in contrast to findings with human lymphocytes, this was thought to be due to a 
potentiation of B cell IgM production (Myers & Petersen, 1985; Dahlgren & Hanson,
1991). Oestrogen was also seen to increase the percentage of CD5+ B cells, correlating 
with a rise in autoimmunity in both normal and autoimmune-prone mice, in terms of 
increased antibodies against bromelain-treated mouse red blood cells (Ansar Ahmed et 
al., 1986).
When various mice strains were orchidectomised and treated with testosterone, there 
was no change in autologous plaque-forming cells, whereas those receiving oestrogen 
had an increase in autoantibodies. This was thought to be due to a direct effect on 
CD5+ B cells, in that oestrogen enhanced the antibody forming capacity of this 
subpopulation (Ansar Ahmed et al., 1989; Talal et al., 1992). CD5+ B cells are 
increased in Sjogren's syndrome and RA, but not in SLE, and are thought to be linked 
to immunoregulation. Indeed, CD5+ B cells have been shown to produce 
autoantibodies in autoimmune mice, and in patients. In RA it is thought that they may 
be under genetic control or serve as an activation marker, as levels are highest in the 
foetus and generally decline during development, but remain elevated in autoimmunity. 
It is thought that their role may include that of first-line defence or general removal of 
cell debris, or that of regulator of B and T cell functions, perhaps by amplifying the 
immune system (reviewed by Plater-Zyberk et al., 1992). Thus, it is possible that B 
cells as well as T cells are an important target for hormonal modulation in 
autoimmunity.
1.6.4 NK Cells
CD3- large granular lymphocytes, or natural killer (NK) cells, found mainly in the 
spleen and blood, provide crucial defence against viral infections. Various groups have 
reported a reduction in NK activity following oestrogen treatment in vivo, in both 
normal and autoimmune models, although high doses of oestrogen were often used 
(Seaman & Gindhart, 1979; Ansar Ahmed et al., 1986). This was thought to depend on 
the bone marrow because it became evident when osteoproliferation caused a reduction 
in bone marrow capacity, also a result of oestrogen therapy. In B/W mice, diminished 
NK levels correlated with an amelioration of disease symptoms, suggesting that this 
cell type may also be important in autoimmunity (Seaman & Gindhart, 1979).
1.6.5 Monocytes/Macrophages
Baranao et al. (1991) studied peritoneal macrophages from BALB/c mice and found 
that following castration of female and male animals a reduction in the numbers of 
functionally active complement (C3b) receptors and a suppressed phagocytic response 
occurred. Oestrogen treatment of ovariectomised mice restored phagocytosis to normal 
levels and treatment with progesterone re-established C3b receptors. DHT had no 
effect, which supports data showing high-affinity binding sites for oestrogen in a 
human monocytic cell line and rat peritoneal macrophages, with receptors for DHT 
being undetectable (Gulshan et al., 1990). Both oestrogens and progesterones have 
also been shown to increase class II expression and 11^  1 production by mouse 
peritoneal macrophages (Flynn, 1986).
1.6.6 Neutrophils
The oxidative metabolism of polymorphonuclear leukocytes (PMNL) was found to be 
increased in vitro when using micromolar concentrations of the oestrogenic hormones, 
p-oestradiol, oestrone, 16a-hydroxyoestrone and oestriol. All were thought to act via 
an increase in myeloperoxidase (Jansson, 1991). The corresponding 2-OH-compounds 
were inhibitory in this system, therefore it may be the ratio of the different oestrogenic 
metabolites which is important in controlling neutrophil oxidative metabolism. Male sex 
hormones were inactive. In contrast, Buyon et al (1984) found that pharmacological 
levels of oestrogen inhibited neutrophil superoxide production and degranulation.
1 .7  SEX HORMONES AND CELL ADHESION
The circulation of immune cells around the body and their passage through tissues is an 
essential part of natural surveillance against infections (reviewed by Springer, 1990). 
This requires rapid transition between non-adherent and adherent states, and vice versa. 
The adhesion molecules are becoming increasingly popular as candidates for many such 
immune interactions and have been proposed as possible inflammatory mediators 
(reviewed by Panayi, 1993).
Three families of adhesion molecules are responsible for mediating an immune 
response. The immunoglobulin superfamily includes the antigen-specific T and B cell 
receptors and the CD4 and CD8 molecules, the role of which has been discussed (see
Section 1.6.2). The lymphocyte function-related antigens, LFA-2 (CD2) and its 
counter-receptor LFA-3, essential for T cell activity, are also members of the 
immunoglobulin family. Selectins are involved in lymphocyte and neutrophil 
interactions with the vascular endothelium and the integrin family are important in the 
dynamic regulation of adhesion and migration (reviewed by Springer, 1990). The three 
families are by no means exclusive, indeed there is considerable overlap in terms of 
receptors and their ligands. This section concentrates on the integrins as they appear to 
play a critical role in the pathogenesis of RA in terms of the infiltration and perpetuation 
of cells within the joint.
The integrins are a superfamily of heterodimers with non-covalently associated a- and 
p-subunits which are responsible for mediating cell-cell and cell-matrix interactions 
(reviewed by Hogg, 1991; Hynes, 1992). Recently the family has been subdivided into 
groups according to the p-subunit with which the a-subunits associate: the VLA 
proteins which share a common pl-subunit; the leukocyte integrin (CD11/CD18) family 
sharing a common p2-subunit, and the cytoadhesins, or p3 type. However, this is 
somewhat of an oversimplification as a total of eight p-subunits have now been 
described, with a total of fourteen a-subunits known to date. In addition, certain a- 
subunits, for example aV, can form multiple p-pairings, such as aVpi, aVp3 and 
aVp5, all of which have different functional roles. It seems that both the a- and p- 
subunits are responsible for the formation of the ligand-binding site. Integrin function 
is either Mg2+- or Ca2+-dependent due to a divalent cation binding site.
The leukocyte integrins include LFA-1 (CDlla/CD18 or aLp2), CR3 or Mac-1 
(CDllb/CD18 or «Mp2) and pl50,95 (CDllc/CD18 or aXp2). CR3 and pl50,95 are 
generally confined to cells of the myeloid lineage and perform functions such as 
monocyte adherence to endothelium, chemotaxis and phagocytosis. LFA-1 is present 
on monocytes and T cells and contributes to the interaction between the two cell types. 
LFA-1 binds ligands ICAM-1 and ICAM-2, which are integral membrane proteins of 
the immunoglobulin superfamily. Other such ligands which can mediate direct cell-cell 
adhesion are ELAM-1 and VCAM-1. ELAM-1 is a member of the selectin family and is 
often termed E-selectin, whereas VCAM-1 belongs to the immunoglobulin adhesion 
molecule family. The leukocyte integrins are essential for interactions in an immune 
response, both between cells and with the extracellular matrix (reviewed by Dransfield,
1991).
The VLA proteins were first identified on T cells in long-term culture, hence the term 
'very late activation' (VLA). They are now known to be expressed on a wide range of
different cell types. The function of the VLA integrins is mainly one of cell-matrix 
interactions with collagen, laminin and fibronectin, but they have recently been 
demonstrated to participate in cell-cell interactions. Low levels of VLA-3 and higher 
levels of VLA-4, VLA-5 and VLA-6 are expressed on resting and memory T cells. 
VLA-1 and VLA-2 are detectable only on activated T cells, and B cells express a 
different array of these integrins (reviewed by Shimizu & Shaw, 1991). The 
cytoadhesins are also found on leukocytes. The receptor GPHb/ma (CD41/CD61) is 
limited to platelets and megakaryocytes, and functions in the clotting cascade, whereas, 
the vitronectin receptor (CD51/CD61) is expressed on a wider range of cell types, 
including tissue culture-matured monocytes, and has recently been shown to engage in 
cell-cell interactions.
Cellular activation is often required for the expression of certain integrins or for ligand- 
binding to occur, and different stages of activation may be necessary to result in a stable 
interaction, with the stimuli dependent on the cell type (reviewed by Dransfield, 1991; 
Hogg, 1991; Hynes, 1992). For example, the VLA binding activity of T cells is rapidly 
and dramatically increased following activation, but without any change in the surface 
expression of these molecules (Shimizu et al., 1990). In addition, costimulation can 
occur between ligand receptors, and it is possible that engagement of an integrin 
receptor can trigger a signal back into the cell to modulate the expression or production 
of some other factor. It is now thought that the 'clustering' of integrins on the cell 
surface can activate tyrosine kinase leading to phosphorylation and signal transduction 
(reviewed by Komberg & Juliano, 1992).
Duke et al. (1982), found that CD4+ T cells were the predominant lymphocyte 
population infiltrating the synovial membrane of affected joints in RA, and it was 
postulated that, during active phases of the disease, it is the 'memory'T cell 
subpopulation of the CD4 subset (CD45RO+) which is increased (Pitzalis et al., 1991). 
Enhanced adhesiveness of the CD4+CD45RO+ T cells is one possible explanation for 
their preferential accumulation within the synovial membrane. Indeed, it has been 
shown that the memory phenotype is associated with binding to ELAM-1 (Shimizu et 
al., 1991). Synovial T cells have been shown to display an enhanced capacity to 
interact with ELAM-1 and VCAM-1 (Postigo et al., 1992), and increased levels of 
circulating ICAM-1 and VCAM-1 have been recorded in RA patients, especially in the 
synovial fluid (Mason et al., 1993). This could occur either by prior activation of the T 
cells and/or by activation of the endothelial cells, causing an upregulation of adhesion 
molecules and hence potentiating the interaction between the two cell types. The release 
of cytokines at an inflammatory site has the potential to mediate such interactions
(reviewed by Pober & Cotran, 1990). In this respect, IL-1 and TNF have been shown 
to increase the expression of ELAM-1, ICAM-1 and VCAM-1 on endothelial cells, and 
both ICAM-1 and VCAM-1 play an important role in binding T cells to resting or IL-1 - 
activated endothelium, respectively (Oppenheimer-Marks etal., 1991). In addition, 
IFN-y increases adhesion for lymphocytes specifically, and can synergise with TNF in 
the induction of ICAM-1 expression (reviewed by Pober & Cotran, 1990).
The transition of monocytes from the general circulation to an inflammatory site is also 
thought to be mediated by adhesion molecules. VLA-4 and all three members of the p2 
(CD 18) leukocyte integrin family are amongst those expressed on the monocyte cell 
surface (reviewed by Carlos & Harlan, 1990). It has been shown that, apart from a 
general upregulation of these molecules and increased binding of VLA-4 to VCAM-1, 
for example, the selectins, in particular P-selectin, are important in monocyte- 
endothelial interactions in RA (Grober et al., 1993). As with other cell types, cytokines 
have the potential to modulate adhesion molecule expression on monocytes . Short-term 
incubation of whole blood with IL-2, interleukin-4 (IL-4), TNF-a or TNF-p altered the 
expression of monocyte CD 18 and/or CD1 la, b and c expression to various extents, 
whereas IL-ip, interleukin-6 (IL-6) and IFN-y were ineffective (Limb et al., 1992). In 
addition, IFN-y, TNF-a, IL-1 and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) all increased ICAM-1 expression on peripheral blood monocytes (Diaz- 
Gonzalez & Alvaro-Gracia, 1992). Lymphocytes require a longer activation period than 
monocytes to observe changes in expression of such molecules.
Subsequent to the adhesion to endothelial cells, migration of lymphocytes and 
monocytes through the endothelium and tissue occurs. It is ICAM-1 rather than 
VCAM-1 which seems to play a crucial role in this respect, hence LFA-l/ICAM-1 
interactions are important (Oppenheimer-Marks et al., 1991).The perpetuation of cells 
within the joint is likely to involve both cell-cell interactions and also binding to the 
extracellular matrix, via the VLA integrins and other non-integrin adhesion molecules 
(reviewed by Shimizu & Shaw, 1991). Synovial fluid T cells (Garcia-Vicuna et al., 
1992; Rodriguez et al., 1992) and macrophages (Diaz-Gonzalez & Alvaro-Gracia,
1992) have been shown to have an upregulation of certain VLA subunits and an 
increased binding to fibronectin when compared to peripheral blood cells, indicative of 
an increased state of activation. The adherence of cells of the immune system to 
fibroblasts has also been reported to be modulated by cytokines (Piela & Korn, 1988; 
Krzesicki et al., 1991; Morzycki & Issekutz, 1991). Fibroblasts, and fibroblast-like 
cells are constituents of the connective tissue matrix and interactions between these and
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immune cells are therefore likely to be of influence in both the infiltration and 
perpetuation of cells at an inflammatory site.
The pattern of integrin expression in bone (Clover et al., 1992) and cartilage (Salter et 
al., 1992) has been defined. The receptor aVp3 has been reported to play a central role 
in the resorptive process which is stimulated by retinoic acid and inhibited by 
oestrogen. In osteoclast precursors, oestrogen is able to inhibit l,25(OH)2D3- 
stimulated aV expression at the mRNA level (Medhora et al., 1991). In contrast to its 
effects on aV, oestrogen enhanced l,25(OH)2D3-induced p3 mRNA in the same cell 
type (Chiba et al., 1992). Oestrogen also increased p-subunit expression in endothelial 
cells, and could potentiate the effect of TNF on the endothelial cell monolayers in terms 
of inducing leukocyte adhesion and upregulating ICAM-1 and ELAM-1 (Cid et al.,
1992). Thus, there is a potential role for systemic hormones in regulating cell-cell and 
cell-matrix interactions via cell adhesion molecules, possibly by modulating the actions 
of other agents rather than a direct effect.
1 .8  CYTOKINES AS POTENTIAL MEDIATORS OF SEX HORMONE 
EFFECTS
Cytokines represent a diverse network of communicative signals between cells of the 
immune system and between the immune system and other organs. These factors were 
originally designated monokines, ie. those originating from monocytes, and 
lymphokines, ie. those originating from lymphocytes. However, the term cytokine has 
now been adopted to encompass a vast array of protein mediators of diverse cellular 
origin and which have the potential to carry out a wide range of functions.
In an immune response, accessory cells release factors such as IL-1 which can function 
as T cell activators. This leads to T cell production of cytokines such as IL-2, IFN-y 
and GM-CSF, which act on a range of cells to produce an ’inflammatory response'. 
These cells, in turn, secrete other cytokines including TNF-a, IL-4, IL-6 and 
interleukin-8 (IL-8). At the same time the response can be downregulated, for example 
by IFN-y and transforming growth factor-p (TGF-p), and the latter cytokine can also 
initiate reparative processes. This is, however, an oversimplified picture of a complex 
cascade of events which require equally intricate control mechanisms to prevent the 
response from continuing ad infinitum (reviewed by Panayi, 1990).
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One possible method of dampening down an inflammatory response would be through 
the release of cytokine inhibitors or antagonists (reviewed by Arend & Dayer, 1990; 
Panayi, 1990). IL-1 inhibitory activity has been demonstrated in the urine from normal 
or febrile patients as well as in body fluids and cell supernatants. The factors reported 
have been of varying size and generally ill-defined. One such inhibitory activity 
however has been characterised. The 22 kD protein, originally defined as a product of 
human monocytes cultured on adherent human IgG, was found to be a specific receptor 
antagonist and was hence named interleukin-1 receptor antagonist protein (IRAP) 
(Arend et al.y 1989). The antagonist was subsequently shown to be produced by cell 
lines of monocytic origin, mononuclear cells and lymphocytes following adherence to 
IgG or stimulation with PMA, GM-CSF, TGF-pl or interleukin-3 (IL-3). IRAP gene 
expression and protein production has been detected in RA and OA synovium (Firestein 
et a l . y 1992). In addition, soluble receptors for TNF, IL-6 and IL-2 have been 
described which are able to bind their respective ligands and hence reduce the levels of 
free, active cytokine. Conversely, autoantibodies to various cytokines have been 
reported, in the normal situation as well as in disease states (reviewed by Bendtzen et 
al.y 1990). It is thought that these may act as physiological carriers and regulators, with 
the production of specific autoantibodies heightened under pathological conditions to 
'mop up1 excess cytokines.
RA is one example of an uncontrolled inflammatory response which is accompanied by 
abnormal cytokine expression (reviewed by Arend & Dayer, 1990; Brennan et al.y 
1991; Wilder et a l . t 1991). Synovial cells produce virtually all cytokines known to 
date. However, the macrophage-derived products, such as IL-1, IL-6, TNF-a and 
IL-8, are present in abundance, whereas the T cell-derived cytokines, including IFN-y, 
IL-2 and TNF-p, are detectable only at the mRNA level. Indeed, data from in situ 
hybridisation studies have suggested that the macrophage-like and fibroblast-like cells 
of the synovium are the primary sources of cytokines, rather than synovial T 
lymphocytes (Firestein et al.y 1990).
TNF-a, IL-1 a, IL-1 (3, IL-6 and TGF-p have been detected in sections of inflamed 
synovial tissue from RA patients, mainly localised to the thickened lining layer of the 
synovial membrane, but all are also found in interstitial tissue and occasionally in 
association with endothelial cells (reviewed by Brennan et al.y 1991). Where there was 
a distinct cartilage/pannus junction (CPJ), observed in areas of active joint destruction, 
TNF-a, IL-1 a, IL-6, GM-CSF and TGF-pl were detected, whereas only TGF-p was 
found at the diffuse fibroblastic CPJ where reparative processes occur (Chu et al. ,
1992). The former pattern of cytokines was also seen for chondrocytes from RA and
normal joints, suggesting that they may be involved in normal cartilage homeostasis, 
with proinflammatory cytokines such as IL-1 balanced by others such as TGF-p.
1.8.1 Interleukin-1
Interleukin-1 (IL-1) was originally termed 'endogenous pyrogen' due to its role as a 
heat-labile protein found in acute leukocytic exudate fluid which, when injected into 
humans or animals, induced fever. Other effects of IL-1 noted included hepatic acute- 
phase protein synthesis, neutrophilia and increased T cell responsiveness to antigen or 
mitogen in vitro. It is now known to elicit a wide range of biological effects (reviewed 
by Dinarello, 1989). The IL-1 family includes the antagonist IRAP and two proteins, 
IL-la and IL-lp, which have distinct primary amino acid sequences but are structurally 
related. Mature IL-1 occurs as a 15-17 kD peptide with IL-lp being the secreted form 
and IL-la remaining associated with the plasma membrane. Both forms are biologically 
active and bind to the same receptors, of which there are two classes, types I and II, of 
high and low affinity, respectively. The receptors are members of an immunoglobulin 
superfamily (reviewed by Foxwell et al., 1992). Type I receptors are found on T cells, 
fibroblasts, monocytes, synovial lining cells, keratinocytes, endothelial cells and 
chondrocytes, whereas type II are expressed on B cells, macrophages and neutrophils. 
IL-1 is structurally similar to the acidic fibroblast growth factor (aFGF) and shares 
many biological responses with TNF and EL-6, the three cytokines being the mediators 
of systemic 'acute phase' responses. IL-1 and TNF in particular share an almost 
identical spectrum of effects, often act synergistically, and are involved in self­
augmentation.
In the immune system IL-1 stimulates T cell activation leading to IL-2 production and 
the expression of EL-2 receptors and acts as a cofactor during B cell activation, 
especially in concert with IL-4. It can also activate NK cells and potentiate macrophage 
cytotoxicity, and is responsible for inducing the production of an array of other 
cytokines. In addition, IL-1 has haematologic, metabolic, vascular and neurological 
actions. Its potent catabolic effects on bone and cartilage, including the release of 
degradative enzymes such as collagenase, proteoglycanase and other 
metalloproteinases, and the activation of osteoclasts, suggests a direct role in bone and 
joint disorders such as RA. The ability to augment fibroblast proliferation and collagen 
synthesis and induce vascular changes also suggests EL-1 as a likely participant in 
pannus formation. Indeed, the intra-articular injection of IL-1 into rabbit knee joints 
was accompanied by a cellular infiltration and loss of proteoglycan (Pettipher et a l ,
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1986) and repeated injections resulted in a chronic synovitis within those joints 
previously subjected to an antigenic challenge, pannus formation and joint destruction 
(Stimpson et al., 1988).
11^ 1 activity has been reported in the synovial fluid from various arthritic states 
including RA (Nouri et al., 1984). However, early observations were made using the 
classical thymocyte bioassays, later shown to be highly susceptible to IL-6 which may 
have accounted for the results obtained. Hopkins et al. (1988) used the DIO bioassay 
and radioimmunoassay to confirm that IL-1 activity was indeed present in RA synovial 
fluid, although the presence of IRAP still makes quantitative analysis difficult. Both 
IL-la and II^lp have been localised to the RA synovial membrane and CPJ, as 
previously described, and primary cultures of human rheumatoid synovial cells were 
found to express binding sites for the two isotypes (Chin et al., 1988). In addition, 
Deleuran et al. (1992) demonstrated the presence of IL-1 type I receptor and IRAP in 
the synovial membrane. However, IRAP was virtually absent at the CPJ where there 
was abundant IL-la and IL-1 type I receptor, suggesting that insufficient production of 
the antagonist may contribute to the cartilage destruction occurring. High levels of 
IL-la and IL-1 type I receptor with correspondingly low levels of IRAP were also 
measured in endothelial cells, further evidence for the importance of II^l in cellular 
migration into the synovium (see Section 1.7). This group also showed that areas 
staining for IL-la overlapped with those showing high levels of TNF-a, supporting an 
interactive role for these two cytokines (see Section 1.8.2).
In the quest for the mechanism behind the bone-sparing effects of oestrogen in OP, 
Pacifici et al (1989) discovered that the IL-1 activity in the monocyte conditioned 
media (MCM) from untreated postmenopausal OP patients was significantly higher than 
in the MCM from either premenopausal females or treated postmenopausal OP patients. 
Whereas in the non-OP group IL-1 levels declined back to premenopausal levels within 
eight years of the menopause, the OP patients had continuing elevated IL-1 levels. 
Treatment with a combination of oestrogen and progesterone for one month was 
associated with a reduction in IL-1 activity in all postmenopausal females tested. 
Subsequently, it was demonstrated that PBMC cytokine production, including IL-1, 
IL-6, TNF-a and GM-CSF, increased in parallel with various indices of bone 
resorption following oophorectomy in a group of premenopausal females (Pacifici et 
al, 1991a; Pioli et al, 1992). Oestrogen replacement therapy reversed these 
abnormalities (Pacifici et al, 1991a) and either oestrogen or an IL-1 receptor antagonist 
were effective in reducing bone loss in ovariectomised rats (Kimble et al, 1992). More 
recently it has been shown that bone matrix fragments, released during increased bone
turnover, have the ability to stimulate IL-1 release from PBMC, suggested to be due to 
a direct contact between the bone-derived factors and PBMC via integrin receptors on 
the cell surface (Pacifici e ta l, 1991b; Pacifici et al., 1992a)
In addition to the above results demonstrating that ovarian steroids can reduce 
postmenopausal increases in IL-1, progesterone and oestrogen have also been shown to 
increase monocyte IL-1 activity (Polan et al., 1988; Polan et al., 1989). However, the 
stimulation occurred at low hormonal concentrations and at higher doses an inhibition 
was seen. In a study of non-OP postmenopausal women, Stock et al. (1989) found that 
oestrogen only reduced IL-1 levels that were abnormally high at the start of treatment, 
suggesting a selective hormonal action. Rather than a role for IL-1 in mediating bone 
loss, it is now thought that inadequate secretion of IL-1 receptor antagonist, ERAP, 
could be a causal factor, and oestrogen in turn may correct abnormal secretion of this 
controlling factor (Pacifici et al., 1992b).
1.8.2 Tumour Necrosis Factor
Tumour necrosis factor (TNF), a peptide of 17 kD, was identified as being analogous 
to 'cachectin', a macrophage-derived hormone which could induce cachexia, a wasting 
syndrome in mice, following injection of endotoxin. It was later renamed for its ability 
to cause the haemorrhagic necrosis of tumours and is now known to elicit an array of 
biological effects (reviewed by Beutler & Cerami, 1987; Vassalli, 1992). Many of its 
effects, such as osteoclast activation, synovial cell prostaglandin E2  (PGE2) and 
collagenase production and the induction of other cytokines, are shared with IL-1 
(reviewed by Dinarello, 1989). Recently, the use of anti-TNF-a antibodies has been 
shown to inhibit synovial cell IL-1 production and it has been suggested that, in RA, 
TNF-a may be the main inducer of IL-1 activity (Brennan et al., 1989). However,
TNF may have beneficial as well as deleterious effects in autoimmunity (reviewed by 
Jacob, 1992). For example, a deficiency in TNF production has been suggested to be 
one of the contributory factors in the B/W lupus model and also in human SLE, and 
treatment with TNF-a delayed the onset of nephritis. In addition, TNF-a can both 
synergise with IFN-yand antagonise IFN-y-mediated upregulation of MHC class II 
expression. There is also some evidence that this cytokine is involved in the 
development of self-tolerance.
The genes for TNF (TNF-a) and lymphotoxin (LT or TNF-p), a tumourolytic protein 
derived from lymphocytes, are closely HLA-linked on chromosome 6, the only known
cytokine genes to date located within the MHC. TNF-a and -p bind to the same receptor 
and appear to evoke similar biological responses. TNF-a is primarily produced by 
stimulated monocytes or macrophages, but can also derive from lymphocytes, PMNL, 
mast cells, endothelial cells and keratinocytes. It is synthesised as a prohormone and 
this synthesis pathway is tightly controlled. There are two TNF receptors of 55 and 75 
kD, types I and n, with different intracellular regions which may represent alternative 
signalling pathways. The two receptors are part of a family of proteins of similar 
structure, including CD27 and the Fas antigen (reviewed by Foxwell et al., 1992).
Both receptors exist in soluble forms identified in vivo, in the plasma of normal 
individuals and in even higher amounts in inflammatory states, the formation of which 
seems to be by proteolytic cleavage of the mature cell surface receptor, similar to the 
generation of the soluble IL-2 receptor a-chain (see Section 1.8.5). It has been 
postulated that these may serve a dual role, to absorb out and inactivate excess TNF, 
and to act as a slow release reservoir (reviewed by Chouaib et al., 1991).
TNF-a, but not TNF-p, has been found in the synovial fluid and sera of RA patients 
and the levels of this cytokine appeared to correlate with disease activity (Saxne et al., 
1988). In one study of sex hormone effects on immune cell TNF production, Ralston et 
al. (1990) found that 17p-oestradiol could inhibit TNF production from unstimulated 
peripheral blood mononuclear cells (PBMC), but in postmenopausal women only. In 
contrast, hydrocortisone was effective in all groups tested, whereas DHT was inactive. 
The majority of postmenopausal women included in this study were suffering from OP, 
hence the effects of oestrogen in this group could have been as a result of the presence 
of OP, or due to the underlying hormonal deficiency.
1.8.3 Interleukin-6
Interleukin-6 (IL-6) was originally termed IFN-p2 or B cell stimulatory factor-2. It is 
now known to function in the more general regulation of immune and acute phase 
responses and haematopoiesis, with effects which include the induction of IL-2 
production and IL-2 receptor expression by T cells, and enhancement of IL-3-induced 
multi-potential colony cell formation (reviewed by Hirano, 1990; Hirano et al., 1990; 
Van Snick, 1990). IL-6 is produced by a wide variety of cell types, including T and B 
cells, monocytes, fibroblasts, endothelial cells and bone marrow stromal cells. The 
IL-6 receptor, a glycoprotein of 80 kD, is a member of the haematopoietic growth 
factor receptor family, and is found on resting T cells, but only on activated B cells. 
Other receptors of the same family include the p- and y-chains of the human IL-2
40
receptor, that for human GM-CSF and murine IL-4, IL-3 and erythropoietin receptors 
(reviewed by Foxwell et al., 1992). It also has several features in common with the GH 
and prolactin receptors. Further studies on the IL-6 receptor revealed an auxiliary 
signalling molecule, gpl30 (p-chain). This molecule can associate with the 
protein/receptor complex to convert the receptor from a low to high affinity state. The 
soluble IL-6 receptor, produced naturally, can also bind IL-6 and mediate an effect
Increased levels of IL-6 have been reported in both the serum and synovial fluid of 
patients with RA and OA, and in situ hybridisation of IL-6 mRNA demonstrated 
positive cells in both lymphocyte-rich aggregates and adjacent to small blood vessels in 
the synovium (Wood et al., 1992). The predominant source appeared to be the synovial 
T cell, and the close proximity of these cells with CD 14+ tissue macrophages suggested 
that cell-cell contact may be required to initiate the production of IL-6. Both TNF and 
EL-1 are known to be potent inducers of EL-6 and could provide the signal from 
macrophage to T cell. IL-1 potentiates IL-6 mRNA expression and protein secretion in 
both human bone (Linkhart et al., 1991) and cartilage (Nietfeld et al., 1990). This 
could provide a means of amplifying the effects of IL-1, as IL-6 is required for IL-1- 
induced inhibition of proteoglycan synthesis, for example (Linkhart et al., 1991), but 
IL-6 alone does not seem to induce human bone cell resorption (Nietfeld et al., 1990; 
Littlewood et al., 1991).
Rifas et al. (1992) were able to inhibit IL-1- and TNF-induced EL-6 secretion from 
human osteoblast-like cells with physiological concentrations of 17p-oestradiol, an 
effect which was repeated in the same cells, and also in bone marrow-derived stromal 
cells, with testosterone and progesterone as well as 17p-oestradiol (Girasole et al.,
1992). Moreover, ovariectomy in mice was found to be associated with increases in 
colony forming units-granulocyte/macrophage, thought to be the osteoclast progenitor 
cell, as well as giving rise to neutrophils and monocytes, an effect which could be 
reversed by treatment with either 17p-oestradiol or a mAb against murine IL-6 (Jilka et 
al., 1992). The mechanism for this regulation of IL-6 by oestrogen was discovered to 
be via an ER-mediated effect on the transcriptional activity of the IL-6 promoter in 
stimulated cells only (Pottratz et al., 1992). Therefore, it seems that in an oestrogen- 
deficient state the upregulation of IL-6 expression and production by immune cells and 
bone-derived cells could lead to osteoclastogenesis and the amplification of other 
cytokine responses, culminating in bone resorption.
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1.8.4 Transform ing Growth Factor
Transforming growth factors (TGF)-a and -p are distinct polypeptides with unique 
biological activities and separate receptors. TGF-a binds to the epidermal growth factor 
(EGF) receptor, and both the sequence and biological effects of TGF-a are 
homologous to those of EGF. TGF-p represents a large family of factors with diverse 
actions on a wide range of target tissues and cells (reviewed by Massague, 1990). 
There are now known to be at least five isotypes, TGF-pl-p5, and a heterodimer 
between TGF-pl and -p2 (TGF-p 1.2) also exists. TGF-p is a 25 kD homodimer which 
was initially described by its ability to induce the phenotypic transformation of non­
neoplastic cells in culture. It is released as part of an inactive complex which requires 
prior activation and release of the TGF-p molecule before receptor interactions can 
occur. The distribution of this cytokine is widespread with the richest cellular source 
being the platelet. It is also found in large quantities in bone. In contrast, TGF-a has a 
very limited location and is not found within the cytoskeleton. The initial observations 
were of a growth differentiating, morphogenetic role for TGF-p. However, it has since 
become clear that it can act in opposing ways to either inhibit or stimulate proliferation 
and is actually one of the most potent growth inhibitors known. Additionally, it has 
important roles in embryogenesis, fibrosis and angiogenesis.
TGF-p has been identified as a crucial factor in the control of inflammation, immune 
regulation and tissue repair (reviewed by Wahl et al., 1989; Palladino et al., 1990), 
with the monocyte/macrophage playing a central role in these proceedings (reviewed by 
Wahl et al., 1990). Theoretically, platelets arriving at an inflammatory site release 
TGF-p which results in the infiltration of other cell types, such as the monocyte, via its 
chemotactic properties. The general production of inflammatory mediators would cause 
monocyte activation, for example TGF-p is able to upregulate FcyRIII (CD 16) 
expression (Welch et al.y 1990), leading to increased phagocytic and lysosomal activity 
and the release of reactive oxygen intermediates. TGF-p is equally able to suppress an 
inflammatory response, and can subsequently initiate tissue repair by stimulating the 
release of other growth factors, and controlling cell adhesion by increasing the 
production of extracellular matrix components and inhibiting their degradation, and by 
stimulating the expression of various cell adhesion receptors. It acts to cause 
immunosuppression, for example by inhibiting IL-2-dependent T cell proliferation and 
IL-2 receptor expression (Kehrl et al., 1986), and by depressing NK cell activity 
(Ortaldo et al.y 1991). Pretreatment with TGF-p generally suppresses stimulated 
cytokine production in vitro (Chantry et al., 1989; Brennan et al., 1990; Turner et al.y
1990), although it has also been reported to have a potentiating effect at the
transcriptional level (Chantry et al., 1989), and can enhance the translation of certain 
factors, such as IL-6 (Turner et al., 1990), which may mediate some of its effects. 
Moreover, TGF-p can autoregulate its own production, which occurs in activated 
monocytes (Wahl et al., 1990) and which is likely to be important in sustaining levels 
of this cytokine in an inflammatory response.
The presence of TGF-p in the synovial fluid and its production by synovium is well 
documented (Brennan et al., 1990; Brennan et al., 1991). In situ hybridisation 
techniques have localised the production in RA synovial tissues to fibroblast-like 
synoviocytes in particular, indicating that this cytokine plays a pivotal role in the 
development of this disease (reviewed by Wilder et al., 1990). Indeed, the induction of 
FcyRIII expression on synovial mononuclear phagocytes from RA patients appears to 
be due, at least in part, to TGF-p (Wahl et al., 1992), which may contribute to the 
tissue damage occurring as a result of the release of toxic oxygen metabolites. It has 
also been suggested that TGF-p may result in the impaired mitogenic responses and 
phenotypic changes seen, such as the inversion of the CD4:CD8 ratio via a selective 
inhibition of CD4+ cell proliferation (Lotz et al., 1990), and may hence account for 
most of the immunosuppressive activity within the synovial fluid. However, as 
synovial cells are pre-activated the effectiveness of TGF-p may be reduced (Brennan et 
al., 1990). Nevertheless, the administration of TGF-p 1 protected against CIA 
(Kuruvilla et al., 1991) and could be crucial to repair within the RA joint, both via its 
effects on matrix synthesis and as a potential 'coupling factor1 between bone resorption 
and formation (reviewed by Centrella et al, 1988).
The effects of the steroid hormones on TGF-p physiology are more widely reported 
than for any other cytokine (reviewed by Wakefield et al., 1990). In breast cancer cells 
oestrogens and/or progestins can modulate the production of TGF-a (Liu et al., 1987) 
and TGF-p (Jeng & Jordan, 1991), which in turn regulates tumour growth and 
differentiation. In vivo oestrogen is reported to increase TGF-p production by 
osteosarcoma cells (Komm et al., 1988) and TGF-p itself appears to stimulate bone 
formation (Noda & Camilliere, 1989). However, effects in vitro are somewhat 
confusing and are dependant on parameters such as the cell type studied and other 
growth factors present. Oestrogen-induced release of TGF-p in human osteoblast-like 
cells was found to be less in the presence of PTH, itself a potent inducer of bone 
resorption and TGF-p production (Keeting et al., 1989; Oursler et al., 1991). Thus, the 
ability of oestrogen to reduce bone resorption may involve the release of TGF-p from 
bone cells. In support of this theory, Finkelman et al. (1992) reported that ovariectomy 
reduced the concentration of TGF-p in rat long bones and this could be reversed by
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treatment with 17p-oestradiol. When studying human osteoblast-like osteosarcoma cells 
it was found that the androgens DHT and testosterone also increase TGF-p expression 
(Benz et al.> 1991), and may therefore, act like oestrogens to inhibit bone resorption.
1.8.5 Interleukin-2
Interleukin-2 (IL-2) was originally discovered for its mitogenic effects on T cells and 
hence received the name'T cell growth factor' (Morgan et al., 1976). Upon activation, 
T cells were found to secrete IL-2 and express IL-2 receptors, which led to an 
autoinduction loop and resulted, along with cytokines such as IL-4 and IL-6, in the 
clonal expansion of B cells and antibody formation (Robb et al.y 1981).
IL-2 exists as a 15 kD peptide and the receptor is composed of at least three distinct 
chains, a, p and y (reviewed by Minami etal., 1993; Taniguchi & Minami, 1993). The 
a-chain is a 55 kD membrane glycoprotein (p55), also known as the Tac protein or 
CD25. The gene encoding the a-chain is undetectable in resting T cells and is induced 
upon activation. The gene for the 70 kD p-chain (p70) is expressed constitutively in 
CD8+ but not CD4+ T cells, and that for the 64 kD y-chain (p64) is expressed 
constitutively in all lymphoid cells. The y-chain can combine with the p-chain alone to 
form a receptor with intermediate binding affinity, or with both the a- and p-subunits to 
form a high-affinity complex, whereas the a-chain alone forms a receptor of low 
affinity. The p-chain is critical for IL-2-mediated signal transduction and causes rapid 
tyrosine phosphorylation, and recent evidence suggests that the y-chain is essential for 
ligand internalisation.
Interestingly, monocytes have now been found to express the p75 IL-2 p-receptor and 
respond to exogenous IL-2 with a general increase in activity, including the induction 
of IL-1 and TNF mRNA, peroxide production and an enhanced microbicidal and 
tumoricidal potential (Espinoza-Delgado et al., 1990). EL-2 was also found to increase 
monocyte IL-6 production which was independent of the IL-1-induced effect, 
suggesting two separate pathways for expanding the immune response. Only the latter 
pathway was blocked by IFN-y, whereas both could be blocked by the addition of 
TGF-p, which may represent a ’safety valve' mechanism against continued stimulation 
(Musso et al., 1992).
The production of IL-2 in response to PHA has been shown to be low in T 
lymphocytes from the peripheral blood, synovial fluid or synovial cells in RA (Combe 
et al.y 1985). RA cells were also poor responders in in vitro assays of cell-mediated
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immune responses which could be reversed by the addition of IL-2 (Emery et al.,
1984). The enzyme polyamine oxidase (PAO) metabolises the polyamines spermine 
and spermidine into hydrogen peroxide, ammonia and different aldehydes. It is 
possible that the products of this reaction inhibit IL-2 production. In support of this 
theory, Flescher et al. (1989) found that polyamine levels were elevated in RA patients 
and a negative correlation between IL-2 production and the concentration of polyamines 
in RA synovial fluid MNC was found (Flescher et al., 1992). In addition, the direct 
interaction between PAO and its substrates was able to inhibit T cell IL-2 production 
(Flescher et al., 1991), and by blocking the production of polyamines with an ornithine 
decarboxylase (ODC) inhibitor, or by blocking polyamine oxidation with an inhibitor of 
PAO, EL-2 production by the rheumatoid cells was seen to increase (Flescher et al., 
1992). Catalase was also effective, providing further evidence for a detrimental effect 
of the oxidation products. As oestrogen has been shown to stimulate the release of 
prolactin, which would subsequently increase the production of polyamines, it is 
possible that depressed levels of IL-2 may be mediated by the sex hormones (see 
Section 1.8.6).
An alternative explanation for the reduced IL-2 production, and/or diminished 
responsiveness to IL-2, is the existence of an inhibitor. Miossec et al. (1987) reported 
the presence of an inhibitor of IL-2 in the synovial fluid from RA patients. This was 
later identified as the soluble form of the IL-2 receptor, high levels of which have been 
measured in both the serum and synovial fluid from RA patients (Miossec et al., 1990). 
The soluble receptors are formed from the proteolytic cleavage of the a-chain and, 
although these low affinity receptors appear unable to bind EL-2 to an extent which 
would interfere with its activity, they may represent a postactivation marker for T cells 
which are poorly responsive to IL-2 or be due simply to an increased T cell turnover.
1.8.6 Prolactin
Prolactin and growth hormone (GH) have highly homologous amino acid sequences 
and receptor structures and were originally thought to be one and the same hormone, 
indeed it is thought that the two hormones, plus placental lactogen, evolved from the 
same ancestral gene. It was eventually determined that the two hormones existed as 
separate entities, and the cDNA sequence for prolactin is now known (Cooke et al., 
1981). Hypothalamic dopamine negatively controls prolactin secretion from the 
pituitary. Prolactin induces a dose-dependent increase in ODC, a key growth-regulatory 
enzyme which is expressed rapidly when cells are recruited into the Gi phase of the cell
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cycle. ODC is the rate-limiting step in the production of polyamines which are involved 
with cell growth and division (reviewed by Russell, 1989).
The earliest observation of a link between pituitary hormones and the immune system 
came in 1930, when Smith reported that hypophysectomised animals demonstrated 
atrophy of their thymus glands. Hypophysectomised animals have since been shown to 
have deficient humoral and cell-mediated immunity which can be restored by 
administering either prolactin, GH or placental lactogen (Nagy et al., 1983a). Dwarf 
animals, which lack prolactin as well as growth hormone (GH), are also compromised 
in their immune response, and altered cellular patterns, such as an increase in T- 
suppressor cells and a reduction in NK cells, has been reported (Gupta et al., 1983). 
The effects of prolactin on the immune system are now widely cited (reviewed by 
Chikanza & Panayi, 1991; Gala, 1991; Jara etal., 1991; Berczi, 1993). In addition, it 
has been shown that the gene for prolactin is found on the short arm of chromosome 6, 
which also carries the MHC (McMichael & McDevitt, 1977), thus suggesting an 
association between the control of prolactin biology and the control of immune cell 
function.
Bromocriptine, a dopamine agonist, was found to inhibit such immune reactions as 
antibody formation and in vitro lymphocyte reactivity in the MLR and, in vivo, the 
development of adjuvant arthritis and graft-versus-host reactions were also suppressed 
(Nagy et al., 1983b; Hiestand et al., 1986). This evidence, along with the finding that 
methylacetylenic putrescine, an inhibitor of ODC, prevented the development of CIA 
(Wolos etal., 1990), suggests that prolactin-induced ODC activity could be an 
important event in the progression from immune stimulus to chronic inflammation. 
Indeed, ODC has been demonstrated as an integral event regulating lymphocyte 
differentiation, proliferation and function (Klimpel et al., 1979).
Increased polyamine production due to excessive ODC activity has also been linked to 
ER dysfunction. Thomas et al. (1991) detected significantly higher DNA binding of 
uterine ER in BALB/c mice compared to the lupus-prone model MRL-lpr. This was 
reversed with the ODC inhibitor difluoromethylomithine (DFMO), indicating that the 
ER dysfunction could be due to an overactivity of ODC. In support of this theory, two- 
to six-fold higher polyamine levels were found in the MRL-lpr mice (Thomas et al.,
1991). It has previously been shown that naturally occurring polyamines play an 
important role in altering the physicochemical properties and enhancing DNA binding 
of the PR (Thomas & Kiang, 1988). Polyamines have also been shown to affect the 
structure and stability of oestrogen-ER complexes (Thomas & Kiang, 1987), and
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elevated levels have been recorded in RA (Flescher et al., 1989) and SLE (Puri et al., 
1978) patients. One theory is that the overproduction of polyamines arises due to 
oestrogen regulation of ODC activity. ODC has previously been shown to be 
upregulated by factors including hormones (Thomas et al., 1989), thus initiating a 
feedback inhibition of ER.
In Section 1.4.1 it was mentioned that prolactin levels were found to be elevated in a 
group of male SLE patients (Lavalle et al., 1987). This has been found to be the case in 
further studies, with one such investigation reporting hyperprolactinaemia in 22% of all 
SLE patients included and those without increased prolactin were in a clinical and 
immunological remission (Jara et al., 1991). Thus, prolactin would seem to be an 
important factor in SLE, but such an association has not been shown in RA patients 
(Folomeev etal., 1990). However, Nagy etal. (1991) showed that whereas 
immunoreactive prolactin was normal in RA patients, there was a significant deficiency 
in the bioactivity of circulating prolactin which was more evident in males than females. 
The increased polyamine levels reported in SLE (Puri et al., 1978) and RA (Flescher et 
al., 1989) may be thought of as being due to prolactin-induced increases in ODC 
activity.
Despite the conflicting evidence, as prolactin is thought to have immuno-potentiating 
actions, a group of patients with active RA were treated with bromocriptine in an 
attempt to suppress the inflammatory response. However, the drug appeared to have 
only weak second-line effects (Marguerie et al., 1990). Prolactin levels have been 
reported to be greater during pregnancy in SLE than in RA patients or healthy controls, 
with levels correlating with disease activity (Jara-Quezada et al., 1991). It is possible 
therefore, that prolactin is one of the contributory factors in pregnancy-induced 
exacerbation of SLE and one could hypothesise that the postpartum flare in RA may 
also be attributed, at least in part, to surges in prolactin. In support of this theory, 
McMurray et al. (1991) measured a hyperprolactinaemia in B/W mice postpartum, and 
Mattson et al. (1991) stated that two hormonal changes were assumed critical for the 
postpartum flare of CIA in DBA/1 mice, the sudden drop in steroid hormone levels 
from those attained during pregnancy, and the surges of prolactin at, and after, 
delivery. Bromocriptine given to arthritic mice postpartum inhibited the clinical 
exacerbation of CIA (Whyte & Williams, 1988).
Human peripheral blood T cells, B cells and monocytes and spleen cells have been 
demonstrated to possess prolactin receptors coupled to ODC (Russell et al., 1984a; 
Russell et al., 1985). Subsequently, a 46 kD prolactin-like protein was found to be
synthesised by ConA-activated murine splenocytes (Montgomery et al., 1987). This is 
considerably larger than anterior pituitary-derived prolactin of 24 kD. mRNA from rat 
lymphocytes hybridised to a rat prolactin cDNA, and this demonstrated a larger 
transcript than pituitary prolactin mRNA, indicating that the protein originating from 
cells of the immune system is a separate entity. Antibodies to pituitary prolactin have 
been shown to inhibit the response of various immune cells to a range of stimuli 
(Hartmann et al., 1989) and to block the response of a murine T-helper cell line to IL-2 
(Clevenger et al., 1990). Prolactin itself is able to induce the expression of IL-2 
receptors on the surface of lymphocytes (Mukherjee et al., 1990), and it has been 
suggested that IL-2 itself can increase prolactin receptors and cause the release of 
sequestered prolactin which, when bound to its receptor, becomes internalised and 
translocates to the nucleus where it elicits cellular proliferation (Clevenger et al., 1990). 
Thus it was hypothesised that prolactin may be important in IL-2-mediated cell cycle 
progression.
These results suggest that the ability of T lymphocytes to respond to an antigenic 
challenge may depend on the presence of pituitary-derived prolactin bound to cell- 
surface receptors and that, when stimulated, the cells produce a prolactin-like substance 
which can amplify the response of the same or other immune cells. Hence, prolactin 
has been termed a new cytokine. It has been postulated that the immunosuppressive 
activity of cyclosporine is due, at least in part, to its ability to block prolactin actions on 
lymphoid organs (Russell et al., 1984a; Russell et al., 1985) and to inhibit T 
lymphocyte proliferation by reducing the intracellular action of prolactin (Russell et al., 
1987). Cyclosporine has been demonstrated to inhibit ODC induction in response to 
prolactin in rat tissues and it was therefore proposed as a prolactin antagonist (Russell 
etal., 1984b). Hiestand et al. (1986) found that prolactin could compete with 
cyclosporine for a common binding site on rat T lymphocytes and that stimulation of 
prolactin secretion reversed cyclosporine-induced immunosuppression.
There is increasing evidence to suggest that the intracellular action of prolactin involves 
the activation of PKC (Russell et al., 1987; Russell et al., 1989). As previously 
described, incubation of PBMC with the enzyme PAO and its polyamine substrate, 
spermine, resulted in decreased IL-2 production (Flescher et al., 1991) (see Section 
1.8.5). This was accompanied by reductions in both PKC activity and the 
phosphorylation of tyrosine residues on endogenous proteins. The mobilisation of 
internal calcium was also suppressed. Results suggested that RA T lymphocytes 
showed an inherent reduction of internal calcium signalling, which may reflect a 
baseline increase in polyamines, due in turn to over-production of prolactin. In the Nb2
rat T lymphoma cell line prolactin is mitogenic and induces the transcription of early T 
cell activation genes, such as c-fos, c-myc and hsp70 (Stevens & Yu-Lee, 1991). 
Alternatively, rather than a direct effect on T cells, prolactin may act indirectly by 
altering the balance of circulating T cell subsets as there have been reports of an 
increase in the number of CD5+ and CD8+ cells following prolactin administration (De 
Bemardi et al., 1990; Mukheijee et al., 1990).
The data discussed support a direct role for prolactin in the pathogenesis of autoimmune 
conditions such a SLE and RA. However, the defect may not occur at the level of this 
hormone but may be due to an underlying defect in oestrogen metabolism. Oestrogen 
has been shown to induce prolactin release, probably via a direct effect on the pituitary 
(Franks, 1983). An increase in prolactin mRNA expression has been detected in 
anterior pituitary lobes from male rats treated with oestrogen and this was blocked by 
using an anti-calmodulin agent suggesting that the calcium-calmodulin system may be 
involved (Martinez-Campos et al., 1991).
1.8.7 Other Cytokines
Interferon-y (IFN-y) is produced by certain classes of lymphocyte in response to an 
antigenic challenge. IFNs have been widely used as chemotherapeutic agents due to 
their ability to inhibit the growth of neoplastic as well as normal cells. However, apart 
from its growth-inhibitory function, its role appears to be mainly stimulatory. Indeed, 
IFN-y is an important controlling factor in immunity with effects such as the promotion 
of lymphocyte responses, macrophage activation, induction of MHC expression and 
the production of other cytokines (reviewed by Trinchieri & Perussia, 1985).
The observation that lymphocytes from female mice secrete higher amounts of IFN-y 
following immune stimulation than the cells from male mice, both in vivo and in vitro 
(Huygen & Palfliet, 1984), implied that this cytokine may be under hormonal control. 
This is supported by the work of Fox et al. (1991) who concluded, from transfection 
studies, that 17p-oestradiol could upregulate the activity of the IFN-y promoter via 
regions in the 5'-flanking region of the IFN-y gene which resembled the ERE. DHT 
has been shown to inhibit anti-CD3-induced IFN-y production from murine T cells in 
vitro, whereas DHT given in combination with dehydroepiandrosterone (DHEA) was 
able to restore T cell IFN-y producing capacity in older mice to that of the younger 
population (Araneo etal., 1991). Therefore, there would seem to be, in animal models 
at least, a complex interaction between various sex steroid metabolites and cells of the
immune system in controlling the production of cytokines such as IFN-y, and hence in 
influencing immune potential.
In addition to the above mentioned cytokines, granulocyte-macrophage colony- 
stimulating factor (GM-CSF) activity has been detected in rheumatoid synovial 
effusions and in the supernatants from cultures of RA synovial tissues (Xu et al., 
1989), although the effect of sex hormones on GM-CSF production and effects have 
yet to be investigated. Thus, there are a vast array of cytokines which have important 
enhancing or suppressive roles in an inflammatory response, and sex hormones have 
the potential to modulate the release or the subsequent effects of these factors.
To date the literature is abundant in clinical and epidemiological studies showing an 
association between heightened immune function in females and increased susceptibility 
to autoimmunity, with trends observed between hormonal fluctuations and alterations in 
immune function or disease activity. However, research which helps to explain the 
actual mechanism of action of sex hormones is inconclusive and often contradictory. 
This project was formulated to investigate the cellular effects of sex hormones with 
specific reference to their possible role in RA. The importance of cytokines is now well 
established and this array of proteins, in association with the family of adhesion 
molecules, are likely to play a key role in the pathogenesis of the disease. Thus, the 
research strategy was directed towards the effects of sex hormones, in particular 
oestrogen, on cytokine production and adhesion molecule expression by human and 
rheumatoid PBMC. In addition, receptors for oestrogen in these cells were studied in 
an attempt to clarify a somewhat confounding literature.
2 .1  MATERIALS
All standard reagents were obtained from Sigma (Poole,UK) or BDH (Lutterworth, 
UK). Details of the origin of the more specialised reagents used are listed below, 
grouped into categories which appear alphabetically.
2 .1 .1  Antibodies
All antibodies used were either ascites purified or supplied as a culture supernatant.
Monoclonal antibodies (mAb) UCHM1 and UCHT1 raised against CD 14 and CD3, 
respectively, were kind gifts from Prof. P. Beverley, ICRF (London,UK). Anti-CD 19 
was a kind gift from Prof. I. MacKlennan, University of Birmingham Medical School 
(Birmingham,UK).
MAbs to oestrogen receptor were purchased from Biogenesis Ltd. (Bournemouth,UK) 
and mAb ER-D5, raised against an oestrogen receptor-related antigen, was obtained 
from Amersham International pic. (Amersham,UK). Anti-topoisomerase and anti- 
centromere antibodies were prepared by Dr. J. Whyte from the sera of systemic 
sclerosis patients.
T52/7 antibody, directed against the a l (CDw49a) subunit of integrin a lp l, was a 
generous gift of Dr. Hemler (Boston,MA) and mAb 23C6, directed against aV subunit 
(CD51), was a kind gift from Dr. Horton (London,UK). MAbs raised against a2 
(CDw49b), a4 (CDw49d), a5 (CDw49e), aL (CD1 la) and p2 (CD 18) were purchased 
from Immunotech (Birmingham,UK). MAbs against a3 (CDw49c), a6 (CDw49f)» aM 
(CDllb) and pi (CD29) were supplied by Bioquote Ltd. (Ilkley.UK), Serotech Ltd. 
(Oxford,UK), Dakopatts (High Wycombe,UK) and Coulter Immunology (Luton,UK), 
respectively.
2 .1 .2  Cytokines
Recombinant human interleukin-6 (rhIL-6) was a generous gift from Dr. L. A. Aarden 
of the Netherlands Red Cross Blood Transfusion Service. A specific activity of 
106 U/pg was determined using the B9 hybridoma cell bioassay. Recombinant human 
tumour necrosis factor a (rhTNFa) was a generous gift from Dr. G. R. Adolf of
Boehringer Ingelheim. The specific activity was determined using a murine I^M cell 
bioassay at 6X107 U/mg. Recombinant human interleukin-2 (rhIL-2) was donated by 
Glaxo with a pre-determined specific activity of 106-107 U/mg.
2 .1 .3  cDNA Probes
11^6 cDNA was a kind gift from J. Brakenhoff, Netherlands Red Cross Blood 
Transfusion Service. IL-lp and TGF-p cDNA probes were generous gifts from Dr. A. 
Shaw and Dr. A. Baxter, both of Glaxo Group Research. The cDNA probe for TNF-a 
was a kind gift from Dr. S. Ralston, Rheumatic Diseases Unit, Northern General 
Hospital (Edinburgh,UK). A prolactin cDNA probe was generously provided by Dr.
D. Sawa, Department of Biochemistry and Physiology, University of Reading 
(Reading,UK) and a cDNA probe for oestrogen receptor was a kind gift from Dr. G.L 
Greene, Ben May Laboratory for Cancer Research, University of Chicago 
(Chicago,USA). GAPDH cDNA was a generous gift from Dr. J. Beresford, now at 
Bath Institute for Rheumatic Diseases, and the probe for p-actin was present in-house.
A summary of cDNA probes used and details such as the vector in which they are 
contained is shown in Section 2.8.7.
2 .1 .4  Hormones
17a- and 17p-oestradiol, testosterone and tamoxifen (citrate salt) were obtained from 
Sigma. Follicle-stimulating hormone (FSH) was purchased from Calbiochem 
Novabiochem (UK) Ltd. (Nottingham,UK).
2 .1 .5  Immunochemicals
All FITC-conjugated antibodies and immunoglobulins were purchased from Sigma. R- 
Phycoerythrin-conjugated monoclonal mouse anti-human B-cell (CD19), T-cell (CD3) 
and monocyte (CD14) antibodies were obtained from Dakopatts (High Wycombe,UK). 
Human AB serum and normal rabbit serum were obtained from GIBCO (Paisley,UK). 
FITC coated latex beads were from Flow Cytometry Standards (Research Triangle 
Park, NC,USA) and sheep anti-mouse IgG Dynabeads from Dynal (UK) Ltd.
(Wirral,UK). Reagents for APAAP staining were purchased from Dakopatts and Diff- 
Quik reagents were from Baxter Dade AG (Dudington, Germany).
2 .1 .6  Kits
The Abbott ER-ICA Monoclonal for detecting oestrogen receptors was supplied by 
Abbott Laboratories Ltd. (Maidenhead,UK), as were control slides for the kit.
DNA was purified using either the Magic Minipreps DNA Purification System from 
Promega Ltd. (Southampton,UK), which relies on a reverse-phase method of 
extraction, or the Qiagen Plasmid Kit distributed by Hybaid Ltd. (Teddington,UK) 
which uses an ion-exchange method to purify DNA. DNA was then further purified 
using either a Geneclean II or Mermaid Kit, distributed by Stratech Scientific Ltd. 
(Luton,UK). cDNA was labelled with [a-32P]dCTP using a Multiprime Kit from 
Amersham International pic. (Amersham,UK). RNA was further purified to mRNA 
using the Promega PolyATtract mRNA Isolation System by Promega Ltd. An 
AmpliTaq Cycle Sequencing Kit was purchased from Perkin-Elmer Ltd. 
(Beaconsfield,UK).
2 .1 .7  Molecular Biology Reagents
All restriction enzymes were purchased from either Northumbria Biologicals (NBL) 
(Cramlington,UK) or Pharmacia Biosystems Ltd. (Milton Keynes,UK). M-MLV and 
Superscript RNase H' reverse transcriptases were supplied by GIBCO (Paisley,UK) 
and Taq DNA polymerase by either NBL, Promega Ltd. (Southampton,UK) or Perkin- 
Elmer Ltd. (Beaconsfield,UK). pd(T)i2_i8 , RNAguard RNase inhibitor and an 
Ultrapure dNTP set were obtained from Pharmacia Biosystems Ltd. DNA markers 
were supplied by either NBL or Promega Ltd. Bacto-agar,-yeast extract and -tryptone 
were obtained from Oxoid (Bristol,UK). Standard agarose was purchased from Sigma 
and NuSieve 3:1 agarose from FMC Bioproducts, the UK distributor of which is 
Flowgen (Sittingbourne,UK). Water-saturated phenol (AquaPhenol) was supplied by 
Appligene (Co. Durham,UK). All oligonucleotide primers were synthesised, according 
to instructions, by Colin Lazarus, Department of Botany, University of Bristol 
(Bristol,UK).
Hybond-N+ was supplied by Amersham International pic. (Amersham,UK) and DE81 
discs and chromatography paper (3MM) were from Whatman Scientific Ltd. 
(Maidstone,UK).
2 .1 .8  Radiochemicals
[2,4,6,7-3H]oestradiol and pH]thymidine were from Amersham International pic. 
(Amersham,UK). [a-32P]dCTP was obtained from ICN Flow (High Wycombe,UK) 
and [y-32P]dATP from NEN-Dupont (UK) Ltd. (Stevenage,UK). Scintillation fluid 
utilised included Optiscint HiSafe and Optiphase HiSafe 3 from Wallac Ltd. (Milton 
Keynes, UK).
2 .1 .9  Tissue Culture Reagents
RPMI1640, Minimal Essential medium (MEM), penicillin-streptomycin, L-glutamine, 
sodium bicarbonate and trypsin-EDTA were all obtained from GIBCO (Paisley,UK). 
Heat-inactivated foetal calf serum (FCS) was obtained from Imperial Laboratories 
(Andover,UK) and for the preparation of charcoal-stripped FCS, high-grade charcoal 
(Norit GSX) from BDH was utilised. Phosphate buffered saline tablets and 
Lymphoprep were purchased from Oxoid (Bristol,UK) and Nycomed (UK) Ltd. 
(Birmingham,UK), respectively. Heparin (Monoparin) was supplied by CP 
Pharmaceuticals Ltd. (Wrexham,UK)
ZR-75 cells were a kind gift from Dr. T. Ruprinak, Glaxo (Greenford,UK) and 
Hs578T cells were purchased from the European Collection of Animal Cell Cultures 
(ECACC) (Salisbury,UK). Synovial fibroblasts were generously donated by Dr. N. 
Jordan, University of Bath (Bath,UK). All other cell types included in this study were 
used routinely in our laboratory.
2 .2 . PREPARATION OF MEDIA AND BUFFERS
RPMI1640 / Minimal Essential medium (MEM") + 10% (v/v) foetal calf serum ("FCS")
RPMI1640 or MEM (10X)
Penicillin (10000 IU/ml) / Streptomycin (10000 jig/ml) 
Glutamine (200 mM)







The above reagents were combined and made up to 500 ml with sterile micronised 
water. The pH was adjusted to 7.3 with sterile 3 M NaOH.
Phenol red-free RPMI 1640 / MEM + 10% (v/v) charcoal-stripped FCS
This was made up as described above, using RPMI or MEM devoid of phenol red 
(10X), which is reported to be weakly oestrogenic (Berthois et al., 1986), and using 
FCS which had been charcoal-stripped to remove endogenous steroids (see below).
Serum-free RPMI 1640 / MEM
RPMI 1640 or MEM (10X) 50 ml
Penicillin (10000 IU/ml) / Streptomycin (10000 ng/ml) 5 ml
Glutamine (200 mM) 5 ml
Sodium bicarbonate (7.5% (w/v)) 15 ml
Transferrin 500 \i\
Insulin (5 mg/ml) 100 \i\
Sodium selenite (3X10-4 M) 50 \d
BSA 0.1% (w/v)
Transferrin was first preloaded with FeC^ by mixing 100 mg transferrin with 100 jxl 
FeCl3  (10-2 M in 1 mM HC1) and 9.9 ml of MEM then leaving for 30 minutes at room 
temperature. The solution was filter sterilised and stored at 4°C. Insulin was dissolved 
in 10 mM acetic acid to 5 mg/ml and stored at -70°C. Sodium selenite was dissolved in 
PBS at a concentration of 3x1 O'4 M. To make up the media, all reagents were mixed
and the volume made up to 500 ml with sterile micronised water. The pH was adjusted 
to 7.3 with sterile 3 M NaOH.
Charcoal-Stripped FCS (CS-FCSi
To 100 ml heat-inactivated FCS was added 4 g of high grade charcoal (Norit GSX) and 
the mixture was stirred, on ice, for 1 hour. Charcoal was separated from the serum by 
centrifuging at 3000 rpm for 10 minutes, and the supernatant was then filtered through 
0.4 pm pre-filters followed by 0.2 pm filters. The serum was re-sterilised by passing 
through a sterile 0.2 pm filter and stored at -20°C.
Phosphate Buffered Saline (PBS)
5 PBS tablets were dissolved in 500 ml micronised water and the solution autoclaved. 
For PBS-G, 0.8 mg medicinal glucose was dissolved in a small volume of sterile PBS 
then filtered back into the buffer.
Tris Buffered Saline (TBSi
Sodium chloride 8 g (0.14 M)
Potassium chloride 0.2 g (0.0026 M)
Tris base 3 g (0.025 M)
The above reagents were dissolved in 800 ml DH2 O, 0.015 g phenol red added and the 
pH adjusted to 7.4 with HC1. Finally, the volume was made up to 1 litre with DH2 O.
Tris-Borate-EDTA (TBEi (5X)
Tris base 54 g (0.445 M)
Boric acid 27.5 g (0.445 M)
EDTA (0.5 M, pH 8.0) 20 ml (0.01 M)
The above reagents were dissolved in DH2O and made up to a final volume of 1 litre.
Tris-Acetate-EDTA (TAE  ^(10X)
Tris base 48.44 g (0.4 M)
Sodium acetate 4.1 g (0.05 M)
EDTA (0.5 M, pH 8.0) 3.72 g (0.01 M)
The above reagents were dissolved in DH2O to a final volume of 1 litre and the pH 
corrected to 8.1 with glacial acetic acid (approximately 12 ml required for 1 litre of 10X 
solution).
MOPS (10x1
MOPS 41.85 g (free acid) or 46.2 g (Na salt) (0.2 M)
Sodium acetate 4.1 g (anhydrous) or 6.8 g (trihydrate) (0.05 M)
EDTA 3.72 g (0.01 M)
The above were dissolved in 1 litre of DH2O and the pH adjusted to 7.0 with NaOH. 
The solution was then autoclaved.
Transformation Buffer 1 (Tfbll
Potassium acetate 0.03 M
Rubidium chloride 0.1 M
Calcium chloride 0.01 M
Manganese chloride 0.05 M
15% (v/v) glycerol was added and the pH adjusted to 5.8 with 0.2 M acetic acid. The 
solution was then filter sterilised.







15% (v/v) glycerol was added and the pH adjusted to 6.5 with KOH. The solution was 
then filter sterilised.
2 .3  PREPARATION OF DRUG SOLUTIONS
17a-oestradiol, 17p-oestradiol, testosterone and tamoxifen were dissolved in ethanol to 
a concentration of 1 mM, as required. Further dilutions were made in the relevant 
culture medium.
Follicle-stimulating hormone (FSH) was dissolved in PBS (pH 7.6) to a concentration 
of 200 pg/ml. Aliquots were stored at -70°C for up to 6 months.
2 .4  TISSUE CULTURE
2 .4 .1  Preparation of Peripheral Blood Mononuclear Cells
Peripheral blood was obtained from normal, healthy volunteers or from rheumatoid 
arthritis patients attending The Royal National Hospital for Rheumatic Diseases. Blood 
was routinely collected between 9.00 a.m. and 12.00 p.m. A record was kept for 
female donors regarding menopausal status, stage of menstrual cycle, parity and use of 
oral contraceptives. Patients used for this study had no history of steroidal use. Most 
were receiving non-steroidal anti-inflammatory drugs (NSAIDs) and a small number 
were also treated with a second-line agent.
Blood obtained was dispensed into heparinised tubes (100 U/ml). After diluting 1:1 
with PBS-G, the blood was separated by density-gradient centrifugation on 
Lymphoprep (density = 1.077 g/ml). The mononuclear cell (MNC) layer was extracted 
from the serum/lymphoprep interface and cells were washed twice in PBS-G, then 
counted using white cell counting fluid (3% (v/v) glacial acetic acid, 0.1% (w/v) 
methylene blue).
2 .4 .2  Purification of T Cells and Monocytes
PBMC prepared as described in Method 2.4.1 were divided into two 15 ml 
polypropylene tubes and pelleted by centrifuging at 1000 rpm for 10 minutes. Cells
were resuspended in either 500 |xl anti-CD14 and 5 pi anti-CD19 mAbs, to purify the T 
cell population, or 500 pi anti-CD3 and 5 pi anti-CD19 mAbs, to purify the monocyte 
population. The cells were incubated at 4°C, with rotation, for 1 hour, then washed 
twice in medium (RPMI supplemented with 10% (v/v) FCS) and resuspended in sheep 
anti-mouse IgG-coated Dynabeads (diluted 1/10 in medium). After a further 1 hour 
incubation at 4°C, with rotation, the cell populations of interest were negatively 
selected, by magnetically drawing the Dynabeads to the sides of the tubes and carefully 
removing the supernatants. The two cell populations were washed twice in medium and 
counted prior to use.
2 .4 .3  Maintenance of Cell Lines
B9 Cells
B9 is a murine myeloma cell line. The cells were maintained in RPMI supplemented 
with 5% (v/v) FCS. To 30 ml of cells were added 15 pi p-mercaptoethanol (p-ME) and 
30 pi monocyte conditioned media (MCM) (prepared by incubating MNC in 10 ml 
media supplemented with 10% (v/v) FCS for 24 hours, centrifuging at 1000 rpm for 10 
minutes, and removing the supernatants which were stored at -20°C).
Fibroblasts
Synovial fibroblasts were grown from synovial explants taken from osteoarthritis 
patients. They were maintained in MEM with 10% (v/v) FCS up to a passage number 
of approximately 10.
Hs578T Cells
Hs578T is a human breast carcinoma cell line of epithelial origin which is oestrogen 
receptor negative. The cells were maintained in RPMI supplemented with 10% (v/v) 
FCS and 10 pg/ml bovine insulin.
T-47D Cells
The T-47D cell line was established from the pleural effusion of a ductal carcinoma of 
the breast of a 54 year old female, and is oestrogen receptor positive. The cells are 
maintained in RPMI with 10% (v/v) FCS.
W EHI164 Cells
W EHI164 subclone 13 is a mouse fibrosarcoma cell line. The cells are maintained in 
RPMI with 10% (v/v) FCS.
ZR-75 Cells
The ZR-75 cell line was established from a malignant ascitic effusion in a 63 year old 
female Caucasian with infiltrating ductal carcinoma. Cells are of epithelial origin and 
are oestrogen receptor positive. They were maintained in RPMI with 10% (v/v) FCS, 
supplemented with 109 M oestradiol.
2 .4 .4  Passaging Cells
Adherent cells were passaged as follows. The medium was removed and the cell 
monolayer rinsed with PBS. 2.5 ml trypsin-EDTA was added to each flask and the 
cells then incubated at 37°C for 5-10 minutes. To ensure that all cells were dislodged, 
the flask was tapped gently, then 10 ml medium was added, the suspension removed 
and the cells pelleted by centrifugation. After washing twice in medium the cells were 
resuspended in medium and split (normally 1:4 to 1:10), then recultured to confluence.
Non-adherent cells were passaged by removing an aliquot of cell suspension from each 
flask and dispensing into flasks containing a relevant volume of culture medium.
2 .4 .5  Freezing Down Cells
Cells were harvested, washed and counted, then resuspended in 50% (v/v) FCS/50% 
(v/v) medium (either RPMI 1640 or MEM) to a concentration of approximately 
10X106 cells/ml. 500 pi aliquots of the cells were dispensed into freezing vials and 
placed on ice. 500 pi of 20% (v/v) dimethyl sulphoxide (DMSO)/80% (v/v) medium 
was added drop-wise to each vial, whilst mixing thoroughly. Vials were then placed 
into a polystyrene container packed with tissue. This was sealed and placed into a 
-70°C freezer overnight before transferring to liquid nitrogen storage.
To set up cells from frozen, a vial was removed from liquid nitrogen storage and 
defrosted rapidly under hot running water. The outside of the vial was then wiped with 
alcohol prior to removing the cells. Cells were washed twice with medium then grown
up overnight in a small (25 cm2) tissue culture flask before transferring to a larger (75 
cm2) flask.
2 .4 .6  Assessing Cell Viability
Cell viability was routinely assessed using the trypan blue exclusion method, by which 
the cell suspension was mixed with an equal volume of trypan blue and incubated for 
between 5 and 15 minutes, at 37°C. Cells were then counted and those which had taken 
up the blue stain (ie. those which were non-viable) were expressed as a fraction of the 
total number of cells present (ie. viable and non-viable), hence percentage viability 
could be calculated. In all experiments recorded, cell viability was found to be greater 
than 90%.
2 .5  BIOASSAYS
2 .5 .1  IL-6 Bioassay (Helle et al., 1988)
The IL^6 bioassay utilises the B9 murine hybridoma cell line. B9 cells are a variant of 
the B13.29 line and proliferate in response to IL-6. Sensitivity for 11^6 is virtually 
100%, except for a slight stimulatory effect with IL-4.
For the bioassay, 10 ml of murine B9 cell suspension was removed and the cells 
washed twice in RPMI1640 supplemented with 5% (v/v) FCS, then resuspended to a 
concentration of 5X104 cells/ml in medium supplemented with 50 nM p-ME. 
Supernatant samples were diluted in a 48-well plate to give final dilutions of 1/100, 
1/1000,1/10000,1/100000 and 1/1000000. Cells were seeded into flat-bottomed 
96-well plates at a concentration of 5x10s cells/well. To the cells were added 100 \i\ 
aliquots of the sample dilutions, each performed in duplicate. A standard curve was 
performed with rhIL-6, diluted to give final concentrations of 100, 30 ,1 0 ,1 and 0.1 
U/ml. Plates were incubated for 72 hours at 37°C, 5%CC>2/95%air. 20 nl 3-(4,5- 
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MIT) (5 mg/ml in PBS) was 
then added to each well, and the incubation continued for a further 2 hours. MTT is a 
pale yellow substrate which produces a dark blue formazan product when incubated 
with living cells. Once a formazan residue had formed, the supernatant was aspirated 
and 100 nl acidified isopropanol (99 ml propan-2-ol + 1 ml HC1) added to each well to 
dissolve the product. Absorbances were read on a Dynatech Automated Micro ELISA
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reader at 570 and 630 nm, reference and test wavelengths, respectively, against blanks 
consisting of acidified isopropanol only.
The dilution giving a reading on the linear portion of the standard curve was selected 
and an extrapolation made to give U/ml IL-6, hence total IL-6 per sample could be 
calculated by multiplying by the relevant dilution factor. A typical standard curve for the 
IL-6 bioassay is shown in Figure 2.1.
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Figure 2.1. A typical standard curve for the IL-6 bioassay.
2 .5 .2  TNF Bioassay (Espevik and Nissen-Meyer, 1986)
The TNF bioassay utilises WEHI 164 subclone 13 cells, derived from WEHI 164 
mouse fibrosarcoma cells. Both TNF-a and TNF-{3 are cytotoxic for this particular cell 
line.
For the bioassay, WEHI 164 cells were prepared to give a concentration of 
2X105 cells/ml in RPMI 1640 supplemented with 10% (v/v) FCS. Cells were seeded 
into 96-well flat-bottomed plates and incubated for 3-4 hours at 37°C, 5%C02/95%air, 
until the cells had adhered. 1/100 dilutions of supernatant samples were added to the 
cells, with each dilution performed in triplicate. A standard curve was performed with
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rhTNFa at 0.001-1000 U/ml. Plates were incubated for 24 hours at 37°C, 
5%CC>2/95%air. 10 pi MTT (5 mg/ml in PBS) was then added to each well and the 
incubation continued for a further 4 hours. Finally, the supernatant was aspirated and 
50 pi acidified isopropanol added to each well to dissolve the formazan residue. 
Absorbances were read at 570 and 630 nm, reference and test wavelengths, 
respectively, against blanks consisting of acidified isopropanol only.
Results were expressed as % cytotoxicity using the formula:
Extrapolations were made from the linear portion of the standard curve and multiplied 
by the dilution factor to give total U/ml TNF per sample. A typical standard curve for 
the TNF bioassay is shown in Figure 2.2.
(1 - P .P. standard/samplel X100 
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Figure 2.2. A typical standard curve for the TNF bioassay
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2 .6  PROLIFERATION ASSAY
Cells were harvested, washed twice in relevant medium and resuspended to a 
concentration of 1X106 cells/ml. The cells were then aliquotted into the wells of a 
96-well round-bottomed plate (1X105 cells/well) along with the stimuli and/or 
inhibitors of proliferation under study. Cells were incubated at 37°C, 5%CC>2/95% air, 
for 72 hours, pulsed with [3H]thymidine (1 pCi/well) and incubated for a further 4 
hours. Cells were harvested onto glass filters using a Skatron Semiautomatic cell 
harvester. The filters were then dried and immersed in 500 pi of Optiscint HiSafe 
scintillation cocktail, in scintillation vials. Counts were made in a LKB 1209 Rackbeta 
liquid scintillation counter.
2 .7  IMMUNOC YTOCHEMISTRY
2 .7 .1  Preparation of Cells for the Analysis of Cell-Surface Antigens by 
Flow Cytometry.
Cells were harvested, washed twice in medium, counted and resuspended to a 
concentration of 1X106 cells/ml. 100 pi aliquots of cell suspension were dispensed into 
FACS tubes and 2 ml PBS/FCS (2% (v/v) FCS in PBS) added. Cells were pelleted by 
centrifuging at 1000 rpm for 5 minutes and the supernatant aspirated using a suction 
pump. The cell pellet was then resuspended in 50 pi mAb (diluted appropriately in 
PBS/FCS) and 10 pi of human AB serum, with the latter added to block Fc receptors 
on the cell surface. Controls were performed by adding either PBS/FCS in place of the 
mAb, or the relevant immunoglobulin (IgG), diluted to the same concentration as the 
highest of mAb. Cells were incubated for 60-90 minutes on ice, then washed once in 
3 ml PBS/FCS and harvested by centrifuging at 1000 rpm for 5 minutes, at 4°C. 50 pi 
of the relevant anti IgG FITC-conjugate (1/20 in PBS/FCS) was added and the cells 
incubated for a further 30 minutes, on ice. The cells were washed as previously 
described and resuspended in 200 pi PBS/FCS and 200 pi 2% (w/v) paraformaldehyde 
in PBS (pH 7.4), then stored at 4°C, in the dark, for up to 2 weeks prior to analysis.
For dual-labelling of cells an additional first antibody was included which was directly 
conjugated to a different fluorochrome, namely phycoerythrin.
2 .7 .2  Saponin-Permeabilisation of Cells for the Analysis of Intracellular 
Antigens by Flow Cytometry (Sander et al., 1991)
Cells were prepared as described in 2.7.1 and resuspended to a concentration of 
2X106 cells/ml in PBS/BSA (0.1% (w/v) bovine serum albumin (BSA) in PBS). Cells 
were aliquotted into FACS tubes (1X105 cells/tube) and an equal volume of 2% (w/v) 
paraformaldehyde solution added in order to fix the cell membrane prior to it being 
rendered permeable. The cells were incubated for 5 minutes on ice, washed once in 
500 pi PBS/BSA and harvested by centrifuging at 1000 rpm for 5 minutes, 4°C. The 
supernatant was removed by aspiration, 500 pi of PBS/saponin (0.1% (w/v) saponin in 
PBS/BSA) added to permeabilise the membrane, and the cells incubated on ice for a 
further 5 minutes. Following a second wash with PBS/saponin, 50 pi mAb (diluted 
appropriately in PBS/saponin) was added and the cells incubated for 60 minutes on ice. 
Controls were performed as in 2.7.1. After incubation with the first antibody, cells 
were washed once in PBS/saponin then 50 pi of the relevant anti-IgG FITC conjugate 
(diluted 1/100 in PBS/saponin) added, and the incubation continued for a further 30 
minutes. Finally, the cells were washed once in PBS/saponin and then in PBS/BSA to 
're-seal' the membrane. Cells were resuspended in 200 pi PBS/BSA and 200 pi 2% 
(w/v) paraformaldehyde and stored at 4°C, in the dark, for up to 2 weeks prior to 
analysis.
2 .7 .3  Analysis of Flow Cytometry Data
FACS samples were analysed on a Becton Dickenson FACS tar Plus, equipped with a 
lOOmW argon ion laser and Consort 32 computer. The principal of flow cytometry is 
that a single cell suspension passes through a light source emitted by a laser. The light 
excites the fluorescent dyes used to label the cells, leading to light amplification. 
Scattered or fluorescent light produced is collected by a photomultiplier tube (PMT) and 
converted to electrical signals and eventually to digital information. The light produced 
is reflected by mirrors, coated such that they reflect only a specific wavelength. 
Therefore, one cell preparation can be labelled with several different fluorochromes 
which all emit a different spectrum of light.
Prior to collecting data, the nozel head was aligned to maximise the detection of 
fluorescent events. This was carried out using a mixture of two latex beads coated with 
FITC of different intensities. When a quantitative analysis of data was required, in 
terms of 'sites per cell', a mixture of six beads were used, standardised in terms of six
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different levels of fluorescence achieved by varying the number of FITC sites per bead.
By plotting a histogram of fluorescence intensity and gating on each of the six peaks the 
mean fluorescence intensity (MFI) for each peak could be calculated. The MFI values 
were entered into a Spreadsheet computer program which extrapolated from a standard 
curve, as shown in Figure 2.3, to calculate antibody sites per cell from the MFI values 
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Figure 2.3. Standard curve for sites per cell analysis
Data were collected as either dot plots or frequency histograms. Dot plots usually 
consisted of side scatter (SSC), relating to cell granularity, versus forward scatter 
(FSC), relating to cell size, or of fluorescence versus FSC. Histograms generally 
depicted fluorescence intensity. The threshold was set such that background noise was 
eliminated. All parameters were first set using a negative control with second antibody 
(ie. FITC-conjugate) only. The remaining samples were then analysed, with all 
comparisons made with the relevant IgG control. Comparisons were made in terms of 
MFI values and % positive cells, with the control antibody set at 5%. Where 
quantitative analysis was performed the number of sites per cell for the IgG control 
were deducted from all other values.
2 .7 .4  Preparation of Slides
Use of the Abbott ER-ICA monoclonal kit for the detection of oestrogen receptors 
required that all slides be treated with the tissue adhesive included in the kit, according 
to instructions. For all other procedures either cytospins were performed with non- 
adherent cells, or for adherent cells, slides were treated with poly-L-lysine, to aid 
attachment, as follows. 100 [d/spot of 100 ng/ml poly-L-lysine was added to 4-spot 
slides, and the slides incubated for 5 minutes at 37°C. The slides were then washed 
three times in sterile micronised water before being left to dry in a sterile environment.
2 .7 .5  Preparation of Cells and Synovial Sections
Adherent cells were cultured onto slides by seeding at a density of approximately 
2X104 cells/spot of a 4-spot slide and incubating in a humidified chamber overnight at 
37°C, 5%CC>2/95%air. Non-adherent cells were prepared as cytospins using a 
Shandon cytospin. Conditions were optimised as 2.5X105 cells/slide, centrifuging at 
500 rpm for 3 minutes. The Diff-Quik method of staining was used to show that cell 
morphology (nuclear and cytoplasmic) is maintained under these conditions (results not 
shown).
Synovial tissue was obtained from a 67 year old female rheumatoid patient with a 25 
year history of RA. Tissue was removed from the active left knee which was described 
as warm and swollen on prior examination. The sample was snap frozen and stored in 
liquid nitrogen prior to cutting into 8 jxm sections on a Bright's cryostat. The sections 
were placed onto slides which were either untreated, or which had been treated 
according to the Abbott kit instructions.
2 .7 .6  Staining for Oestrogen Receptor Using the Abbott ER-ICA 
Monoclonal Kit
Slides were fixed following instructions in the kit and stored at -20°C in the specimen 
storage medium described, for up to 4 months. The cells were then treated according to 
instructions, incubating with either the H222 anti-ER rat mAb or the control normal rat 
antibody. Abbott control slides were used to ensure that the procedure was working 
optimally. To produce a more intense staining, the incubation times were increased 
from 30 to 60 minutes.
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Cells were examined using a Leitz Laborlux S microscope equipped with a Leitz Wild 
46/52 Photoautomat.
2 .7 .7  Alkaline Phosphatase-Antialkaline Phosphatase (APAAP) Staining
4-spot slides onto which cells were cultured overnight were drained to remove excess 
medium, rinsed in TBS and fixed in acetone for 5 minutes. Slides were then wrapped 
in aluminium foil and stored at -20°C prior to use. Cytospins and cryostat sections 
were fixed directly in acetone for 1 minute or 10 minutes, respectively, and stored as 
described above.
The APAAP procedure was carried out according to Dakopatts' instructions. Briefly, 
slides were immersed in TBS for 5 minutes then blocked with normal rabbit serum 
(NRS) (20% (v/v) in TBS) for 20 minutes. The slides were 'flicked' to remove excess 
NRS and the primary mAb or a control IgG added, at an appropriate dilution in TBS. 
After 30 minutes incubation in a humidified chamber, at room temperature, slides were 
washed for 1-2 minutes in TBS prior to adding the second antibody (diluted 1/25 in 
TBS) and incubating for a further 30 minutes. After washing, the APAAP complex 
(1/50 dilution in TBS) was added for 30 minutes and, after washing once again, the 
alkaline phosphatase substrate (substrate 1, see below) was applied to the slides for 
15-20 minutes. Finally, slides were washed in TBS, then in tap water, counterstained 
with haematoxylin for 30 seconds and mounted in 2% glycerol/PBS. Cells were 
examined as described in Method 2.7.6.
Substrate 1
Naphthol AS-MX phosphate 2 mg
Dimethylformamide 0.2 ml
0.1 M TRIS buffer pH 8.2 9.8 ml
1 M Levamisole 10 pi
Fast-Red TR salt 10 mg
The solution was prepared by dissolving the Napthol AS-MX phosphate in 
dimethylformamide in a glass tube and diluting to 10 ml with TRIS buffer. Levamisole 
was added to block endogenous alkaline phosphatase activity. Substrate 1 was stored at 
-20°C. The Fast-Red salt was added immediately prior to use and the solution filtered 
directly onto the slides.
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2 .8  ANALYSIS OF RNA AND DNA
The preparation of RNA requires that all solutions be sterile and treated with 
diethlypyrocarbonate (DEPC) to eliminate RNase activity.
2 .8 .1  RNA Extraction (Chomczynski & Sacchi, 1987)
Cells were lysed in solution D (see below) (106 cells/100 pi) and transferred to 
microfuge tubes. 50 pi 2 M sodium acetate pH 4.0,500 pi water-saturated phenol 
(AquaPhenol) and 100 pi chloroform-isoamyl alcohol (49:1) were added sequentially, 
mixing by inversion between each addition. Tubes were shaken vigorously for 10 
seconds then cooled on ice for 15 minutes. After centrifugation at high speed (13000 
rpm) in a microfuge for 10 minutes, the top aqueous layer was removed and an equal 
volume of chloroform-isoamyl alcohol added. Tubes were shaken vigorously once 
again then centrifuged at 13000 rpm for 5 minutes. A second extraction with 
chloroform-isoamyl alcohol was performed if necessary and the final aqueous layer 
was precipitated with an equal volume of isopropanol at -20°C overnight. RNA was 
then spun out at 13000 rpm for 10 minutes, the supernatant removed and the pellet 
redissolved in 150 pi solution D. The RNA was precipitated by adding 150 pi 
isopropanol and storing at -20°C overnight. Finally, the RNA was pelleted by 
centrifugation at 13000 rpm for 10 minutes, the pellet washed twice in 70% (v/v) 
ethanol and once with absolute ethanol, then dried down under vacuum prior to being 
resuspended in 200 pi DEPC water.
Solution D
Guanidinium thiocyanate 250 g
0.75 M Sodium citrate, pH 7.0 17.6 ml
10% (w/v) N-Laurylsarcosine (sodium salt) 26.4 ml
The above were dissolved in 293 ml sterile DEPC-treated water at 65°C and stored at 
4°C. For use, solution D was prepared by adding 72 pi 2-mercaptoethanol to 10 ml of 
the stock solution, and stored for up to two weeks.
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2 .8 .2  Quantification of RNA and DNA
10 \d aliquots of DNA and RNA samples were diluted to 250 \i\ in water and the 
absorbances read at 260 and 280 nm in a LKB Ultrospec II spectrophotometer. The 
ratios of A2 6 0/A2 8O were calculated. These should be 1.8 for DNA and 2.0 for RNA, 
with lower values indicating impurities or contamination by phenol or protein. The 
concentration of DNA or RNA was calculated by the formulae:
A26O X 40 X dilution factor = ng/ml RNA
A2 6 0  X 50 X dilution factor = ng/ml DNA
The quality of RNA prepared was assessed by electrophoresing through a 1.2% (w/v) 
agarose gel (see section 2.8.3). This should show two clear ribosomal bands.
2 .8 .3  Agarose Gel Electrophoresis
Horizontal submarine gel electrophoresis was used for the analysis of DNA and RNA 
Unless otherwise stated, 1% (w/v) agarose in TAE was used for DNA and 1.2% (w/v) 
agarose in TAE for RNA analysis. The agarose was added to the buffer and heated until 
melted then allowed to cool to approximately 60°C. Ethidium bromide was added to 
give a final concentration of 0.5 pig/ml. Ethidium bromide contains a planar group 
which intercalates between staked bases of single- or double-stranded DNA causing the 
fluorescent intensity of the dye to increase, hence the DNA or RNA product can be 
visualised under UV light. A perspex mould with two solid sides was prepared by 
forming the remaining two sides with masking tape and placing a comb approximately 
1 cm from one end, ensuring that it was not touching the bottom of the mould. The 
cooled agarose was poured into the mould and allowed to set at room temperature.
Once set, the comb was carefully removed and the gel placed into the manifold with the 
wells towards the cathode. The gel was then covered in IX TAE, the running buffer. 
DNA samples were loaded in DNA loading dye (15% (w/v) ficoll, 0.25% (w/v) xylene 
cyanol, 0.25% (w/v) bromophenol blue) and for RNA samples an RNA loading dye 
was used (20% (w/v) ficoll, 0.2% (w/v) bromophenol blue). RNA was denatured at 
65°C for 10 minutes then quenched on ice prior to loading onto the gel. The samples 
were electrophoresed at 60 V, unless otherwise stated, until the leading dye was at least 
three-quarters of the way down the gel. The gel was visualised using a UV
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transilluminator. Appropriate DNA markers were used to assist in the detection of DNA 
fragments of a specific size.
2 .8 .4  Dot-BIot Analysis of RNA
Samples were standardised to contain equal quantities of RNA/50 pi. The 50 pi aliquots 
of RNA were mixed with 50 pi formamide and denatured at 65°C for 10 minutes then 
quenched on ice. 8 pi of 3 M sodium acetate, pH 5.2, was added and the volume made 
up to 200 pi with solution A (see below). Two-fold serial dilutions were made with 
solution A in a 96-well plate, on ice. The dot-blot manifold was soaked in 0.1% (v/v) 
DEPC water for 30 minutes prior to assembling with the Hybond-N+, which had been 
pre-wetted with DEPC-water, then with 20x SSC. 100 pi samples were applied by 
suction at a rate of approximately 100 pl/20 minutes, then washed with 100 pl/well 
solution A. The RNA was fixed onto the filter by soaking in fresh 50 mM NaOH for 5 
minutes. After rinsing in 2x  SSC, the filter was sealed in Saran Wrap and stored at 
4°C.
The above reagents were mixed and stored for up to 2 weeks at 4°C.
2 .8 .5  Northern Blot Analysis of RNA (Herrin and Schmidt, 1988)
A formaldehyde gel was constructed using 1% (w/v) agarose in IX MOPS (diluted 
from 10X stock using 1 part formaldehyde:6 parts water), with IX MOPS used as a 
running buffer. 10 pg samples of RNA were dried down under a vacuum, resuspended 
in 10 pi loading buffer (50% (v/v) formamide (pure), 16.7% (v/v) formaldehyde in IX 
MOPS), then denatured at 65°C for 10 minutes and quenched on ice. 1 pi RNA loading 
dye was added to each sample which were then loaded onto the gel. Small gels were 
run at a constant current of 30 mAmps for approximately 2 hours, and large gels at 75 
mAmps for approximately 5 hours.
Solution A 
Formamide (pure)






When the gel had finished running it was removed from the tank, trimmed to remove 
the wells, and measured to enable a piece of Hybond-N+ to be cut to the same size. A 
comer was cut from the gel and from the corresponding piece of Hybond-N+ to enable 
the orientation to be assessed after blotting. The Northern blot was constructed as 
shown in figure 2.4. Care was taken not to trap any air bubbles between the layers, and 
any gel and wicks visible were covered with cling film to prevent short-circuiting and 
evaporation of the buffer. The blot was run overnight then carefully dismantled. To 
check for ribosomal bands the filter was first fixed in 50 mM NaOH (RNA-side down), 
then rinsed in 2x SSPE before placing in 0.02% (w/v) methylene blue (RNA-side up) 
(ribosomal bands should appear within 3 minutes). Finally the filter was washed in IX 















Figure 2.4. Northern Blotting
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2 .8 .6  Southern Blot Analysis of DNA (Southern, 1975)
A restriction endonuclease digest was carried out initially, according to Method 2.8.7
(iv) to 'release' the fragment of DNA of interest. The DNA was electrophoresed on a 
0.8% (w/v) agarose gel, with markers, then observed under UV light. The distance of 
the marker bands was measured for future reference. The gel was placed into 0.25 M 
H Q  until the dyes had changed colour (bromophenol blue to green; xylene cyanol to 
yellow), rinsed in distilled water and left to soak in 0.4 M NaOH whilst the blotting 
apparatus was constructed (Figure 2.4). Blotting was carried out as for Northern 
blotting and the DNA allowed to transfer for 2-3 hours. The Hybond-N+ membrane 
was then removed, washed briefly by immersion into 2X SSPE, then wrapped in Saran 
Wrap and stored at 4°C.
2 .8 .7  Preparation of cDNA Probes
cDNA probes were generally supplied as recombinants. To maintain sufficient stocks 
of the cDNA, the plasmids were transformed into competent cells and stored at -70°C. 
Cells were then grown up from the frozen stocks, hence the amount of cDNA could be 
amplified. Table 2.1. summarises details of the probes used.
PROBE NAME VECTOR RESISTANCE ENZYME SIZE
TNF-a (PAT 153) PAT 153 Tet. PstI 1200
IL-ip pGeml LL-ip pGem-1 Amp. EcoRI+PstI 320
IL-6 (pSP64) pSP64 Amp. Sall+EcoRI 300
TGF-p pGHTGFB-27 pGem Amp. HindM+EcoRI 300
p-Actin pHFbA-3'UT pBR322 Amp. EcoRI+BamHI 700
GAPDH pG3PCR-4 pUC 18 Amp. BamHI 1000
ER pER35 pGem3 Amp. Sphl+EcoRI 1800
Prolactin pJMBG61 pUR291 Amp. PstI 588
Table 2.1. cDNA Probes
(i) Competent cells
A streak was made onto an agar plate from a frozen stock of bacteria, and incubated at 
37°C overnight. A single fresh colony was then used to innoculate 5 ml of LB and the 
culture incubated at 37°C, with shaking, until the cells had reached early log phase of 
growth (O.D. 550 = 0.3). Bacteria were then subcultured (1:20) into 100 ml of LB, 
prewarmed to 37°C, and grown for a further 2 hours, or until the O.D. reading had 
reached 0.48. After chilling on ice, the culture was centrifuged in Corex tubes in a 
Beckman J2-21 centrifuge, at 5000 rpm for 10 minutes, 4°C. Cells were resuspended 
in 2/5 volume of Tfbl and left on ice for 5 minutes. A second centrifugation was 
performed as before, then the cells were resuspended in 1/25 volume of Tfb2 and left 
on ice for a further 15 minutes. Finally, suitable aliquots were dispensed into pre­
chilled freezing vials, snap frozen in dry ice and stored in liquid nitrogen.
(ii) Transformation of competent cells
Competent cells were placed at room temperature until just thawed, then left on ice for 
10 minutes. Plasmid DNA was added up to 2/5 the volume of cells (no more than 
100 ng/200 \i\ cells) and the cells incubated on ice for 30 minutes. The cells were heat 
shocked by placing at 42°C for 90 seconds then returned to ice for 2 minutes. 
Approximately 2 volumes of LB were added at room temperature and the cells then 
incubated at 37°C for 60 minutes with gentle shaking, to allow plasmid establishment. 
The culture was plated out onto agar plates, with the appropriate selection, and 
incubated for 30 minutes at 37°C, then the plates were inverted and the incubation 
continued overnight. A control culture was also performed whereby no DNA was 
added to the cells. This was plated out in the same manner (hence no colonies should 
form).
(iii) Plasmid preparation
Plasmid preparations were carried out on either a small or large scale, depending on the 
final quantity of DNA required. For small scale preparations, colonies from the above 
prepared agar plates (Section 2.8.7(H)) were innoculated into 10 ml of LB containing 
either ampicillin or tetracycline (50 ng/ml) and incubated for 4-6 hours at 37°C, with 
shaking. A Magic Minipreps DNA Purification System was used according to the 
instructions in the kit, to purify plasmid DNA. For large scale plasmid preparations the
initial 10 ml culture was grown up as described above, then added to 490 ml of LB and 
the incubation continued overnight. The culture was spun at 4000 rpm for 10 minutes, 
4°C, and the supernatant discarded. The plasmid DNA was then extracted from the 
bacterial pellet using a Qiagen Plasmid Kit, following the instructions for Maxi 
preparations. The concentration of DNA obtained was assessed as described in method 
2 .8 .2 .
(iv) Restriction endonuclease digestion
To 'release' the cDNA fragment from the plasmid in which it was contained a digest 
was performed. For this, purified DNA (volume equivalent to 1 ng) was mixed with 
the appropriate buffer (diluted 10-fold to its working concentration) and restriction 
endonuclease (1 U/ng DNA) in an eppendorf tube, ensuring that the enzyme did not 
exceed 10% of the final volume. After mixing thoroughly, the tube was placed at 37°C 
for 90 minutes. The reaction was stopped by placing the tube on ice and the sample 
analysed by agarose gel electrophoresis, as in method 2.8.3, with the undigested DNA 
included as a control.
When a double digest was carried out, both enzymes could be added together, provided 
that they shared a common buffer. If a separate buffer was required to ensure maximal 
efficiency of the second enzyme, then the sample buffer was adjusted after 60 minutes 
incubation with the first enzyme, and the incubation then continued at 37°C for a 
further 60 minutes with both enzymes.
(v) Purification of DNA from agarose
The fragment produced by restriction endonuclease digestion was excised from the 
agarose gel and purified using either a Geneclean Kit, designed to purify DNA of 
greater than 500 bp to 1.5 kb in length, or a Mermaid Kit, designed to purify DNA 
from 10 bp to 1 kb in length. Both kits utilise the fact that single and double stranded 
DNA is able to bind to the specially formulated silica matrix whilst DNA contaminants 
cannot. The resulting DNA was then analysed by agarose gel electrophoresis to ensure 
that it had been efficiently eluted from the silica matrix.
(vi) Verification of cDNA probes
cDNA probes require verification in terms of assuring that the probe is able to bind to 
the mRNA transcript of the correct size. This was carried out by labelling the cDNA as 
described in Section 2.8.8 and hybridising to a Northern blot filter, as in Section 2.8.9. 
The filter was then autoradiographed and the position of the resulting band(s) compared 
to the 18S and 28S ribosomal bands detected by staining the filter with 0.02% (w/v) 
methylene blue (Section 2.8.5).
2 .8 .8  Labelling of DNA
DNA was labelled using a Multiprime Kit based on the random sequence 
hexanucleotide priming method of Feinberg & Vogelstein (1983), using Klenow. Prior 
to labelling, the DNA sample (volume equivalent to 10-20 ng DNA) was diluted with 
sterile micronised water to give a final volume of 50 nl and heated at 95°C for 2-5 
minutes to denature the DNA, which was then added to the standard Multiprime 
reaction and labelled for 3-5 hours, at room temperature, using [a-32P]dCTP. The 
labelling reaction was terminated by the addition of 20 mM EDTA, and the volume 
made up to 100 [xl with water.
To measure the incorporation of radioactive label into the DNA, 1 \d of the reaction mix 
was spotted onto the centre of each of two 2.3 cm discs of Whatman DE81 ion 
exchange paper. The paper is ionically charged such that DNA will bind but 
unincorporated nucleotides do not. One disc was washed three times, for 5 minutes 
each wash, in 0.5 M Na2HPC>45 then rinsed in water and finally in absolute ethanol. 
Once dry, an approximation of the percentage incorporation could be made using a 
Series 900 mini monitor, but for an accurate assessment the filters were counted in a 
LKB 1209 Rackbeta liquid scintillation counter, using Optiphase HiSafe 3 scintillant.
2 .8 .9  Hybridisation
Prior to hybridisation, any residual methylene blue stain was removed from the surface 
of filters by washing in 0.2X SSPE, 1% (w/v) SDS for 15 minutes, with gentle 
agitation, according to the method of Herrin & Schmidt (1988). The prehybridisation 
solution was prepared as described below, and approximately 20 ml of the solution was 
used per hybridisation bottle. The filters were placed into the bottles with the
76
RNA/DNA side facing inwards, and incubated in a Hybaid rotary hybridisation oven, 
at 65°C overnight for Southern blots, and at 50°C for 3-5 hours for Northern blots and 
dot-blots. The labelled cDNA probe (Method 2.8.8) was denatured at 95°C for 5 
minutes, quenched on ice, then added to the prehybridisation mix and the blots 
incubated at the above temperatures overnight.
Following the overnight incubation, the hybridisation fluid containing the probe was 
removed and stored at 4°C for future re-use. Southern blot filters were washed at 
65°C, twice in 100 ml 2X SSPE, 0.5% (w/v) SDS for 15 minutes each wash, and once 
in 100 ml 0.2X SSPE, 0.5% (w/v) SDS for 10 minutes. Northern blot and dot-blot 
filters were washed twice in 100 ml 2X SSC, 0.5% (w/v) SDS, at 65°C, except when 
p-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probes were 
used, when higher stringency washes of 0.5X SSC, 0.1% (w/v) SDS were required. 
Blots were then wrapped in Saran Wrap and autoradiographed by exposing to X-ray 
film at -70°C, with an intensifying screen. Autoradiographs were analysed using a 
hand-held densitometer.
The radioactive probe was removed from the filters by placing them into a boiling 
solution of 0.1% (w/v) SDS and leaving until cool. Blots were then rinsed in 2X SSC, 
sealed in Saran Wrap and stored at 4°C.
Prehvbridisation solution /Northern and dot blots")
50% (w/v) Dextran sulphate 10 ml (10%)
Formamide 16.5 ml (33%)
Denhardt's solution was prepared by dissolving 1% (w/v) ficoll, 1% (w/v) PVP and 
1% (w/v) BSA in micronised water, filtering, and storing in aliquots at -20°C. A 
solution of 10 mg salmon sperm DNA/ml water was sheared by passing through a 19- 
gauge hypodermic needle several times. The solution was then denatured in a boiling 
water bath for 10 minutes, chilled quickly on ice, and stored at -20°C in small aliquots. 
The prehybridisation solution was then prepared by mixing all of the above reagents. 





10 mg/ml Salmon sperm DNA
10 ml (2X)
1.25 ml (0.5%) 
200 (xl (2 mM)
10 ml (10X) 
1 ml (0.2 mg/ml)
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Prehvbridisation solution f Southern blots")
30X SSPE
50X Denhardt's solution 
50% (w/v) Dextran sulphate 
20% (w/v) SDS 
10 mg/ml Salmon sperm DNA 
Water
10 ml (6X) 
5 ml (5x) 
5 ml (5%) 
2.5 ml (1%)
250 pi (50 Mg/ml) 
27 ml
The solution was made up as described above.
2.8.10 Reverse Transcription of RNA
RNA was reverse transcribed to form cDNA prior to amplification in the polymerase 
chain reaction (PCR). Approximately 320 ng of total RNA, prepared as in Method
2.8.1, was mixed in an eppendorf tube with 50 mM Tris-HCl (pH 8.3), 75 mM KC1,
3 mM MgCl2, 10 mM DTT, 0.5 mM each of dGTP, dATP, dTTP and dCTP, 1.5 pM 
pd(T)i2 -i8, 30 units RNAguard RNase inhibitor and 400 units M-MLV reverse 
transcriptase. The volume was made up to 30 pi with DEPC-water and the tube placed 
into a Perkin-Elmer Cetus DNA Thermal Cycler set at 37°C, for 60 minutes. When 
Superscript RNase H- reverse transcriptase was used in place of M-MLV, the order of 
addition of reagents and temperatures used were followed according to instructions.
The reaction was terminated by heating to 95°C for 10 minutes then placing on ice. 
Samples were either used directly in the PCR (Method 2.8.11), or were stored at -20°C 
for future use.
2.8.11 Amplification of DNA (Saiki et al., 1988)
Amplification was carried out in a final volume of 100 pi containing 2 pi of the above 
reaction mix (Method 2.8.10), 200 pM each of dGTP, dATP, dTTP and dCTP, 1 pM 
of each of two oligonucleotides, specific for the DNA sequence, 2.5 units Thermus 
aquaticus (Taq) DNA polymerase (Chein et a l , 1976), MgCl2 at its optimised 
concentration and IX buffer, specific for the Taq DNA polymerase used. The mixture 
was overlayed with 100 pi of mineral oil to minimise evaporation, and amplification 
carried out in the Perkin-Elmer Cetus DNA Thermal Cycler. The DNA was denatured at 
95°C, the oligonucleotides annealed at a temperature which depended on their
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composition, and the DNA extended at 72°C. The length of each stage of the reaction 
and the number of cycles required to achieved maximal amplification depended on the 
primers used. Finally, 10 id of the reaction mix was analysed by agarose gel 
electrophoresis, as in method 2.8.3. For a clearer resolution of bands, NuSieve 3:1 
agarose was used, according to instructions.
2.8.12 Quantification of the PCR (Wiesner, 1992)
RNA was reverse transcribed as outlined (Method 2.8.10) and amplified by PCR using 
method 2.8.11 and including 100 nCi [<x-32P]dCTP in the PCR reaction. At alternate 
cycles, 2 id of the reaction mix was removed and added to an eppendorf tube containing 
5 id of unlabelled PCR product, to facilitate visualisation of bands at early cycle 
number, and 3 [d water. Tubes were placed on ice to terminate the reaction and, once all 
samples had been collected, 1 id DNA loading dye was added and the samples loaded 
onto a 4% (w/v) NuSieve 3:1 agarose gel. Bands were visualised under UV light and 
excised from the gel, then placed into scintillation vials. To measure background levels 
of radioactivity, slices were cut from nearer to the anode. The vials were left at 80°C 
overnight to dry the gel slices, 500 id Optiphase HiSafe 3 added and counts made in a 
LKB 1209 Rackbeta liquid scintillation counter.
2.8.13 Sequencing
Sequencing reactions were performed using an AmpliTaq Cycle Sequencing Kit, which 
is based on the chain-termination DNA sequencing method (Sanger et al., 1977). 
Primers were end-labelled with [y-32P]dATP using T4 polynucleotide kinase. Both the 
forward and reverse primers for the DNA under examination were labelled, and the 
forward primer alone from the kit was used with the control DNA. The cycling reaction 
was spiked with an additional 0.5 id Taq DNA polymerase, and 1 fd [a-32P]dCTP, to 
enhance the result.
Samples were analysed by denaturing gel electrophoresis, for which a denaturing gel 
was constructed as described below. Two glass plates, which had been soaked in 2 M 
KOH overnight, were rinsed in water and cleaned using absolute ethanol then air-dried. 
The top plate was treated with dimethyldichlorosilane solution to prevent the gel from 
sticking, then cleaned with water and ethanol as before. The bottom plate was treated 
on the gel-side with a solution of 20 ml ethanol, 120 id glacial acetic acid and 200 |xl
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silane for 2 minutes, to facilitate the adherence of the gel, and was then cleaned once 
again with water and ethanol. The bottom plate was then prepared with spacers along 
its edges and the gel poured using the sliding plate technique. A shark's tooth comb 
was inserted into the gel upside-down and the plates clamped together until the gel had 
polymerised. Immediately prior to loading, the sequencing reactions were denatured at 
75°C for 2 minutes. The comb was placed in the gel the right way up and 5 *d of 
reaction mix loaded into each well. The gel was run in TBE buffer at 1200 V, 30 mA 
for the appropriate amount of time. The top plate was then levered off and the gel 
soaked in 10% (v/v) methanol, 10% (v/v) HAc for 20 minutes. Finally, the gel was 




40% (w/v) Acrylamide 10 ml
10X TBE 5 ml
16% (w/v) Ammonium persulphate 100 \x\
N,N,N',N'-Tetramethylethylenediamine (TEMED) 100 [xl
A 40% (w/v) solution of acrylamide was made by dissolving 38 g acrylamide (DNA- 
sequencing grade) and 2 g N,N'-methylenebisacrylamide in 100 ml water. This could 
be stored in the dark, at 4°C, for several weeks. The urea was then dissolved in the 
acrylamide solution and TBE by heating gently. The solution was cooled and, 
immediately prior to pouring the gel, the ammonium persulphate and TEMED were 
added.
2 .9  STATISTICAL ANALYSIS
Data was expressed as mean ± SEM and analysed using an unpaired or paired 
Student's T-test where the number of experiments included did not exceed five. Where 
six or more experiments were included for analysis, the Mann-Whitney U test or 
Wilcoxon signed-rank test were employed. Each data point was compared separately to 
the control and corrections were not made for any statistical errors which may have thus 
arisen.
CHAPTER THREE
SEX HORMONE MODULATION OF 
CYTOKINE EXPRESSION
3 .1  INTRODUCTION
The complex cellular interactions which occur during a normal inflammatory response 
appear to be governed, at least in part, by an equally complex array of inter- and 
intracellular mediators, including cytokines. The same factors are also likely to be 
involved in chronic inflammatory conditions such as RA. As was discussed in Chapter 
One, cytokine products such as IL-la, IL-lp, TNF-a, IL-6 and TGF-p have been 
detected in the synovial fluid and synovial membrane from RA patients (reviewed by 
Brennan et al, 1991), often in close proximity to areas of active joint destruction (Chu 
et al., 1992). The release of such cytokines by cells within the joint may contribute to 
the pathogenesis of the disease. IL lp  and TNF-a, for example, share a vast spectrum 
of biological effects including the release of degradative enzymes, osteoclast activation 
and fibroblast proliferation (reviewed by Dinarello, 1989). Both IL-1 and TNF-a can 
induce IL-6 release which may act to amplify the destructive processes initiated by the 
latter two cytokines, as well as contributing with its own effects (reviewed by Van 
Snick, 1990). In addition, the cytokine TGF-p is critical to both the induction and 
potentiation of immune and inflammatory responses and also to the reparative processes 
which follow (reviewed by Wahl et al., 1990).
The effect of sex hormones on cytokine production is not widely reported and the 
results that have appeared in the literature have been mainly concerned with hormonal 
modulation of bone cell cytokine expression and release. Therefore, experiments were 
designed to study the effects of the sex hormones oestrogen and testosterone on PBMC 
cytokine expression. PBMC were studied from pre-, peri- and postmenopausal female 
controls and RA patients in order to assess whether endogenous fluctuations in 
hormone levels also affect cytokine production. Cells were initially obtained from 
normal controls and cultured with various concentrations of 17p-oestradiol or 
testosterone. The release of IL-6 and TNF into the culture supernatant after 24 hours of 
incubation was studied by means of bioassays. Following this, a comparison was made 
between control and RA PBMC in terms of cytokine mRNA expression, using cDNA 
probes for IL lp , TNF-a, IL-6 and TGF-p. Cells were cultured for differing lengths of 
time with a range of oestrogen concentrations. In addition, the expression of prolactin 
mRNA was studied in response to oestrogen treatment. Prolactin has been termed a 
new cytokine as it has the potential to act on human lymphocytes which express 
specific receptors (Russell et al., 1984a), and these cells can then release a prolactin­
like substance (Montgomery et al., 1987) which also binds to the receptors on the 
surface of immune cells. It is thought to have an important role in immune function,
either per se, or through the induction of ODC and the subsequent production of 
poly amines (see Introduction, Section 1.8.5).
The release of oestrogen is under the control of FSH from the pituitary. As it is 
possible that an effect of hormones on the immune system may be via FSH rather than 
oestrogen itself, the effect of this hormone was studied on cytokine mRNA expression 
by PBMC obtained from normal male and female controls. PBMC were cultured for 24 
hours with a range of FSH concentrations and the expression of ILrlp, TNF-a, IL^6, 
TGF-p and prolactin mRNA studied.
The sex hormones have been reported to affect immune function although the 
mechanism is still unclear (see Introduction, Section 1.6). Cellular proliferation in 
response to exogenous stimuli is the basis of cell-mediated immunity. Therefore, 
PBMC from controls and RA patients were incubated for 72 hours with PHA, an anti- 
CD3 mAb, 11^2 or a combination of the latter two stimuli, alone or with 17p-oestradiol 
or testosterone at various concentrations. An IL-2 dysfunction has been reported in RA 
(Combe et a/., 1975; Emery et al., 1984), and the response of rheumatoid PBMC to 
PHA and anti-CD3 mAb have been reported to be abnormal (van den Brink et al., 
1992). Thus, by studying the proliferative response of both control PBMC and those 
from RA patients to these stimuli, as well as the expression and release of cytokines, in 
the presence and absence of sex hormones, it was hoped to gain more knowledge into 
the activity of rheumatoid immune cells and hormonal modulation of immune function.
3 .2  METHODS
3 .2 .1  The Effect of Oestrogen and Testosterone on PBMC Cytokine 
Production
PBMC were prepared from the peripheral blood obtained from normal male and female 
controls (Method 2.4.1) and resuspended in phenol red-free RPMI supplemented with 
10% (v/v) CS-FCS to a concentration of 1X106 cells/ml. Cells were aliquotted into a 
24-well plate at 1X106 cells/well and cultured for 24 hour at 37°C, 5% 00^95%  air, in 
the presence of medium alone (basal control), ethanol, at a dilution equivalent to that of 
the highest hormone concentration (vehicle control), 1 ng/ml LPS or 17a-oestradiol, 
17p-oestradiol or testosterone at final concentrations of 10_12-10-8 M. Following 24 
hours incubation, cells were pelleted by centrifuging the plate at 1200 rpm for 10 
minutes and the cell supernatants removed into 1.5 ml eppendorf tubes and stored at
-20°C prior to analysis. The IL-6 or TNF content of the supernatants was determined 
by bioassay (Method 2.5) with the values obtained spectrophotometrically and 
extrapolated from the relevant standard curve to give U/ml IL-6 or TNF, as described 
(see Methods 2.5.1 and 2.5.2).
3 .2 .2  The Effect of Oestrogen on Control and RA PBMC Cytokine 
mRNA Expression
PBMC were prepared from the peripheral blood obtained from male and female 
controls and RA patients (Method 2.4.1) and resuspended in either phenol red-free 
RPMI supplemented with 10% (v/v) CS-FCS or serum-free RPMI to a concentration of 
1X106 cells/ml. Cells were aliquotted into 5 cm2 petri dishes at 10X106 cells/dish and 
cultured at 37°C, 5% C02/95% air. In all experiments untreated cells were incubated 
with a vehicle control, consisting of ethanol at a dilution equivalent to that of the highest 
hormone concentration and treated cells consisted of those incubated with 17p- 
oestradiol at concentrations between 10'13 and 10-7 M. Additionally, in one experiment, 
the inactive enantiomer 17a-oestradiol was included at 10‘9 M, and in two experiments, 
LPS was included as a positive control, at a final concentration of 1 ng/ml.
Routinely, cells were harvested at 24 hours. In one experiment cells were harvested at 6 
and 24 hours and a time course was constructed with time points at 7,12, 24,48 or 72 
hours. To harvest cells the non-adherent cells were first removed into centrifuge tubes 
and the adherent cells then dislodged from the surface of the petri dish with a cell- 
scraper, using ice-cold PBS to facilitate the process. Both cell populations were 
combined and pelleted by centrifuging at 1000 rpm for 10 minutes. Cell pellets were 
lysed in Solution D (see Method 2.8.1) and stored at 4°C for up to 1 week. RNA was 
prepared using the guanidinium-isothiocyanate method (Method 2.8.1) and quantified 
(Method 2.8.2) prior to either Northern blotting (Method 2.8.5) or dot-blotting 
(Method 2.8.4). Cytokine cDNA probes were prepared (Method 2.8.7) and labelled 
(Method 2.8.8) before hybridising to the Northern blot and dot-blot filters (Method
2.8.9) which were then autoradiographed. Scanning densitometry was used to compare 
bands or dots for alteration of mRNA expression. Filters were stripped (see Method
2.8.9) and stored at 4°C between hybridisations.
3 .2 .3  The Effect of FSH on PBMC Cytokine mRNA Expression
PBMC were prepared from the peripheral blood obtained from normal male and female 
controls (Method 2.4.1) and resuspended in serum-free RPMI to a concentration of 
lXlO6 cells/ml. Cells were aliquotted into 5 cm2 petri dishes at 10X106 cells/dish and 
cultured at 37°C, 5% C02/95% air. Untreated cells were incubated with a vehicle 
control, consisting of ethanol at a dilution equivalent to that of the highest hormone 
concentration, and treated cells consisted of those incubated with FSH at concentrations 
between 1010 and 107 M. After 24 hours, cells were harvested, the RNA extracted and 
analysed by dot-blotting, and the filters hybridised to cytokine cDNA probes as 
described (Section 3.2.2).
3 .2 .4  The Effect of Testosterone and Oestrogen on Control and RA 
PBMC Proliferation
PBMC were prepared from the peripheral blood obtained from male and female 
controls and RA patients (Method 2.4.1) and resuspended in phenol red-free RPMI 
supplemented with 10% (v/v) CS-FCS to a concentration of 1X106 cells/ml (Method 
2.6). Cells were cultured with either a vehicle control, consisting of ethanol at a dilution 
equivalent to that of the highest hormone concentration, 109 M 17p-oestradiol or 
10*9 M testosterone, and either medium alone, an anti-CD3 mAb (aCD3) at a 1/100 
dilution, lpg/ml PHA, 500U/ml rhIL-2 or a combination of aCD3 and rhIL-2. After 72 
hours, cells were pulsed, harvested and counted (Method 2.6). Results were analysed 
as counts (CPM) obtained in the absence of oestrogen or testosterone, or a comparison 
was made between counts obtained with and without the addition of either hormone.
3 .3  RESULTS
3 .3 .1  The Effect of Oestrogen and Testosterone on PBMC Cytokine 
Production
The effect of oestrogen and testosterone on cytokine production by PBMC from normal 
male and female controls was assessed by bioassay in terms of EL-6 and TNF 
production (Method 3.2.1). The general pattern of EL-6 or TNF release was the same 
for male and female PBMC, and no obvious correlation was found between oral 
contraceptive use, menopausal status or stage of menstrus and cytokine production, in
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the absence or presence of sex hormones. Therefore, results obtained for male and 
female PBMC were combined, with the data from five separate IL-6 bioassays and six 
TNF bioassays pooled and analysed.
As shown in Figure 3.1 A and B, 1 (ig/ml LPS induced significant PBMC IL-6 and 
TNF release, with the basal production of IL-6 increased from 12860 to 143200 U/ml 
and basal TNF production increased from 47 to 1564 U/ml. Cytokine production in the 
presence of vehicle was not significantly different to that of the basal control (medium 
alone) with the respective levels of IL-6 being 14800 and 12860 U/ml and that of TNF 
being 35 and 47 U/ml. 17a-oestradiol, 17p-oestradiol and testosterone, at 
concentrations ranging from 10-12 to 10'8 M, had no significant effect on IL-6 or TNF 
production. There appeared to be some dose-related effect of testosterone with IL-6 and 
TNF release increased to 38680 and 70 U/ml, respectively, at 108 M, however this 
was found to be not significant when analysed using a paired Student's T-test.
3 .3 .2  The Effect of Oestrogen on PBMC TGF-p mRNA Expression
The effect of oestrogen on PBMC cytokine mRNA expression was initially studied by 
Northern blot analysis, as demonstrated in Figure 3.2, using a TGF-p cDNA probe. 
Both experiments (lanes 1-4 and 5-10) utilised PBMC from normal premenopausal 
female controls. Results demonstrated that the TGF-p cDNA probe annealed to two 
transcripts of 2.5 and 4.1 kb, corresponding to TGF-p 1 and TGF-p2, respectively 
(Madisen et al., 1988). PBMC were seen to express predominantly the TGF-pl 
transcript. In the first experiment there appeared to be a slight enhancement of TGF-p 
mRNA expression with 10*9 M 17p-oestradiol, as can be seen by comparing lanes 1 
(control) and 4 (17p-oestradiol). 109M was chosen to represent a physiological 
concentration of oestrogen. In contrast, 17a-oestradiol seemed to depress TGF-p 
mRNA expression (lane 3) and 1 pg/ml LPS had no effect (lane 2). However, this 
experiment involved incubating PBMC with the various stimuli for 6 hours in phenol 
red-free RPMI supplemented with 10% (v/v) CS-FCS, and CS-FCS, although devoid 
of endogenous steroids, contains growth factors, including TGF-p itself, which may 
mask any effect with LPS or oestrogen. Indeed, the basal level of TGF-p mRNA 
expression in RPMI containing CS-FCS (lane 1) was seen to be considerably higher 
than that in serum-free medium (lane 5) at 6 hours, and this level had declined further at 
24 hours (lane 8). Cells cultured in the serum-free medium appeared to demonstrate a 
considerable upregulation of TGF-p mRNA expression with 109 M 17p-oestradiol at 
24 hours (lane 10), whereas the same concentration of 17a-oestradiol had little effect at
6 (lane 6) or 24 hours (lane 9). Therefore, serum-free medium was used in all 
subsequent experiments studying hormonal modulation of PBMC cytokine mRNA 
expression.
As a result of a problem with the NaOH fixation of the filter prior to hybridising with 
the TGF-p probe, further hybridisations could not be carried out, hence the data were 
not normalised and the oestrogen effects seen could not be validated. Thus, the 
experiment was repeated and filters were hybridised to a range of cytokine probes and 
also to p-actin or GAPDH cDNA, to evaluate whether the results observed were 
genuine, or simply due to loading inaccuracies.
3 .3 .3  The Effect of Varying Incubation Times with Oestrogen on PBMC 
Cytokine mRNA Expression
Based on the preliminary results obtained with oestrogen, as described in Section
3.3.2, a time-course was carried out by incubating PBMC from a normal 
premenopausal female control with either medium alone or 10*9 M 17p-oestradiol, and 
assessing the mRNA expression at various time points by dot-blotting. Results in 
Figure 3.3D illustrate that 17p-oestradiol had no effect on the expression of TGF-p at 
either 7, 12, 24,48 or 72 hours. The filter was reprobed for IL-lp (A), IL-6 (B), 
TNF-a (C) and prolactin (E), all of which show the same pattern of mRNA expression, 
with oestrogen treatment of the cells being ineffective throughout. The filter was 
normalised by probing for the house-keeping gene, p-actin (Figure 3.3E inset), which 
showed equal loading.
3 .3 .4  The Effect of a Range of Oestrogen Concentrations on PBMC 
Cytokine mRNA Expression
It was considered that the negative results obtained from the time-course experiment 
may have been due to the use of an inadequate concentration of 17p-oestradiol, 
therefore a wider range of concentrations was tested. PBMC from a normal 
premenopausal female control were cultured for 24 hours with 10*7-10*13 M 17p- 
oestradiol, the results of which are shown in Figure 3.4. Hybridisation to IL-lp (A), 
IL-6 (B), TNF-a (C) and TGF-p (D) cDNA probes demonstrated identical patterns of 
mRNA expression, with an apparent potentiation at 10*10 and 10*13 M 17p-oestradiol 
(lanes 5 and 8, respectively). However, the results with p-actin (Figure 3.4D inset) also
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showed the same pattern of mRNA expression indicating that this was due to unequal 
loading and not to an effect of oestrogen on the PBMC.
3 .3 .5  The Effect of Oestrogen on Control and RA PBMC Cytokine 
mRNA Expression
Previous experiments failed to demonstrate an oestrogen effect using a range of 
hormone concentrations (Figure 3.4) and various incubation times (Figure 3.3). 
However, both experiments used PBMC from normal premenopausal female controls, 
therefore PBMC from a wider spectrum of controls and also RA patients were 
examined. Cells were incubated with 17p-oestradiol at concentrations of 1 O'8-10'12 M 
and the RNA analysed by dot-blotting and hybridising the filter to a range of cytokine 
cDNA probes. A GAPDH cDNA probe was used to normalise the data as it has been 
reported that p-actin can be induced by oestrogen (Hsu & Frankel, 1987). However, as 
Figure 3.6 illustrates, hybridisation to GAPDH and p-actin cDNA probes produced 
identical patterns of expression (E inset). Figures 3.5 and 3.6 illustrate the results 
obtained with PBMC from pre- and peri-menopausal female and male controls, 
whereas Figures 3.7 and 3.8 illustrate the results with PBMC from pre-, peri- and 
postmenopausal female and male RA patients. There is no evidence of an oestrogen 
effect on the mRNA expression of any cytokine tested, although the cells were 
responsive in culture as 1 pg/ml LPS induced an upregulation of both IL-6 (figure 
3.5B, lane 2) and TNF-a (Figure 3.5C, lane 2) mRNA expression at 6 hours. 
However, IL-lp (A), TGF-p (D) and prolactin (E) expression remained unchanged in 
the presence of LPS. To further assess the ability of PBMC maintained in serum-free 
medium to respond to an exogenous stimulus, proliferation to ConA was studied, and 
found to be comparable to that obtained with cells cultured in medium supplemented 
with serum (results not shown).
3 .3 .6  The Effect of FSH on PBMC Cytokine mRNA Expression
PBMC from a normal premenopausal female control were cultured for 24 hours with 
FSH at concentrations 10*7-10'10 M. Total cell RNA was analysed by dot-blotting and 
hybridising to EL-ip, IL-6, TNF-a, TGF-p and prolactin cDNA probes. As shown in 
Figure 3.9, FSH had no effect on the expression of any of the cytokines examined.
3 .3 .7  The Effect of Oestrogen and Testosterone on Control and RA 
PBMC Proliferation
The effect of 10-9 M oestrogen and testosterone on the proliferation of PBMC obtained 
from a range of RA patients and controls to various stimuli was assessed. There was 
considerable individual variation in the response to the stimuli tested, thus each 
individual was included as a separate data point. Initially proliferation to PHA, an anti- 
CD3 mAb (aCD3), EL-2 or a combination of aCD3 and IL-2 was compared for control 
and RA PBMC, in the absence of oestrogen or testosterone (Figure 3.10). An unpaired 
Student's T-test was employed to compare the response of control and RA cells and no 
statistical difference was found. In addition, neither 17p-oestradiol nor testosterone had 
any effect on the response of control or RA PBMC to the various stimuli, as shown in 
Figure 3.11. Basal proliferation increased slightly in the presence of the two hormones, 
from 584 to 1041 and 1173 CPM with oestrogen and testosterone, respectively, for 
control PBMC, and from 551 to 618 and 730 CPM with oestrogen and testosterone, 
respectively, for RA PBMC. However, this was not significant when analysed using a 
paired Student's T-test (results not shown).
3 .4  SUMMARY
The results showed that there was no effect of oestrogen or testosterone, at any of the 
concentrations tested, on control PBMC IL-6 or TNF-a production. There was also no 
effect of oestrogen or FSH on control or RA PBMC IL-lp, IL-6, TNF-a, TGF-p or 
prolactin mRNA expression, using a range of hormone concentrations and various 
incubation times. The cells were shown to be responsive in culture by the addition of a 
positive control (LPS). The conclusion of experiments investigating the effects of 
oestrogen and testosterone on control and RA PBMC proliferation was that neither of 
the sex hormones affected PBMC response to the stimuli included, and there was no 
difference in the response of PBMC from controls and RA patients to the stimuli when 
































Figure 3.1 The effect of oestrogen and testosterone on PBMC cytokine production
PBMC were obtained from normal male and female controls and cultured for 24 hours 
in medium alone (basal, B), 0.01% (v/v) ethanol (vehicle, V), 1 pg/ml LPS (L) or 17a- 
oestradiol, 17(3-oestradiol or testosterone at various concentrations. Supernatants were 
harvested and assayed for (A) IL-6 or (B) TNF content. Results are expressed as U/ml 
IL-6 or TNF with the data from five or six separate experiments pooled to give mean ± 
SEM, and analysed using a paired Student's T-test by comparing each treatment group 
to basal.
89
Figure 3.2 The effect of oestrogen on PBMC TGF-p mRNA expression
PBMC were obtained from two normal female controls and cultured in either phenol 
red-free RPMI supplemented with 10% CS-FCS (lanes 1-4) or in serum-free medium 
(lanes 5-10). Lanes 1-4 represent cells which were either untreated or treated with 1 
pg/ml LPS, 10’9 M 17a-oestradiol or 17p-oestradiol, respectively, for 6 hours. Lanes 
5-7 and 8-10 represent cells which were untreated or treated with 10'9 M 17a-oestradiol 
or 17p-oestradiol, respectively, for 6 (lanes 5-7) or 24 (lanes 8-10) hours. 9 pg total 
RNA was loaded onto each lane and analysed by Northern blotting. The filter was 
hybridised with a TGF-p cDNA probe and autoradiographed.
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Figure 3.3 The effect of varying incubation times with oestrogen on PBMC 
cytokine mRNA expression
PBMC were obtained from a normal female control and cultured with medium alone or 
10'9 M 17p-oestradiol for varying periods of time. Lanes 1, 3, 6 and 8 represent 
untreated cells at 7, 12, 48 and 72 hours, respectively. Lanes 2, 4, 5 ,7 and 9 represent 
oestrogen-treated cells at 7, 12, 24, 48 and 72 hours, respectively. Total RNA was 
analysed by dot-blotting and the filter was then hybridised to a range of cytokine cDNA 
probes and autoradiographed: (A) IL-lp; (B) IL-6; (C) TNF-a; (D) TGF-p and (E) 
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Figure 3.4 The effect of a range of oestrogen concentrations on PBMC cytokine 
mRNA expression
PBMC were obtained from a normal female control and cultured for 24 hours with 
varying concentrations of 17p-oestradiol or with medium alone. Lane 1 represents 
untreated cells and lanes 2-8 represent cells treated with 10‘7-1013 M 17p-oestradiol, 
respectively. Total RNA was analysed by dot-blotting and the filter was then hybridised 
to a range of cytokine cDNA probes and autoradiographed: (A) IL-lp; (B) IL-6; (C) 
TNF-a and (D) TGF-p. All samples were normalised with a p-actin cDNA probe as 
shown in (D) inset.
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Figure 3.5 Oestrogen modulation of cytokine mRNA expression by PBMC from 
pre- and perimenopausal female controls
PBMC were obtained from a normal premenopausal (lanes 7-11) or perimenopausal 
(lanes 1-6) female controls and cultured for 24 hours without stimulus (lanes 1 and 7) 
or in the presence of 10*8-1 0 12M (lanes 3-6) or lO M O 12 M (lanes 8-11) 17p- 
oestradiol, or for 6 hours with 1 pg/ml LPS (lane 2). Total RNA was analysed by dot- 
blotting and the filter was then hybridised to a range of cytokine cDNA probes and 
autoradiographed: (A) DL-lp; (B) IL-6; (C) TNF-a; (D) TGF-p and (E) prolactin. All 
samples were normalised with a GAPDH cDNA probe as shown in (E) inset.
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Figure 3.6 Oestrogen modulation of cytokine mRNA expression by PBMC from a 
male control
PBMC were obtained from a normal male control and cultured for 24 hours without 
stimulus (lane 1) or with 10'8-1 0 12M 17p-oestradiol (lanes 2-6). Total RNA was 
analysed by dot-blotting and the filter was then hybridised to a range of cytokine cDNA 
probes and autoradiographed: (A) IL-lp; (B) IL-6; (C) TNF-a; (D) TGF-p and (E) 
prolactin. All samples were normalised with p-actin and GAPDH cDNA probes as 
shown in (E) insets.
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Figure 3.7 Oestrogen modulation of cytokine expression by PBMC from pre- and 
postmenopausal female and male RA patients
PBMC were obtained from a premenopausal (lanes 1-5) and postmenopausal (lanes 9- 
11) female RA patient and from a male RA patient (lanes 6-8). Cells were cultured for 
24 hours without stimulus (lanes 1, 6 and 9) or with lO'MO'11 M (lanes 2-5) or 109 
and 10'11 M 17p-oestradiol (lanes 7 and 8 and lanes 10 and 11, respectively). Total 
RNA was analysed by dot-blotting and the filter was then hybridised to a range of 
cytokine cDNA probes and autoradiographed: (A) EL-ip; (B) IL-6; (C) TNF-a; (D) 
TGF-p and (E) prolactin. All samples were normalised with a GAPDH cDNA probe as 
shown in (A) inset.
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Figure 3.8 Oestrogen modulation of cytokine expression by PBMC from 
perimenopausal female and male RA patients
PBMC were obtained from a perimenopausal female RA patient (lanes 7-12) and from a 
male RA patient (lanes 1-6). Cells were cultured for 24 hours without stimulus (lanes 1 
and 7) or with 10_8-10'12M 17p-oestradiol (lanes 2-6 and 8-12). Total RNA was 
analysed by dot-blotting and the filter was then hybridised to a range of cytokine cDNA 
probes and autoradiographed: (A) EL-1 p; (B) IL-6; (C) TNF-a and (D) TGF-p. All 
samples were normalised with a GAPDH cDNA probe as shown in (D) inset.
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Figure 3.9 The effect of FSH on PBMC cytokine mRNA expression
PBMC were obtained from a normal female control and cultured for 24 hours in the 
absence of stimulus (lane 1) or with 10'7-10*10M FSH (lanes 2-5). Total RNA was 
analysed by dot-blotting and the filter was then hybridised to a range of cytokine cDNA 
probes and autoradiographed: (A) IL-lp; (B) IL-6; (C) TNF-a; (D) TGF-p and (E) 
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Figure 3.10 Proliferation of PBMC from controls and RA patients
PBMC were obtained from one pre- and one postmenopausal female and two male 
controls, and from three pre- and three postmenopausal female and three male RA 
patients. Cells were cultured with medium alone (control), 1 pg/ml PHA (PHA), 1/100 
dilution anti-CD3 mAb (aCD3), 500 U/ml rhIL-2 (IL-2) or aCD3 in combination with 
rhIL-2 (aCD3 + IL-2). After 72 hours cells were pulsed with [3H]thymidine for 4 
hours, harvested and counted, and proliferation assessed. Results are expressed as 
CPM, with the data for each individual included as a separate point, and analysed using 
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Figure 3.11 The effect of oestrogen and testosterone on control and RA PBMC 
proliferation
PBMC were obtained from one pre- and one postmenopausal female and two male 
controls, and from three pre- and three postmenopausal female and three male RA 
patients. Cells were cultured with medium alone (control), 1 pg/ml PHA (PHA), 1/100 
dilution anti-CD3 mAb (aCD3), 500 U/ml rhIL-2 (IL-2) or aCD3 in combination with 
rhIL-2 (aCD3 + IL-2), in the presence or absence of 10 9 M 17p-oestradiol or 10 9 M 
testosterone. After 72 hours cells were pulsed with [3H]thymidine for 4 hours, 
harvested and counted, and proliferation assessed. Results are expressed as CPM, with 
the paired samples representing cells cultured in the absence (-) and presence (+) of 




4 .1  INTRODUCTION
Chapter Three discussed the findings of experiments investigating the effect of sex 
hormones, in particular oestrogen, on PBMC cytokine production, at the protein and 
transcriptional level, and on PBMC proliferation. The results obtained were negative, 
which questioned the activity of the 17p-oestradiol used and the expression of ER by 
the cells. There are few reports of ER expression by cells of the immune system, and 
those studies cited in the literature have concentrated on the detection of ER protein 
rather than mRNA expression. For example, oestrogen binding sites were detected on 
human leukaemic cells (Danel et al., 1981) and later on human PBMC (Danel et al., 
1983), in particular it appeared that the CD8+ T cell population was ER positive with 
CD4+ cells being negative (Cohen etal., 1983; Stimson, 1988). ERs have also been 
demonstrated on a human monocytic cell line and on rat peritoneal macrophages 
(Gulshan et al., 1990). However, a recent review doubted previous findings as 
attempts to demonstrate the expression of mRNA in T cells were unsuccessful (Lahita, 
1990).
Experiments were designed based on the necessity to validate previous negative results. 
In the first instance the efficacy of 17p-oestradiol used in studies reported in Chapter 
Three was assessed using cell lines known to be either oestrogen responsive or 
unresponsive, namely the breast carcinoma cell lines, ZR-75, T-47D and Hs578T. The 
ZR-75 (Engel et al., 1978) and T-47D (Keydar et al., 1979) cell lines are ER-positive 
and oestrogen-responsive, whereas the Hs578T cell line is ER-negative and oestrogen- 
unresponsive (Hackett et al., 1977). The proliferation of the three cell lines was studied 
in response to 17p-oestradiol and the less active enantiomer, 17a-oestradiol. In 
addition, the anti-oestrogen, tamoxifen, was used to determine the specificity of cell 
responses to oestrogen.
Secondly, the expression of ER by PBMC, both from controls and RA patients was 
assessed in order to attempt to clarify contradictions in the literature. The cell lines 
discussed above were included as positive and negative controls, and, as the joint is the 
centre of activity in RA, synovial fibroblasts and sections of RA synovial tissue were 
also studied. The initial investigations of sex hormone receptors published in the 
literature involved the use of binding assays using radiolabelled steroid, in particular the 
dextran-coated charcoal assay. However, this is an indirect measurement and does not 
allow for the discrimination between heterogeneous cell populations. In addition, 
contamination of samples with other steroid-binding proteins could bias results. The 
necessity for more sensitive and specific ER detection methods for breast carcinoma
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evaluation led to the development of the immunocytochemical assay (ICA), using 
specific anti-ER mAbs. However, initial studies carried out as part of this project, with 
a mAb reported to be directed against human ER, proved unsuccessful, as the antibody 
reacted non-specifically with all cells tested.
The Abbott ER-ICA kit, which employs the H222 mAb to recognise a portion of the 
ER molecule separate from the oestrogen-binding site, has provided an efficient and 
specific ER detection system and is now used routinely for diagnostic purposes (Allred 
et al., 1990). H222 was one of a range of ER-specific mAbs which enabled the nuclear 
localisation of the ER to be determined and which hence led to the disproval of the 
'two-step' model for oestrogen action (see Introduction, Section 1.2.2) (King & 
Greene, 1984; Greene & Press, 1986). Applications for the H222 mAb do not seem to 
be limited to the detection of ER in breast tumour cells and oestrogen-responsive 
tissues, in that it has been used to detect ER in human osteoclasts (Pensler et al., 1990). 
Therefore, the ER-ICA kit was employed with ZR-75 and Hs578T cell lines, PBMC, 
synovial fibroblasts and synovium sections. Flow cytometry provides a means of 
accurately distinguishing, qualitatively and quantitatively, between cell populations 
expressing specific antigenic markers, by labelling with fluorescent conjugates. Thus, a 
modification of the paraformaldehyde-saponin procedure (Sander et al., 1991) was 
employed, as the ER is present intracellularly, and the above cell types were labelled 
with the H222 mAb and examined by FACS analysis.
The expression of ER in cells and tissues which are thought of as being 'non-oestrogen 
responsive', such as cells of the immune system, is hampered by the very low 
concentration of receptor sites. The use of the H222 mAb for immunocytochemistry 
and flow cytometry proved to be unsuccessful and therefore a more sensitive means of 
detecting the limited number of ER was sought. An antibody has been described which 
coprecipitates radiolabelled ER from human breast tumour and endometrial preparations 
(Coffer et al., 1985a). The ER-D5 antibody was raised in mice against a partially 
purified ER preparation from human myometrium and was found to recognise a 29 kD 
cytoplasmic serine phosphoprotein (p29), which is distinct from the ligand binding unit 
of ER (Coffer & King, 1988). p29 appears to be closely associated with the ER in that 
there was a strong correlation between ER-D5 binding and ER sites in a series of 
human breast tumours (Coffer et al., 1985b), and the antigen has been shown to be at 
least as effective as ER in predicting the hormone sensitivity of breast tumours (Cano et 
al., 1986). As p29 is thought to be present at approximately one thousand times the 
concentration of ER in oestrogen-responsive tissues, and the ER-D5 was successful in 
detecting ER in human bone-derived cells where the H222 mAb failed (Colston et al.,
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1989), ER-D5 was used with cells and sections in the APAAP immunocytochemical 
assay and cells were also examined by FACS analysis.
The use of the antibody ER-D5 to detect p29 antigen may provide a sensitive method in 
situations where ER protein is below the detection limit of conventional anti-ER 
antibodies, but the specificity of this antigen has yet to be confirmed. Therefore, as an 
alternative to studying the expression of ER protein, ER mRNA expression was 
investigated. Greene et al. (1986) published the sequence for human ER cDNA and 
from this a cDNA probe was designed which hybridised to the 6.2 kb ER mRNA 
transcript of MCF-7 cells and coded for the synthesis of immunoreactive 65 kD ER. 
The ER cDNA was used with mRNA from bone cells to detect an ER mRNA transcript 
of 6-6.2 kb (Eriksen etal., 1988; Komm et al., 1988). Therefore, to analyse ER 
mRNA expression, total RNA was obtained from PBMC and from the cell lines 
ZR-75, T-47D and Hs578T, and Northern blotted. The filter was hybridised to an ER 
cDNA probe and analysed by autoradiography.
In recent years, the PCR has gained precedence as an extremely sensitive method for 
amplification of a specific cDNA sequence by the use of two primers which flank the 
sequence of interest. Reverse transcription provides the ability to produce single­
stranded cDNA from total RNA, hence the two techniques can be combined, RT-PCR, 
to enable the detection of small amounts of mRNA. In addition, RT-PCR has been used 
for the detection of ER mRNA, and has gained application in situations where Northern 
blot analysis was unsuccessful (Hirata et al., 1992; Liu et al., 1992). Using this 
information, specific primers were designed based on the human ER cDNA sequence, 
and RNA from PBMC, synovial fibroblasts and cell lines was reverse transcribed and 
amplified using the oligonucleotide primer set, in an attempt to detect the presence of 
ERmRNA.
4 .2  METHODS
4 .2 .1  The Effect of Oestrogen on ZR-75, T-47D and Hs578T Cell 
Proliferation
Confluent ZR-75, T-47D and Hs578T cells were trypsinised, washed twice in the 
relevant culture medium and resuspended in phenol red-free RPMI supplemented with 
10% (y/v) CS-FCS to a concentration of 1X106 cells/ml (Method 2.6). Cells were 
cultured with either a vehicle control, consisting of ethanol at a dilution equivalent to
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that of the highest hormone concentration, or 10'7-10'13 M 17a-oestradiol or 17(3- 
oestradiol, with each test performed in triplicate. After 72 hours, cells were pulsed, 
harvested and counted (Method 2.6). Results were analysed as average counts (CPM) 
for each triplicate and the effect of oestrogen on cell proliferation assessed.
4 .2 .2  The Effect of Tamoxifen on Oestrogen-Induced ZR-75 Cell 
Proliferation
Confluent ZR-75 cells were trypsinised, washed twice in the relevant culture medium 
and resuspended in phenol red-free RPMI supplemented with 10% (v/v) CS-FCS to a 
concentration of lXlO6 cells/ml (Method 2.6). Cells were cultured with either a vehicle 
control, consisting of ethanol at a dilution equivalent to that of the highest hormone 
concentration, 109 M 17p-oestradiol, or with tamoxifen alone, at a concentration of 
10'5 M, or in combination with 109 M 17p-oestradiol, at concentrations 10*n -10’5 M, 
with each test performed in triplicate. After 72 hours, cells were pulsed, harvested and 
counted (Method 2.6). Results were analysed as average counts (CPM) for each 
triplicate and the effect of tamoxifen on basal cell proliferation and oestrogen-induced 
cell proliferation assessed.
4 .2 .3  Northern Blot Analysis of ER mRNA Expression
Total cell RNA was prepared from freshly purified PBMC obtained from a normal 
female control, and from confluent ZR-75, T-47D and Hs578T cells (Method 2.8.1) 
and was Northern blotted (Method 2.8.5). The ER cDNA probe was prepared from 
pER35 (Method 2.8.7), labelled (Method 2.8.8) and hybridised to the Northern blot 
filter. A modified method of hybridisation was used, whereby the filter was added to a 
prehybridisation solution (5X SSPE, 5X Denhardt's, 0.5% (w/v) SDS, 50% (v/v) 
formamide, 20 pg/ml salmon sperm DNA) and incubated at 50°C for 5 hours. The 
labelled ER cDNA probe was then added to the prehybridisation mix and the filter 
incubated at 42°C overnight. After removing the hybridisation solution containing the 
probe, the filter was washed at 65°C, twice in I X SSPE, 0.1% (w/v) SDS for 15 
minutes each wash, and twice in 0.1X SSPE, 0.1% (w/v) SDS for 10 minutes each 
wash, then autoradiographed.
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4 .2 .4  Southern Blot Analysis of ER cDNA
1 i^g plasmid DNA containing ER cDNA was subjected to a restriction nuclease 
digestion to release the ER cDNA insert, and electrophoresed on a 0.8% (w/v) agarose 
gel with XHE as a marker, and Southern blotted overnight (Method 2.8.6). The filter 
was hybridised to an ER cDNA probe (Method 2.8.9), prepared and labelled as 
described (Methods 2.8.7 and 2.8.8), and autoradiographed.
4 .2 .5  Designing Oligonucleotide Primers for the Amplification of ER 
cDNA
Hirata et al. (1992) reported the amplification of ER cDNA utilising a primer set which 
flanked the oestrogen binding domain region of rat ER cDNA. Based on this, 
oligonucleotide primers were designed which corresponded to the same region of the 
human ER cDNA sequence (Greene et al., 1986) and synthesised by Colin Lazarus 
(Bristol University, Bristol, UK). The forward primer (hE 101 IS) 5'-CAGTGAAGCT 
TCGATGATGG-3' (nucleotides 1011-1030) and the reverse primer (hE1297AS) 5- 
ATGATGTAGCCAGCAGCATG-3' (nucleotides 1297-1278) frame a 287 bp-long 







4 .2 .6  Analysis of ER mRNA Expression by RT-PCR
Total cell RNA prepared from a range of cell types including control and RA PBMC, 
synovial fibroblasts and the cell lines ZR-75, T-47D and Hs578T, was reverse 
transcribed using either M-MLV or Superscript reverse transcriptase (Method 2.8.10). 
The single stranded cDNA obtained was amplified during 32 cycles with Taq DNA 
polymerase and the gene-specific primers hElOl IS and hE1297AS by PCR (Method





2.8.11). Each cycle consisted of denaturation at 95°C for 1 minute, annealing at 55°C 
for 1 minute and extension at 72°C for 1 minute. The annealing (or melting) 
temperature (Tm) was calculated using the following equation:
Tm= 81.5 - 16.6(Logi0[Na+]) + 0.41 (%G+Q - (600/N)
The PCR product was analysed by agarose gel electrophoresis.
Taq DNA polymerase from NBL was supplied with a 10X buffer containing 15 mM 
MgCl2 , whereas that obtained from Promega Ltd. or Perkin Elmer Ltd. was supplied 
with a MgC^-free buffer, and thus a MgCl2  titration was carried out in order to 
determine the optimal concentration required for each enzyme. This was achieved by 
amplifying ZR-75 cell cDNA by PCR, as described above, in a reaction mixture 
containing 0-6 mM MgCl2 , with the concentration giving optimal DNA amplification 
chosen for use in all subsequent reactions.
4 .2 .7  Purification of Individual PCR Products by Band-Stab PCR
To purify two separate products occurring as individual bands in the same PCR 
reaction, a band-stab PCR method was employed (Bjourson & Cooper, 1992). This 
comprised of electrophoresing the product through a 4% (w/v) NuSieve low melting 
temperature agarose gel, stained with ethidium bromide, which was then viewed on a 
UV transilluminator. The appropriate bands were stabbed with a sterile hypodermic 
needle which was subsequently inserted into a reaction mix containing all PCR 
components except the DNA (Method 2.9.11). The two products were re-amplified and 
analysed as before.
4 .2 .8  Sequencing ER cDNA
ZR-75 cell RNA was reverse transcribed and amplified with the gene specific primers, 
hElOllS and hE1297AS, designed to flank a 287 bp region of the human ER 
hormone-binding domain, as described (see Section 4.2.6). The cDNA product was 
then sequenced, using end-labelled forward and reverse oligonucleotide ER primers 
(Method 2.8.12).
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4 .3  RESULTS
4 .3 .1  The Effect of Oestrogen on ZR-75, T-47D and Hs578T Cell 
Proliferation
To assess the effectiveness of the active enantiomer, 17p-oestradiol, in comparison to 
the less active enantiomer, 17a-oestradiol, the proliferation of cell lines reported to be 
either ER-positive or -negative was studied. Following 72 hours culture with 
10‘13-10'7M 17a-oestradiol the proliferation of T-47D and Hs578T cells remained 
unchanged, as shown in Figure 4.1B and C, respectively. 17p-oestradiol had a 
tendency to suppress the proliferation of these two cell lines, which was significant 
(p<0.05) at 10-11 M for T-47D (B) and at 1042 and 1040 M for Hs578T (C). In 
contrast, the proliferation of ZR-75 cells was increased with concentrations of 17p- 
oestradiol from 1041 to 10_7 M (Figure 4.1A). A maximum was reached at 10'8 M 17p- 
oestradiol of 180% compared to the control, significant at p<0.001. With respect to 
17a-oestradiol, at concentrations below 10-8 M ZR-75 cell proliferation was 
suppressed, and this inhibition was found to be significant ,when comparing to the 
basal control, at 1042 M (p<0.05) and 1040 M (p<0.01) (Figure 4.1A). Concentrations 
of 10'8 M 17a-oestradiol and above were stimulatory, with proliferation reaching a 
significant level of approximately 155% at 10'7 M (p<0.05), when comparing to the 
control value. The potency of the 17a- enantiomer was approximately 100-fold lower 
than that of 17p-oestradiol.
4 .3 .2  The Effect of Tamoxifen on Oestrogen-Induced ZR-75 Cell 
Proliferation
The specificity of the proliferative response of ZR-75 cells to 17p-oestradiol was 
assessed by culturing the cells with either 1040 or 10'9 M 17p-oestradiol, previously 
shown to produce a sub-maximal effect (Figure 4.1 A), in the presence of tamoxifen at 
concentrations ranging from 1041 to 10-5 M. As illustrated in Figure 4.2, tamoxifen 
inhibited the response to both 10~9 (A) and 1040 M (B) 17p-oestradiol. The effect with 
the higher oestrogen concentration, 10-9 M, was more variable (Figure 4.2A), in that 
the lowest (1041 M) and highest (10-5 M) tamoxifen concentrations studied caused 
significant inhibition of ZR-75 cell proliferation in response to oestrogen of 50% 
(p<0.01) and 110% (p<0.05), respectively, whereas the inhibition achieved at 
concentrations between 1041 and 10-5 M tamoxifen varied between 20 and 80% and 
was not significantly different to the control with oestrogen alone. By using a lower
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concentration of 17p-oestradiol to induce ZR-75 cell proliferation (10*10M), significant 
inhibition was seen with 10'6 M tamoxifen (p<0.05) (Figure 4.2B). At lower 
concentrations of tamoxifen a potentiation of the effect of 10'10M 17p-oestradiol was 
seen, which was significant at 10-9 M tamoxifen (pcO.OOl).
4 .3 .3  Immunocytochemical Analysis of ER Expression by Cells and 
Synovial Sections
The expression of ER was studied using an immunocytochemical assay kit from Abbott 
Laboratories Ltd. (ER-ICA). ERs are detected by way of a specific rat anti-ER mAb, 
H222, which is complexed to a bridging anti-rat IgG antibody and hence to a 
peroxidase/anti-peroxidase complex. Finally a chromogen-substrate solution containing 
hydrogen peroxide and diaminobenzidine 4 HC1 is added to allow visualisation of the 
receptors. Synovial fibroblasts, PBMC, ZR-75 and Hs578T cells and sections of RA 
synovial tissue were prepared and examined using the kit. The control slides supplied 
for use with the ER-ICA kit gave positive reddish-brown nuclear staining of varying 
intensities with the H222 antibody (Figure 4.3A (+)), compared to negative staining 
obtained from incubation with the control antibody (normal rat antibody) (Figure 4.3A 
(-)). Positive staining was also seen with the H222 mAb using preparations of ZR-75 
cells which had been maintained in oestrogen-supplemented medium (Figure 4.3B (+)), 
although slightly less intense than that obtained with cells on the control slide, whereas 
ZR-75 cells which were cultured in oestrogen-depleted medium for 7 days failed to 
demonstrate ERs (Figure 4.3C (+)). The relevant negative staining for ZR-75 cells, 
with control antibody, is shown in Figures 4.3B and C (-). Hs578T were essentially 
negative, as shown in Figure 4.3D, and incubation of PBMC from controls or RA 
patients with the H222 mAb also failed to detect expression of ER. An example of the 
negative results obtained are illustrated with PBMC from a female RA patient (Figure 
4.3E). In addition, staining of synovial fibroblasts and RA synovium with the ER-ICA 
kit gave negative results (Figures 4.3F and G, respectively). Attempts to visualise ER 
using the H222 mAb by FACS analysis were unsuccessful with all cell types and 
studies using a different anti-ER mAb resulted in a high level of non-specific staining, 
hence this latter antibody could not be used in further experiments (results not shown).
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4 .3 .4  Preparation of Cells for FACS Analysis of ER Expression
Examination of ER expression by FACS analysis involves permeabilising the cell 
membrane prior to incubating with the anti-ER mAb, as the receptor occurs 
intracellularly. The saponin-permeabilisation technique did not significantly alter cell 
morphology, as illustrated by the dot plots of granularity (side scatter, SSC) versus size 
(forward scatter, FSC) in Figure 4.4 for ZR-75 cells (A), Hs578T cells (B), synovial 
fibroblasts (C) and PBMC (D). To ensure that cells were permeabilised using this 
method, PBMC were incubated with antibodies directed against two intracellular 
proteins, namely centromere and topoisomerase. Figure 4.5B demonstrates that the 
cells were indeed permeabilised as a result of saponin treatment as there was a 
significant increase in fluorescence with the two antibodies compared to that with the 
control antibody, whereas neither of the antibodies bound to non-permeabilised cells 
(Figure 4.5A). Cells were routinely fixed with 1% (w/v) paraformaldehyde following 
preparation for FACS analysis, prior to analysis. Figure 4.6 illustrates that PBMC 
morphology, in terms of size and granularity, was not altered by this fixation method. 
This applied to all cell types studied (results not shown).
Prior to the analysis of fluorescence changes as a result of labelling with specific mAbs, 
cells which had been incubated with control antibody were observed, and a 
homogeneous cell population selected. This was achieved by gating the area of greatest 
fluorescence intensity, as shown in Figure 4.7 for ZR-75 cells (A), Hs578T cells (B), 
synovial fibroblasts (C) and PBMC (D). With PBMC preparations, the aim was to 
select the T cell/monocyte population and exclude any contaminating cell types, such as 
PMNL. The purity of the gated cells was assessed by staining with an anti-CD3 mAb. 
This demonstrated that the majority of the PBMC included within the gate were T cells 
and hence stained positively with the anti-CD3 mAb (Figure 4.7D). Very few T cells 
were excluded, and the non-T cell population included within the gated region was a 
minority and assumed to be monocytes.
4 .3 .5  The Expression of p29 Antigen by Cells and Synovial Sections
The failure of the H222 mAb to detect ER in all but the ZR-75 cell line led to the use of 
the ER-D5 mAb, which recognises a 29 kD human-specific cytoplasmic, non-hormone- 
binding protein associated with the ER. Cells were examined by FACS analysis 
following the saponin-permeabilisation method of preparing cells, and all cell types 
studied were gated as described in Section 4.3.4. Figure 4.8 illustrates histograms of
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fluorescence intensity. Saponin-permeabilised ZR-75 cells (A), Hs578T cells (B), 
synovial fibroblasts (C) and PBMC (D) all stained positively with the ER-D5 mAb 
(second peak), shown as a shift in fluorescence compared to that with the control 
antibody (first peak). All results depict the change in fluorescence with a 1/10 dilution 
of ER-D5, therefore a comparison can be made in terms of cellular expression of the 
p29 antigen. In this respect, the order of expression of the p29 antigen was seen to be: 
ZR-75 cells > synovial fibroblasts > Hs578T cells > PBMC. In contrast there was no 
change in the basal level of fluorescence with ER-D5 mAb when cells used were non- 
permeabilised. Therefore, the expression of the p29 antigen is exclusively intracellular.
The results obtained for p29 expression by FACS analysis were comparable to those 
obtained by immunocytochemistry. Cells and RA synovial tissue were prepared and 
stained with the ER-D5 mAb using the APAAP technique. Intense cytoplasmic staining 
was seen with ZR-75 cells (Figure 4.10A (+)) and synovial fibroblasts (Figure 4.10E 
(+)), with the expression of p29 greater in the former cell type. All cells tested with the 
ER-D5 mAb were also incubated with a control antibody, which consistently produced 
negative results (Figure 4.10 (-)). PBMC from both controls and RA patients incubated 
with ER-D5 showed weak staining which appeared to be more diffuse than with ZR-75 
cells or synovial fibroblasts. The staining was more intense for the female RA patient 
(Figure 4.10D (+)) than for the female control (Figure 4.10C (+)) illustrated, in this 
instance, although in general no trend was seen for male and female controls and RA 
patients of various ages using the APAAP procedure. When synovial tissue sections 
from a postmenopausal female RA patient were tested with the ER-D5 mAb, specific 
areas of positive and negative staining were seen (Figure 4.1 OF (+)). There was weak, 
diffuse staining of the synovial lining layer and endothelial cells appeared to be negative 
for p29 expression. In contrast, there were intense areas of staining which occurred in 
distinct clusters of infiltrating cells and which seemed to be cell-specific. This was 
observed in sequential sections and thus was unlikely to be artefactual (results not 
shown).
4 .3 .6  FACS Analysis of p29 Antigen Expression by Control and RA 
PBMC
A comparison was made between p29 expression in PBMC from RA patients and age- 
and sex-matched normal controls. Cells were prepared for FACS analysis using ER-D5 
mAb at dilutions ranging from 1/6.25 to 1/100 and the results obtained as either % 
positive cells or MFI. In contrast to the results illustrated in Figure 4.10C and D
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showing APAAP staining of control and RA PBMC with the ER-D5 mAb, the 
expression of p29 antigen in RA PBMC was seen to be considerably less than that with 
control PBMC, at all mAb dilutions, in terms of the number of cells expressing the 
antigen (% positive cells) (Figure 4.9A) or the number of antigenic sites per cell (MFI) 
(Figure 4.9B). However, when comparing control and RA data using a Mann-Whitney 
U Test, only the 1/100 dilution of ER-D5, when considering MFI, showed a significant 
difference (p<0.05) (Figure 4.9B).
4 .3 .7  Analysis of ER mRNA Expression by Northern Blotting and RT- 
PCR
As attempts to localise ER protein in PBMC and synovial fibroblasts were 
unsuccessful, except for the demonstration of the ER-related antigen p29, experiments 
were carried out to investigate ER mRNA expression. RNA was prepared from ZR-75, 
T-47D and Hs578T cells and control PBMC and Northern blotted. The filter was 
hybridised to an ER cDNA probe which initially failed to detect any mRNA species, 
although a Southern blot constructed with ER plasmid DNA and hybridised to the ER 
cDNA demonstrated that the probe was capable of hybridising to itself (Figure 4.11). A 
GAPDH probe was used to ensure that the RNA had not been removed from the 
surface of the Northern blot filter. Figure 4.12A demonstrates that the filter was able to 
hybridise to the GAPDH cDNA and that the RNA was therefore intact. Hence, various 
hybridisation techniques were tested with the Northern blot filter, and one procedure 
was successful in detecting a very faint band which corresponded to the 6.2 kb 
transcript for ER mRNA (see Method 4.2.3) (Figure 4.12B). The band was seen for 
ZR-75 cells only. Further purification of total RNA to poly(A) RNA (ie. mRNA 
enriched) did not improve the ability of the ER cDNA to hybridise (results not shown).
RT-PCR has been developed as an extremely sensitive method for detecting gene 
expression at the RNA level. Oligonucleotide primers designed to frame a 287 bp 
segment of human cDNA within the oestrogen-binding domain (see Method 4.2.4) 
were initially tested using human ER-containing plasmid DNA, which resulted in a 
PCR product of the expected size (results not shown). Therefore, RNA from ZR-75, 
T-47D and Hs578T cells, synovial fibroblasts and from both control and RA PBMC 
was prepared and reverse transcribed to single stranded cDNA which was then 
amplified by the PCR, using this set of oligonucleotide primers. As shown in Figure 
4.14A the expected 287 bp fragment was amplified from both the ZR-75 and T-47D 
cell lines (lanes 1-3 and lane 6, respectively), whereas no product was amplified for the
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Hs578T cell line (lane 4). A PCR reaction with no RNA or DNA added was also 
negative (results not shown). PBMC RNA reverse transcribed and amplified to give the 
287 bp fragment and a slower migrating species was also detected (lane 5). ZR-75 cells 
demonstrated the greatest amount of product. Synovial fibroblast RNA also showed a 
287 bp fragment on amplification (Figure 4.14B). RNA from a range of premenopausal 
and male controls was analysed with the results demonstrated in Figure 4.15A and B, 
with the amount of the 287 bp product obtained differing between donors. PBMC RNA 
from one of the female controls gave two bands (Figure 4.15A, lane 5) and with two of 
the male control PBMC samples the 287 bp fragment was either undetectable (Figure 
4.15B, lane 4), or present at only a very low level (Figure 4.15B, lane 3). RA PBMC 
also demonstrated the RT-PCR 287 bp product (Figure 4.15C), although bands were 
too faint to determine whether there were any quantitative differences in expression 
between the peri- and postmenopausal female and male patients examined.
The unavailability of NBL Taq polymerase enzyme after initial RT-PCR experiments 
resulted in the use of Promega and then Perkin-Elmer Taq polymerase enzymes. The 
NBL enzyme was supplied with a MgCl2-containing buffer, whereas the latter were 
supplied with MgC^-free buffers. Hence MgCl2 titrations were carried out, with 
concentrations ranging from 0.5 to 6.0 mM. As demonstrated in figure 4.13A and B, a 
concentration of 1.5 mM MgCl2 gave optimal amplification of ZR-75 cDNA, and thus 
this was used for all PCR reactions with these two enzymes. Interestingly, 
concentrations of Perkin-Elmer Taq polymerase enzyme above 1.5 mM also resulted in 
a second slower-migrating species (Figure 4.13B). Initial experiments used M-MLV 
reverse transcriptase, but as the RNase H- Superscript reverse transcriptase enzyme 
was more efficient in terms of the amount of final product achieved after PCR (Figure 
4.13C), this was used for later experiments.
The 287 bp fragment amplified from ZR-75 cells was sequenced and found to be 
identical to the corresponding region of the human cDNA (Greene et al., 1986) (results 
not shown). An attempt was made to separate, and hence sequence, the two products 
seen with certain PBMC samples using a band-stab PCR method (see Method 4.2.6). 
However, this consistently resulted in one PCR product. Alternative methods of 
purification were also unsuccessful and therefore the identity of the unknown PCR 
product could not be assessed. Further analysis of ER mRNA expression using the RT- 
PCR method was hindered by experimental difficulties, and attempts to quantify the 
PCR and hence make direct comparisons between the level of ER mRNA expression in 
different cell types were also unsuccessful (results not shown).
4 .4  SUMMARY
Results demonstrated that the ZR-75 cell line responded to 17p-oestradiol in a dose- 
dependent manner, with an increase in proliferation. The 17a-enantiomer also 
stimulated ZR-75 cell proliferation, but was approximately 100-fold less active. Neither 
the T-47D orHs578T cell lines proliferated in response to 17a- or 17p-oestradiol. The 
proliferative response of ZR-75 cells in response to 17p-oestradiol was inhibited with 
the anti-oestrogen tamoxifen. ER was detected in ZR-75 cells at the protein and mRNA 
level, whereas with T-47D cells, ER protein could not be detected although the mRNA 
was present. Hs578T cells were ER-negative. ER mRNA was detected in both control 
and RA PBMC and in synovial fibroblasts, but the protein was undetectable with the 
assay systems employed. Using a mAb directed against an ER-related protein, p29, all 
cells tested demonstrated positivity to a certain extent. When comparing PBMC from 
normal controls and RA patients, the rheumatoid cells appeared to express less p29, 
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Figure 4.1 The effect of oestrogen on ZR-75, Hs578T and T-47D cell 
proliferation
ZR-75, Hs578T and T-47D cells were cultured with 10 13-10-7 M 17a- or 17|3- 
oestradiol. After 72 hours incubation cells were pulsed with [3H]thymidine, harvested, 
counted and proliferation assessed. Tests was performed in triplicate and the three 
values (CPM) combined to give an average. The control, ie. 72 hour proliferation in the 
absence of hormone, was set at 100% and results are expressed relative to this. Each 
point represents the mean ± SEM of five or six separate experiments. Data was 
analysed using a paired Student's T-test by comparing to the control value.
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Figure 4.2 The effect of tamoxifen on oestrogen-induced ZR-75 cell proliferation
ZR-75 cells were cultured with (A) 10’9 M 17p-oestradiol or (B) 10 10 M 17p-oestradiol 
in the presence or absence of 10_11-10-5 M tamoxifen. After 72 hours incubation cells 
were pulsed with [3H]thymidine, harvested, counted and proliferation assessed. Tests 
were performed in triplicate and the three values (CPM) combined to give an average. 
The negative control, ie. cells cultured in the absence of 17p-oestradiol and tamoxifen, 
was set at 100%, and the positive control, ie. cells cultured in the presence of 17p- 
oestradiol alone, was set at 0%. All data was then expressed as % inhibition relative to 
this. Each point represents the mean ± SEM of two or three separate experiments. Data 
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Figure 4.3 Detection of oestrogen receptor in cells and synovial sections
ZR-75 cells maintained in oestrogen-supplemented medium (B) or oestrogen-depleted 
for 7 days (C), Hs578T cells (D), PBMC (E), synovial fibroblasts (F) and RA synovial 
tissue (G) were stained with an anti-ER mAb (H222) (+) or a control antibody (-), 
using an Abbott ER-ICA kit. Results were compared with those obtained with control 
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Figure 4.4 The effect of saponin permeabilisation on cellular integrity
(A) ZR-75 cells, (B) Hs578T cells, (C) synovial fibroblasts and (D) PBMC were either 
non-permeabilised or were saponin-permeabilised, prior to being incubated with mouse 
IgG followed by an anti-mouse IgG FITC-conjugate, and cellular integrity determined 








Figure 4.5 Assessing the effectiveness of saponin permeabilisation
PBMC were either (A) non-permeabilised or (B) saponin-permeabilised prior to being 
incubated with anti-topoisomerase or anti-centromere antibodies at 1/100 dilution, or 
the equivalent concentration of human IgG, followed by an anti-human IgG FITC- 
conjugate. Cells were then examined by FACS analysis. Results are expressed as 
histograms of fluorescence intensity, with the first peak representing the control IgG 
and the second peak representing the test antibody.
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Figure 4.6 The effect of paraformaldehyde fixation on cellular integrity
PBMC were incubated with mouse IgG followed by an anti-mouse IgG FITC- 
conjugate and were either examined by FACS analysis immediately (A), or were fixed 
with 1% (w/v) paraformaldehyde prior to analysis (B). Results are expressed as dot- 
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Figure 4.7 Obtaining a homogeneous cell population for FACS analysis
Cells were prepared for FACS analysis and, prior to observing fluorescence intensities 
with the mAbs under examination, a homogeneous cell population was selected. This 
was achieved by observing a dot-plot of side scatter (SSC) versus forward scatter 
(FSC) and setting a gate which encompassed the area of greatest cellular intensity. 
Results demonstrate typical homogeneous cell populations selected for (A) ZR-75 cells,
(B) Hs578T cells, (C) synovial fibroblasts. PBMC were compared after incubating 
with control antibody (Neg.) or anti CD3 mAb (CD3), with the gate set for the control 
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Figure 4.8 FACS analysis of the cellular expression of p29 antigen
(A) ZR-75 cells, (B) Hs578T cells, (C) synovial fibroblasts and (D) PBMC were either 
untreated or saponin-permeabilised prior to being incubated with ER-D5 mAb at 1/10 
dilution, or the equivalent concentration of mouse IgG, followed by an anti-mouse IgG 
FITC-conjugate. Cells were then examined by FACS analysis. Results are expressed as 
histograms of fluorescence intensity, with the first peak representing the control IgG 
and the second peak representing the mAb.
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Figure 4.9 FACS analysis of p29 antigen expression in control and RA PBMC
PBMC were obtained from pre-, peri- and postmenopausal female and male RA 
patients and age-and sex-matched healthy controls. Cells were saponin-permeabilised 
and incubated with ER-D5 mAb at varying concentrations, or mouse IgG at a 
concentration equivalent to the highest mAb dilution, followed by an anti-mouse IgG 
FITC-conjugate. Cells were then examined by FACS analysis. Each dilution was 
performed in duplicate and the two values obtained were combined to give an average. 
Results are expressed as (A) % positive cells, relative to the control IgG which is set at 
5%, or (B) mean fluorescence intensity (MFI), which has been corrected for the control 
IgG. Each point is the mean ± SEM of six separate experiments. Data was analysed 
using the Mann-Whitney U test by comparing values for the RA group to those for the 
controls.
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Figure 4.10 Detection of p29 antigen in cells and synovial sections
ZR-75 cells (A), Hs578T cells (B), PBMC from a control (C) and an RA patient (D), 
synovial fibroblasts (E) and RA synovial tissue (F) were stained with ER-D5 mAb, 
directed against p29 antigen (+), or a control antibody (-), using an APAAP procedure. 




Figure 4.11 Southern blot analysis of oestrogen receptor cDNA
Oestrogen receptor plasmid DNA was Southern blotted and the filter was hybridised to 
cDNA obtained from the same plasmid, labelled as a probe, and autoradiographed. 
Lane 1 represents XHE marker and lane 2 represents the oestrogen receptor plasmid 
DNA.
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Figure 4.12 Detection of oestrogen receptor mRNA by Northern blot analysis
Total cell RNA was obtained from control PBMC (lane 1), Hs578T cells (lane 2), 
ZR-75 cells (lane 3) or T-47D cells (lane 4). 10 pig RNA was loaded onto each lane and 
















Figure 4.13 Optimisation of conditions for the RT-PCR
Total cell RNA was obtained from ZR-75 cells and (C) reverse transcribed using either 
Superscript (lane 2) or M-MLV (lane 3) reverse transcriptase, then amplified in a PCR 
using specific oligonucleotide primers designed from the published sequence of the 
human ER cDNA to flank a region within the DNA-binding domain. Reverse 
transcribed ZR-75 cell RNA was amplified with either (A) Promega or (B) Perkin- 
Elmer Taq polymerase with MgCh concentrations ranging from 0-4 mM ((A) lanes 2- 
10) or 0-6 mM ((B) lanes 2-11), using ER-specific primers. 10 j j .1 of the PCR reaction 
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Figure 4.14 Detection of oestrogen receptor mRNA by RT-PCR
Total cell RNA was obtained from (A) ZR-75 cells (lanes 1-3), Hs578T cells (lane 4), 
control PBMC (lane 5) and T-47D cells (lane 6), and from (B) synovial fibroblasts 
(lanes 2 and 3). RNA was reverse transcribed then amplified in a PCR using specific 
oligonucleotide primers designed from the published sequence of the human oestrogen 
receptor cDNA to flank a region containing the DNA-binding domain. 10 pi of the PCR 
reaction was run on each lane against Hae III digested <t>X-174-RF DNA marker ((A) 


















Figure 4.15 Detection of PBMC oestrogen receptor mRNA by RT-PCR
Total cell RNA was prepared from PBMC obtained from (A) premenopausal female 
controls (lanes 3-5), (B) male controls (lanes 2-4) and (C) perimenopausal (lane 4) and 
postmenopausal (lane 5) female and male (lane 3) RA patients. RNA was reverse 
transcribed then amplified in a PCR using specific oligonucleotide primers designed 
from the published sequence of the human oestrogen receptor cDNA to flank a region 
containing the DNA-binding domain. ZR-75 cell RNA was included as a positive 
control ((A) and (C) lane 2). 10 |il of the PCR reaction was run on each lane against 
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SEX HORMONE MODULATION OF 
INTEGRIN EXPRESSION
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5 .1  INTRODUCTION
Adhesion molecules play a crucial role in mediating interactions between cells, and also 
between cells and the extracellular matrix, the integrins are one of three major families 
of adhesion molecules able to function in such interactions. The integrin superfamily 
exist as heterodimers, with non-covalently associated a- and p-subunits (reviewed by 
Springer, 1990; Hogg, 1991; Hynes, 1992). In RA it is thought that the infiltration and 
perpetuation of inflammatory cells in the joint is mediated, at least in part, by adhesion 
molecules such as the integrins (reviewed by Panayi, 1993). Moreover, certain of the 
receptors and their ligands have been shown to be upregulated on inflammatory cells 
and endothelial cells by inflammatory mediators, such as the cytokines IL-1 and TNF 
(reviewed by Pober & Cotran, 1990). This may contribute to the increase in cell 
migration into the synovium and synovial fluid. The upregulation of certain of the VLA 
integrins on infiltrating cells would also increase interactions with the extracellular 
matrix and with other cells (reviewed by Shimizu & Shaw, 1991) and hence contribute 
to the retention of these cells within the joint (see Introduction, Section 1.7).
In Chapter Four, ZR-75 cells were cultured in the presence and absence of oestrogen in 
order to assess the effect on ER expression. During the period of oestrogen-depletion a 
change in cellular growth and morphology was observed. Oestrogen is required to 
maintain ZR-75 cell growth under normal culture conditions and has been shown to 
induce proliferation of these cells (see Section 4.3.1). However, the alteration in 
morphology, in terms of loss of adherence, reduced granularity and colony formation, 
was unexpected. It was hypothesised that these changes, in particular the loss of 
adherence, might be due to a change in the level of certain adhesion molecules. As the 
VLA integrins are known to mediate cellular interactions with extracellular matrix 
components such as laminin, fibronectin and collagen (reviewed by Hogg, 1991; 
Hynes, 1992), the expression of these molecules, in terms of specific a- and p- 
subunits, was assessed in cells cultured in the absence and presence of oestrogen. For 
this purpose FACS analysis of cells incubated with a range of anti-integrin subunit 
mAbs was carried out. Integrin expression was examined at various time points after 
transferring the cells to oestrogen-depleted conditions, and also after reculturing the 
cells in oestrogen-supplemented medium following a period of oestrogen-deprivation.
Adhesion molecules play a crucial role in the immune system, both in mediating 
specific cellular interactions (reviewed by Springer, 1990), and in regulating the 
migration of immune cells within various microenvironments (reviewed by Shimizu & 
Shaw, 1991). In this respect, PBMC would be expected to express a wide range of
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adhesion molecules, including several members of the integrin family. In addition, this 
spectrum of adhesion molecules would differ depending on the percentage of certain 
cell types within the PBMC population, as each cell type has its own array of such 
molecules which enable cell-specific interactions to occur. Therefore, apart from 
investigating which integrin subunits were expressed on resting control PBMC, T cells 
and monocytes were purified and incubated with the same range of mAbs, and the 
spectrum of integrin subunits expressed by the two cell populations ascertained by 
FACS analysis.
The observation that ZR-75 cell morphology was dependent on the presence of 
oestrogen and thus that, prima facie, sex hormones may be involved in the control of 
integrin expression, raised the question, was oestrogen able to differentially regulate 
integrin expression by PBMC in controls and RA patients? If so, then this would have 
important implications for the cellular interactions occurring in both the normal and 
pathogenic state. Oestrogen has been reported to modulate integrin expression in bone 
cells (Medhora et al., 1991; Chiba et al., 1992) and endothelial cells (Cid etal., 1992). 
However, there are no such reports of a sex hormone effect on immune cell integrin 
expression. Therefore, experiments were designed to compare basal levels of the 
integrin subunits on PBMC from control and RA patients, and then to reassess the 
expression of the various subunits following culture of the cells with and without 
oestrogen. Results were analysed with respect to each individual subunit expressed by 
the cells and its role in mediating cell-cell and cell-extracellular matrix interactions.
5 .2  METHODS
5 .2 .1  The Effect of Oestrogen-Depletion on ZR-75 Cell Morphology
ZR-75 cells were routinely cultured in RPMI supplemented with 10% (v/v) FCS and 
10‘9 M 17p-oestradiol (Method 2.4.3). To assess the effect of oestrogen-depletion on 
ZR-75 cell morphology, cells were transferred to phenol red-free RPMI supplemented 
with 10% (v/v) CS-FCS alone, or with 10'9 M 17a-oestradiol or 10'9 M 17p-oestradiol. 
Cells were cultured for up to 10 days, passaging when confluent (Method 2.4.4) but 
maintaining the oestrogen-depleted or oestrogen-supplemented culture conditions. 
Morphology was examined on a daily basis by phase-contrast microscopy.
To assess the recovery of ZR-75 cell morphology following oestrogen-depletion, cells 
were either maintained in phenol red-free RPMI supplemented with 10% (v/v) CS-FCS
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and 10"9 M 17p-oestradiol or were cultured for 7 days in oestrogen-depleted conditions 
and then transferred into oestrogen-supplemented medium and cultured for a further 7 
days. Cells were examined daily by phase-contrast microscopy.
5 .2 .2  The Effect of Oestrogen-Depletion on ZR-75 Cell Integrin Subunit 
Expression
Integrin subunit expression on ZR-75 cells was evaluated for cells maintained in normal 
culture conditions (Method 2.7.1). ZR-75 cells were then transferred to oestrogen- 
depleted or oestrogen-supplemented medium as described in Section 5.2.1. After 7 or 
10 days, cells were harvested and incubated with antibodies directed against the integrin 
subunits known to be expressed under normal culture conditions, then examined by 
FACS analysis. Data were collected as % positive cells or MFI, with the latter being 
converted to sites per cell (Method 2.7.3). In addition, a time course was carried out by 
culturing ZR-75 cells with and without oestrogen and observing changes in integrin 
expression at 1, 3 and 7 days, as before. All cells were then transferred back into 
oestrogen-supplemented medium and the 'recovery' of integrin expression analysed, 
again at 1,3 and 7 days. Comparisons for the time course of changes in integrin 
subunit expression and 'recovery' were made as sites per cell.
5 .2 .3  Analysis of Integrin Subunit Expression by T Cells and 
Monocytes
PBMC were prepared from peripheral blood of a normal female control (Method 2.4.1) 
and further purified as described (Method 2.4.2) to give T cell and monocyte cell 
populations. Cells obtained were analysed for their integrin subunit expression by 
incubating with mAbs directed against subunits previously shown to be expressed on 
resting PBMC from a normal female control, followed by incubation with an anti-IgG 
FITC-conjugate. T cells and monocytes were dual labelled with anti-CD3 or anti-CD 14 
R-phycoerythrin-conjugated antibodies, respectively (Method 2.7.1). Controls 
consisted of cells incubated with either the anti-integrin mAbs and anti-IgG FITC 
conjugate, or with the R-phycoerythrin antibodies, and a negative control was 
performed by incubating with second antibody, ie. fluorochrome, only. Data were 
obtained by FACS analysis by comparing the expression of FITC to that of R- 
phycoerythrin and hence determine the spectrum of integrin subunit expression for each 
of the cell populations.
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5 .2 .4  The Effect of Oestrogen on Control and RA PBMC Integrin 
Subunit Expression
PBMC were prepared from peripheral blood obtained from male and female controls 
and RA patients (Method 2.4.1) and resuspended in phenol red-free RPMI 
supplemented with 10% (v/v) CS-FCS to a concentration of 1X106 cells/ml. Cells were 
cultured in 10 cm2 petri dishes with either a vehicle control, consisting of ethanol at a 
concentration equivalent to that of the highest hormone concentration, or 10'9 M 170- 
oestradiol, for 48 hours. Cells were harvested by removing the supernatant and 
incubating with Versene for approximately 5 minutes, 4°C, to enable collection of the 
adherent cells from the surface of the petri dish. Adherent cells were combined with the 
supernatants and cells pelleted by centrifuging at 1000 rpm for 5 minutes. Integrin 
subunit expression was assessed by FACS analysis (Method 2.7.1), with data obtained 
as % positive cells or MFI, and the latter subsequently converted to sites per cell 
(Method 2.7.3).
5 .3  RESULTS
5 .3 .1  The Effect of Oestrogen on ZR-75 Cell Morphology
ZR-75 cells were transferred from their normal oestrogen-supplemented culture 
conditions to an oestrogen-depleted environment and observed over a period of 10 
days. The change from RPMI supplemented with 10% (v/v) FCS to phenol red-free 
RPMI supplemented with 10% (v/v) CS-FCS itself did not alter cell growth and 
morphology, as can be seen in Figure 5.1 by comparing ZR-75 cells under normal 
culture conditions (A), to ZR-75 cells grown for 7 days in the oestrogen-depleted 
medium, but with 109 M 170-oestradiol added (B). 10 9 M is the concentration of 170- 
oestradiol routinely added to ZR-75 cell cultures to maintain cell growth, and previous 
experiments have demonstrated that this produces sub-maximal cell proliferation (see 
Section 4.4.1). 109 M 17a-oestradiol also maintained cell integrity over a 7 day period 
(Figure 5.1C). However, when oestradiol was omitted from the culture medium for a 
total of 10 days, there was an inhibition of ZR-75 cell growth and the cells were seen 
to become less adherent (Figure 5. ID). In contrast to the cells maintained in oestrogen- 
supplemented culture conditions which formed large granular colonies and rapidly 
became confluent, cells grown in oestrogen-depleted medium became less granular and 
less adherent, formed only small colonies or existed as single cells in suspension, and
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hence did not reach confluence. The change in morphology was gradual with a 
difference noted at day 7. These changes appeared to be maximal by day 10.
A more detailed time-course demonstrated that at day 1 both cell cultures exhibited 
similar morphology with cells settling after passaging (Figure 5.2A). ZR-75 cells 
which were grown under oestrogen-depleted conditions showed little change in growth 
or morphology at day 3 (Figure 5.2B (-)). By day 7, there was a certain degree of 
colony formation, but many of the cells were non-adherent and cell growth was 
noticeably reduced (Figure 5.2C (-)). In contrast, ZR-75 cells grown in phenol-red free 
RPMI supplemented with 10% (v/v) CS-FCS were virtually all adherent by day 3, with 
considerable cell growth and colony formation (Figure 5.2B (+)), and 7 days post- 
passaging the cells were virtually confluent (Figure 5.2C (+)).
To assess whether the change in ZR-75 cell growth and morphology following a 7 day 
period of oestrogen-depletion was reversible, cells were transferred to phenol red-free 
RPMI containing 10-9 M 17p-oestradiol, and compared to those cells which had been 
maintained in the latter medium throughout. After 1 day under these culture conditions 
there was little change in cell growth (Figure 5.3A (-/+)), whereas by day 3 almost all 
cells were adherent and there was a significant increase in growth and colonisation 
(Figure 5.3B (-/+)). The two cell populations were indistinguishable by day 7 (Figure 
5.3C), with the ZR-75 cells transferred from oestrogen-depleted to oestrogen- 
supplemented conditions having almost reached confluence.
5 .3 .2  FACS Analysis of ZR-75 Cell Integrin Subunit Expression
A possible explanation for the alteration in ZR-75 cell morphology and the loss of 
adherence, as a result of oestrogen-depletion, was that the culture conditions 
determined integrin subunit expression by the cells. Therefore, ZR-75 cells were 
screened with a range of anti-integrin subunit antibodies, to determine which subunits 
were being expressed by the cells maintained under normal culture conditions, prior to 
investigating whether this expression was altered during oestrogen-deprivation. Cells 
were examined by FACS analysis, first selecting a homogeneous cell population (see 
Section 4.4.4), and the fluorescence obtained with the specific mAbs then compared to 
that of the control antibody. This illustrated that the subunits a2, a3, a6 and pi were 
constitutively expressed on ZR-75 cells, whereas staining for a l, a4, a5 and aV 
subunits was negative (Figure 5.4). Titrations were made with each of the positively 
staining mAbs, to give saturating concentrations for use in subsequent experiments
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(Figure 5.5). A 1/100 dilution was seen to give saturation of binding sites for each of 
the mAbs (Figure 5.5A-D).
5 .3 .3  The Effect of Oestrogen on ZR-75 Cell Integrin Subunit 
Expression
ZR-75 cells were cultured for 7 or 10 days in phenol red-free RPMI supplemented with 
10% (v/v) CS-FCS alone, or with the addition of 10*9 M 17p-oestradiol. Integrin 
subunit expression was assessed for the two cell populations, as described above 
(Section 5.3.2). Results obtained for the oestrogen-depleted cells were expressed as a 
percentage of those for the cells maintained in the presence of 109 M 17p-oestradiol. As 
shown in Figure 5.6, depriving the cells of oestrogen resulted in a significant 
downregulation of a6 expression (p<0.001). In contrast, the expression of a2, a3 and 
pi was unaltered. The downregulation occurred in terms of the number of ZR-75 cells 
expressing a6 (% positive cells) (Figure 5.6A) and the number of ot6 sites per cell 
(Figure 5.6B). However, the maximal suppression in terms of % positive cells 
occurred at day 10, with levels reduced to 30% control (ie. 70% inhibition), compared 
to only 60% inhibition at day 7. In contrast, the depression of a6 sites per cell was 
maximal by day 7, with 75% inhibition of control levels, and this degree of inhibition 
was unchanged at day 10.
Further examination of the downregulation of ZR-75 cell a6 sites per cell in oestrogen- 
depleted culture conditions revealed that after only 1 day in culture without oestrogen 
there was a 30% inhibition, which was increased to 50% by day 3 and was maximal by 
day 7 at 60% (Figure 5.7A). After 7 days, the ZR-75 cells were transferred back to 
oestrogen-supplemented medium to assess the 'recovery' of a6, in terms of number of 
sites per cell of this integrin subunit. Figure 5.7B demonstrates that a6 expression 
returns to the normal level, ie. that seen for ZR-75 cells which had been maintained in 
medium supplemented with 109 M 17p-oestradiol, with the recovery being complete by 
day 7, although a certain degree of upregulation of a6 was seen at days 1 and 3. 
Preliminary data obtained suggested that incubation of ZR-75 cells with 10'10M 17p- 
oestradiol and 106M tamoxifen also resulted in downregulation of a6 expression, 
further indicating that the modulation of integrin expression was a direct result of 
oestrogen deprivation (results not shown).
The Hs578T cell line are ER-negative and hence oestrogen unresponsive. It was 
hypothesised that a6 expression may be constitutively lower in these cells, and
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therefore a comparison was made between the ZR-75 and Hs578T cell lines, in terms 
of basal integrin expression. The results presented in Table 5.1 demonstrate that the 
Hs578T cell line has a different pattern of integrin expression, with all subunits tested 
shown to be positive. Whereas the expression of the a3 and pi subunits was very 
similar between the two cell types, expression of a l and a6 was considerably lower in 
the Hs578T cells.
Integrin Expression (sites per cell)
subunit ZR-75 (n=6) Hs578T (n=2)
al Negative 40921 (5590)
a2 376968 (78067) 17478 (862)
a3 205339 (36793) 207406 (32409)
a4 Negative 37894 (1100)
a5 Negative 17190 (2606)
a6 88355 (17391) 31688 (6480)
aV Negative N.D.
PI 596103 (98571) 475662 (51427)
Table 5.1 ZR-75 cell and Hs578T cell basal integrin subunit expression
ZR-75 and Hs578T cells were incubated with a range of antibodies directed against 
integrin subunits, diluted 1/50, or with an appropriate dilution of control antibody, 
followed by an anti-IgG FITC conjugate. Cells were examined by FACS analysis, with 
the data obtained as MFI which was subsequently converted to sites per cell. Results 
tabulated represent the means (SEM) of two or six separate experiments.
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5 .3 .4  FACS Analysis of Control and RA PBMC Integrin Subunit 
Expression
Following the observations with ZR-75 cell integrin expression in the presence and 
absence of oestrogen, the effect of oestrogen on PBMC integrin subunit expression 
was examined, using PBMC from normal male and female controls and RA patients.
As with the ZR-75 cells, initial experiments were performed to determine the integrin 
subunits expressed on resting cells, for which control PBMC were employed. This 
revealed significant expression of the subunits a4, a6, ocL, aM, pi and p2, whereas a2 
and a3 were detectable at only very low levels and the staining for a l, a5 and p3 was 
essentially negative (Figure 5.8). Therefore, the former six were chosen for subsequent 
investigations. MAb titrations demonstrated that a 1/50 dilution of the antibodies was 
sufficient to produce saturation of binding sites (Figure 5.9).
In an attempt to gain more information as to the integrin subunit expression of specific 
cell types within the PBMC population, T cells and monocytes were negatively selected 
following incubation with specific antibodies directed against either monocytes and B 
cells, or T and B cells, respectively. Each cell population was then dual-labelled with 
the anti-integrin subunit mAbs described above and an antibody directed against the cell 
population of interest. Results were analysed as the percentage of cells expressing both 
fluorochromes compared to the percentage of cells expressing either FITC or R- 
phycoerythrin. Gates were initially set on the negative control which consisted of cells 
incubated with fluorochrome alone. T cells were shown to express all integrin subunits 
present on PBMC. The p2 and aL subunits were present on approximately 70-80% of 
T cells, pi, a4 and aM on approximately 50%, 40% and 25% cells, respectively, and 
a6 on only 10% of all T cells (Figure 5.10A). In contrast, p2 and aM subunits were 
detected on 75-85% of monocytes, with the expression of pi and aL being 60-70% and 
the levels of the subunits a4 and a6 were negligible (Figure 5.10B).
5 .3 .5  The Effect of Oestrogen on Control and RA PBMC Integrin 
Subunit Expression
Prior to assessing whether control and RA PBMC respond differently to oestrogen, in 
terms of patterns of integrin expression, basal levels of a4, a6, aL, aM, pi and p2 
subunits were compared on control and RA PBMC. In addition, an anti-a5 mAb was 
included as there is some indication that the a4 and a5 integrins may be important in T 
cell accumulation within the joint in RA, via binding to fibronectin (Garcia-Vicuna et
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a l 1992; Rodriguez e ta l , 1992). Although in initial experiments screening PBMC for 
a range of integrin subunits, a5 was not expressed (Figure 5.8), the later studies 
showed that although the number of a5 binding sites per cell is low (Figure 5.1 IB), 
there are a significant number of positively staining cells (Figure 5.11 A). When 
comparing control and RA cells, the pi subunit was seen to be significantly lower on 
RA PBMC (P<0.05), in terms of % positive cells or sites per cell (Figure 5.11A and 
B), and the otL subunit was also lower on RA PBMC, but this was only significant 
when considering sites per cell (p<0.05) (Figure 5.1 IB). With the exception of the 
number of a6 sites per cell, all integrin subunits were constitutively lower on RA than 
control PBMC. The variable number of experiments included in Figure 5.11 was due to 
exclusion of the anti- a5 mAb in earlier experiments and the failure of a4 and otL 
antibodies to bind to cells in one particular experiment.
To evaluate the effect of oestrogen treatment on control and RA PBMC integrin 
expression, cells were cultured for 48 hours with or without 10*9M 17p-oestradiol. 
Cells were then examined for expression of the integrin subunits shown to be present 
on resting control PBMC (see Section 5.3.4). For ZR-75 cells, the oestrogen-depleted 
population were considered to be the treatment group and the integrin expression of 
these cells was compared to that of the cells maintained in medium supplemented with 
109M 17p-oestradiol. However, as it was the effect of oestrogen on PBMC integrin 
expression which was under observation, results with the oestrogen-treated group were 
compared to those of the oestrogen-depleted group. Preliminary results obtained by 
comparing integrin expression on resting PBMC to the expression following 48 hours 
of culture suggested that oc4, pi and ctL expression was increased on culturing cells, 
whereas aM expression was reduced slightly and a6 and p2 remained unchanged 
(results not shown). Figure 5.12 illustrates that integrin expression was essentially 
unchanged in the PBMC cultured with 109M 17p-oestradiol, compared to cells cultured 
in medium alone. The aM subunit appeared to be significantly higher on RA than 
normal PBMC following oestrogen treatment (p<0.05) (Figure 5.12B). However, the 
low number of experiments included make these results somewhat tenuous.
5 .4  SUMMARY
Results demonstrated that ZR-75 cells cultured under oestrogen-depleted conditions 
became less adherent, with a general reduction in cell growth and colony formation 
observed. This was reversible following reculture in oestrogen-supplemented medium. 
Changes in morphology were associated with a significant inhibition of a6 subunit
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expression by ZR-75 cells, whereas the levels of the other subunits constitutively 
expressed remained unchanged. The subsequent reculturing of the cells in the presence 
of oestrogen was sufficient to cause the upregulation of a6 expression to levels 
comparable with those seen under normal culture conditions. PBMC expressed a 
different spectrum of integrin subunits to ZR-75 cells, and within the PBMC 
population, T cells and monocytes also differed in terms of levels of these subunits. 
Examination of the basal levels of the subunits on resting PBMC from normal controls 
and RA patients revealed a slight suppression in RA patients. However, oestrogen had 
no effect on the integrin expression of control or RA PBMC.
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Figure 5.1 Continued..
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Figure 5.1 The effect of oestrogen on ZR-75 cell morphology
ZR-75 cells were cultured for 7 days in (A) RPMI supplemented with 10% FCS and 
10*9 M 17p-oestradiol, or phenol-red free RPMI supplemented with 10% CS-FCS and 
10"9 M 17p-oestradiol (B) or 10*9 M 17a-oestradiol (C), or in the absence of oestrogen 












Figure 5.2 Time-course for modulation of ZR-75 cell morphology
ZR-75 cells were transferred from RPMI supplemented with 10% FCS and 10*9 M 170- 
oestradiol to phenol-red free RPMI supplemented with 10% CS-FCS and were cultured 
for (A) 1 day, (B) 3 days or (C) 7 days in the presence (+) or absence (-) of 10'9 M 
170-oestradiol. Cell morphology was observed by phase-contrast microscopy.
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Figure 5.3 Recovery of ZR-75 cell morphology
ZR-75 cells were either maintained in phenol red-free RPMI supplemented with 10% 
CS-FCS and 10*9 M 17p-oestradiol (+/+), or were cultured for 7 days in oestrogen- 
depleted medium and then transferred to medium containing 10'9 M 17p-oestradiol (-/+) 











Figure 5.4 FACS analysis of ZR-75 cell integrin subunit expression
ZR-75 cells were incubated with mAbs directed against integrin subunits, all of which 
were diluted 1/50 except for the anti-aV mAb which was used neat, or with control IgG 
diluted to the appropriate concentration. Cells were then incubated with an anti-IgG 
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Figure 5.5 Titration o f anti-integrin antibody binding to ZR-75 cells
ZR-75 cells were incubated with mAbs directed against the integrin subunits (A) al,
(B) a3, (C) a6 or (D) p i, or with control IgG diluted to the same concentrations. Cells 
were then incubated with an anti-IgG FITC conjugate and examined by FACS analysis. 
Results are expressed as mean fluorescence intensity (MFI) and plotted as a titration 
curve.
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Figure 5.6 Oestrogen modulation of ZR-75 cell integrin subunit expression
ZR-75 cells were cultured in phenol red-free RPMI supplemented with 10% (v/v) CS- 
FCS in the presence or absence o f 10*9 M 17p-oestradiol. After 7 or 10 days, cells were 
harvested and incubated with anti-a2, -a3, -a6 or -pi mAbs at saturating 
concentrations, or with control IgG diluted to the same concentration. Cells were then 
incubated with an anti-IgG FITC-conjugate and examined by FACS analysis. Data was 
obtained as % positive cells relative to the control IgG which was set at 5% (A), or 
mean fluorescence intensity which was converted to sites per cell (B). Antibody 
dilutions was performed in triplicate and data obtained was combined to give an average 
value. Results are expressed as % control, ie. integrin expression o f ZR-75 cells 
cultured in the presence o f oestrogen. Each histogram represents the mean ±  SEM of 
five or six separate experiments. Data is analysed using a paired Student's T-test by 
comparing with the control values.
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Figure 5.7 Time-course for downregulation and recovery of ZR-75 cell a6 
expression
ZR-75 cells were either used directly or cultured in phenol red-free RPMI supplemented 
with 10% (v/v) CS-FCS in the presence or absence of 17p-oestradiol. Cells were 
analysed at 1, 3 and 7 days for a6 expression by incubating with a saturating 
concentration of the mAb or control IgG diluted to the same concentration, followed by 
incubation with an anti-IgG FITC-conjugate (A). Alternatively, cells were either 
maintained in medium containing 10'9 M 17p-oestradiol or were oestrogen-depleted for 
7 days then transferred to oestrogen-supplemented medium for a further 1, 3 or 7 days 
and a6 expression analysed as described above (B). Cells were examined by FACS 
analysis. Data was obtained as mean fluorescence intensity which was convened to 
sites per cell. Antibody dilutions was performed in triplicate and data obtained was 
combined to give an average value. Results are expressed as %  control, ie. integrin 
expression of ZR-75 cells cultured in the presence of oestrogen. Each histogram 








Figure 5.8 FACS analysis of PBMC integrin subunit expression
PBMC were obtained from a normal, healthy female volunteer and incubated with 
mAbs directed against integrin subunits, all of which were diluted 1/50, or with control 
IgG diluted to the appropriate concentration. Cells were then incubated with an anti-IgG 
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Figure 5.9 Titration of anti-integrin antibody binding to PBMC
PBMC were obtained from a normal, healthy female volunteer and incubated with 
mAbs directed against the integrin subunits (A) a4, (B) a6, (C) aL, (D) aM, (E) pi or 
(F) p2, or with control IgG diluted to the same concentrations. Cells were then 
incubated with an anti-IgG FITC conjugate and examined by FACS analysis. Results 
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Figure 5.10 PBMC separation and dual labelling for integrin subunit expression
PBMC were obtained from a normal, healthy female volunteer and were further 
separated into T cells and monocytes. T cells and monocytes were incubated with anti- 
a4, -a6, -aL, -aM, -p i or -p2 mAbs and either anti-CD3 (A) or anti-CD 14 (B) R- 
phycoerythrin-conjugated mAbs, respectively. Cells were then incubated with an anti- 
IgG FITC-conjugate and analysed by FACS analysis. Results are expressed as contour 
plots o f  R-phycoerythrin fluorescence versus FITC fluorescence, with the number of  
cells in each quadrant entered as a percentage o f total cells.
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Figure 5.11 Basal integrin subunit expression on control and RA PBMC
PBMC were obtained from one pre-, one peri- and one postmenopausal female and two 
male RA patients and from age- and sex-matched normal controls. Cells were incubated 
with anti-a4, -cx5, -a6, -aL, -aM, -pi and -p2 mAbs at saturating concentrations, or 
control IgG diluted to the same concentration, followed by an anti-IgG FITC conjugate. 
Cells were then examined by FACS analysis. Data was obtained as mean fluorescence 
intensity which was converted to sites per cell, or % positive cells relative to the control 
IgG which was set at 5%. Antibody dilutions was performed in triplicate and data 
obtained was combined to give an average value. Results from are expressed mean ±  
SEM % positive cells (A) or sites per cell (B). Each histogram represents five separate 
experiments, unless otherwise stated. Data is analysed using an unpaired Student's T- 




















Figure 5.12 Oestrogen modulation of control and RA PBMC integrin subunit 
expression
PBMC were obtained from one pre-, one peri- and one postmenopausal female and two 
male RA patients and from age- and sex-matched normal controls and cultured in 
phenol red-free RPMI supplemented with 10% (v/v) CS-FCS, in the absence or 
presence of 109M 17p-oestradiol. After 48 hours, cells were incubated with anti-a4,- 
a6, -aL, -aM, -pi and -p2 mAbs at saturating concentrations, or control IgG diluted to 
the same concentration, followed by an anti-IgG FITC conjugate. Cells were then 
examined by FACS analysis. Data was obtained as % positive cells relative to the 
control IgG which was set at 5% (A), or mean fluorescence intensity which was 
converted to sites per cell (B). Antibody dilutions were performed in triplicate and data 
obtained was combined to give an average value. Results are expressed as % control, 
ie. cells cultured in the absence of oestrogen. Each histogram represents two or three 
separate experiments. Data is analysed using a paired Student's T-test by comparing to 
the control values.
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CHAPTER SIX 
DISCUSSION
There is much evidence to date which supports a role for the sex hormones in immune 
regulation. Females exhibit an enhanced capacity to mediate both humoral immunity, 
seen in terms of increased antibody production and resistance to infections, and cell- 
mediated immunity, in terms of increased skin-graft or tumour rejection capacity and 
relative resistance to tolerance (reviewed by Grossman, 1984; Lahita, 1990). There is 
also a female preponderance in many autoimmune conditions, including RA and SLE. 
Animal data provides additional evidence for sex hormone modulation of the immune 
system in that the incidence of certain autoimmune diseases is sex-linked and can be 
altered by gonadectomy and hormone replacement (reviewed by Grossman, 1984; 
Ansar Ahmed & Talal, 1990).
When considering situations of altered hormonal balance, such as pregnancy and the 
menopause, different effects on the autoimmune conditions RA and SLE are seen, in 
that a remission can occur during pregnancy in RA but symptoms are often exacerbated 
in SLE (see Introduction, Sections 1.3 and 1.4). The onset of RA has been linked to 
the menopause (McHugh, 1990), whereas susceptibility to SLE is greatest during 
child-bearing age (reviewed by Lahita, 1985). This has been simplified to sex 
hormones having differing effects on T cells and B cells, with RA considered a T cell- 
mediated disease and SLE mediated by B cell hyperactivity. In this hypothetical scheme 
of events, elevated sex hormone levels, or fluctuations in levels, would potentiate B cell 
activity and hence trigger or perpetuate SLE. In contrast, loss of the sex hormones, or a 
sudden fall in levels, modulates T cell functioning in such a way that the onset or 
worsening of RA occurs. In addition, animal data suggest that oestrogen is beneficial in 
models of arthritis, whereas this hormone is detrimental in models of SLE and 
androgens are beneficial. However, the vast array of potential contributory sex 
hormones, releasing hormones and metabolites, and the complexities of the immune 
system mean that this hypothesis is likely to be a gross oversimplification of in vivo 
interactions.
When studying the effects of individual hormones in in vitro assays of immunity, using 
mixed cell populations or specific cell types, the results are often contradictory and it is 
difficult to extrapolate findings to the in vivo situation. The immune system would 
appear to be central to the pathogenesis of RA, therefore any studies of sex hormone 
effects in this disease are directed to looking at hormonal modulation of immune 
function. The aim of this project was to investigate the role of sex hormones, in 
particular oestrogen, on in vitro models of immune cell activity, considered to be 
directly relevant to cellular events occurring in RA.
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6 .1  SEX HORMONE MODULATION OF CYTOKINE EXPRESSION
In RA, immune cells infiltrate the joint and release factors such as cytokines which have 
the potential to mediate many of the changes which occur within the joint in this 
disease. In particular, IL-1 and TNF-a have the capacity to be at least partly responsible 
for the destruction of the joint architecture, to initiate inflammatory reactions and 
systemic effects, as well as perpetuating the disease by increasing the production of one 
another, other cytokines such as 11^6, and the expression of various adhesion 
molecules (see Introduction, Sections 1.7 and 1.8).
To investigate the effect of 17p-oestradiol and testosterone on PBMC cytokine 
production, concentrations of 10_8-10'12 M were employed, which encompasses the 
natural range of endogenous hormone levels. Plasma testosterone, ie. free and bound, 
is approximately 22X10-9 M and oestrogen levels in women peak at around 2X10'9 M 
during the menstrual cycle and reach 1X10-7 M during pregnancy. Results of studies in 
Chapter Three failed to demonstrate an effect with either of these sex hormones on the 
release of IL-6 or TNF from PBMC obtained from normal, healthy controls, although 
LPS was still able to induce significant release of the two cytokines, illustrating that the 
cells were responsive in culture. In contrast, Ralston et al. (1990) reported a dose- 
dependent inhibition of PBMC TNF release with concentrations of 17p-oestradiol from 
10-6 to 10'12 M. However, this was only shown for postmenopausal women and no 
consistent effect was found with either premenopausal females or males, whereas the 
negative findings reported here were obtained using pre- or perimenopausal female and 
male controls. Testosterone was found to be inactive in all groups tested. It was also 
shown that an anti-TNF-a mAb could neutralise the TNF released by the PBMC, 
indicating that this protein was responsible for the cytotoxic activity measured in the 
bioassay (Ralston et aL, 1990).
The postmenopausal females included in experiments by Ralston's group were 
suffering from osteoporosis. In their ex vivo studies, Pacifici et aL (1989) 
demonstrated that 11^  1 release by circulating monocytes from osteoporotic 
postmenopausal females was significantly reduced following ovarian steroid therapy. 
Levels of II^l were constitutively high in this group and it is possible that oestrogen is 
only active where such an abnormal production of 11^ 1 occurs (Stock et aL, 1989). 
Nevertheless, there have also been reports that 17p-oestradiol can modulate IL-1 release 
from cultured blood cells where there is no underlying abnormality. Using peripheral 
blood monocytes Polan et al. (1988) found that low concentrations (10*9-10'10 M) of 
17p-oestradiol were stimulatory and high concentrations (10*7 M) inhibitory.
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As stated, both IL-1 and TNF can induce IL-6 release, and it has been suggested that 
IL-6 may mediate or amplify the effects of the former two cytokines. In bone cells, 
physiological concentrations of both 17p-oestradiol (Girasole et al., 1992; Rifas et al., 
1992) and testosterone (Girasole et al., 1992) inhibited IL-1- and TNF-induced IL-6 
secretion. However, no effect was seen in terms of basal IL-6 production with PBMC. 
It is possible that the sex hormones are only active in inhibiting cytokine-induced IL-6 
production in PBMC, in the same way that bone cell induced IL-6 release was 
suppressed and only abnormally high IL-1 levels appeared to be affected. However, 
this possibility has yet to be explored.
The measurement of cytokine expression by bioassay is fraught with difficulties. For 
example, the bioassay is unlikely to be entirely specific for the cytokine of interest and 
may be influenced by others present. In addition, cell supernatants contain inhibitory 
factors which neutralise cytokine activity, hence the supernatant samples have to be 
diluted considerably before any activity can be measured. Loss of biological activity 
through long-term storage of samples, or repeated freeze-thawing is also likely to bias 
results. Because of these problems, mRNA levels were studied as a more accurate 
predictor of cytokine expression. However, mRNA transcripts are not always 
translated to protein, and therefore changes in expression at the transcriptional level are 
not necessarily reflective of post-transcriptional modifications.
The initial results suggested that 10'9 M 17p-oestradiol may upregulate TGF-p mRNA 
expression in control PBMC. This effect was only demonstrated in the absence of 
serum, as serum contains growth factors, including TGF-p, which are known to 
increase TGF-p expression and hence mask any additional upregulatory hormonal 
effect. However, these data could not be normalised, and subsequent experiments 
which were carried out showed the same pattern of expression for the cytokine and the 
house-keeping gene, p-actin, illustrating that any variation in expression seen was due 
to loading inaccuracies rather than an effect of oestrogen per se. Filters were probed for 
mRNA encoding IL-lp, TNF-a, IL-6 and prolactin as well as TGF-p, and both control 
and RA PBMC were included, using pre-, peri- and postmenopausal females and 
males, with no difference in cytokine expression seen.
Polan et al. (1989) demonstrated that 17p-oestradiol increased IL-lp mRNA levels in 
LPS-stimulated human peripheral blood monocytes to a maximum at a concentration of 
10-9 M. At concentrations above this a reduction was seen. The effect of oestrogen on 
LPS-induced cytokine mRNA expression was not examined here. Treatment of PBMC 
with 1 pg/ml LPS for 6 hours increased TNF-a and IL-6 mRNA expression, but no
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effect was seen for IL-lp. The reason for this is unclear, but may have been due to an 
inadequate concentration of LPS being employed, or too long a period of incubation, as 
the effect is transient. Alternatively, the presence of TGF-p 1 in the cell cultures may 
have inhibited any LPS-induced effect on IL-1 mRNA expression, as both IL-1 and 
TNF have been reported to be inhibited in the presence of LPS and TGF-p 1 in human 
PBMC (Turner et al., 1990). However, TNF mRNA expression was enhanced in the 
presence of LPS where IL-1 levels remained unchanged, therefore this is unlikely to 
explain the findings here. Polan et al. (1989) utilised 10 pg/ml LPS and measured a 
maximal stimulation at 3 hours, although with this concentration of LPS the effect as 
still evident at 24 hours. However, 10 pg/ml is an excessive dose of LPS to employ, 
and such a high concentration could modulate cell function non-specifically. In such an 
artificial situation one cannot draw any conclusions from the effects of 17p-oestradiol 
reported.
In human osteoblast-like cells 17p-oestradiol has been shown to increase TGF-p mRNA 
expression (Oursler et al., 1991), although this was not always seen with lower 
concentrations, and it has been suggested that the effect of oestrogen on these cells is at 
the post-transcriptional level (Keeting et al., 1989). In contrast, Girasole et al. (1992) 
found an inhibition of IL-1- and TNF-a-induced IL-6 mRNA expression with 17p- 
oestradiol using rodent and human osteoblastic cells and bone marrow-derived stromal 
cells. This could reflect an inhibition of the IL-6 promoter activity (Pottratz et al.,
1992). There are no reports of such an effect with oestrogen on peripheral blood cell 
TGF-p or IL-6 expression, at the mRNA or protein level.
Prolactin has been reported to be involved in the control of immune function and also in 
autoimmunity (reviewed by Jara et al., 1991), and cells of the immune system both 
express prolactin receptors (Russell et al., 1984a) and produce a prolactin-like 
substance (Montgomery et al., 1987). Oestrogens are important physiological 
regulators of prolactin secretion, thought to be via a direct effect on the pituitary in the 
case of 17p-oestradiol (Franks, 1983). Treatment of rat anterior pituitary lobes with 
oestrogen in vivo caused a three- to four-fold increase in prolactin mRNA expression 
(Martinez-Campos et al., 1991). Therefore, filters were hybridised to a prolactin cDNA 
probe to investigate the effect of oestrogen on the expression of this hormone in 
immune cells. Results showed that PBMC express prolactin mRNA, confirming the 
results of Hiestand et al. (1986) demonstrating that rat lymphocyte RNA hybridised to a 
prolactin-specific probe. However, as stated, no effect was seen with 17p-oestradiol on 
control or RA PBMC prolactin mRNA expression.
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The observation that the pattern of cytokine expression following oestrogen treatment 
was consistently the same as that for the house-keeping gene p-actin, posed the 
question was p-actin itself being modulated by this sex hormone. Indeed, it has been 
reported that the p- and y-cytoskeletal actins as well as the smooth muscle actin could be 
induced in rat uterus by treatment with oestradiol (Hsu & Frankel, 1987), although this 
was only a transient induction, up to two-fold, and the effect was measured in vivo. 
Nevertheless, to ensure that oestrogen modulation of p-actin was not occurring in 
experiments performed with PBMC, filters were hybridised to a GAPDH cDNA probe. 
GAPDH has been shown to be transcribed at the same rate in all tissues and therefore 
regulated post-transcriptionally (Piechaczyk et al., 1984). Results showed the same 
pattern of mRNA expression for GAPDH as for p-actin and all cytokines examined, 
thus it was concluded that there was no effect of oestrogen throughout. LPS- 
stimulation of the cells demonstrated that culturing in serum-free medium did not affect 
cell activity, and in addition, cells were shown to respond normally to ConA under 
these culture conditions (results not shown). Therefore it can be concluded that 
oestrogen has no effect on the expression of any of the cytokines tested here, at the 
transcriptional level, in circulating mononuclear cells.
The anterior pituitary hormone, FSH, controls oestrogen secretion, and oestrogen in 
turn can regulate the level of FSH via feedback pathways. It was hypothesised that 
effects thought to be due to oestrogen may in fact be due to FSH. For example, 
elevations measured in oestrogen could be a result of a rise in FSH, and the 
administration of oestrogen may be acting indirectly through modulation of this second 
hormone. Therefore, the effect of FSH was studied on control PBMC cytokine mRNA 
expression. The results obtained however were the same as those for oestrogen, with 
no effect on any of the cytokines tested. At a higher level still, LHRH from the 
hypothalamus is responsible for controlling the pituitary secretion of both LH and 
FSH, which in turn regulate sex hormone levels in vivo. Rat lymphocytes have been 
reported to contain immunoreactive LHRH which appeared to be bioactive in that it 
could induce the secretion of LH from rat anterior pituitary cells (Emanuele et al.,
1990), and it has been hypothesised that this may be involved in lymphocyte activation 
and general immune function (Morale et al., 1991), for example by increasing IL-2 
receptor expression (Batticane et al., 1991). The role of this hormone in assays of 
human PBMC cytokine expression has not been studied but it may prove to be 
important in the sex hormone/immune system story in the future.
In addition to studying PBMC cytokine expression in the presence of sex hormones, 
PBMC proliferation was examined as another parameter of immune cell function.
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Previous results showed that the proliferative response to PHA was reduced in RA 
patients compared to healthy controls, whereas the response to an anti-CD3 mAb was 
more variable, in that proliferation was increased in patients with mild or moderate 
disease and depressed in patients with severe disease (van den Brink et al., 1992). The 
results demonstrated here showed little difference between the controls and RA patients 
in terms of their response to PHA, but the response to anti-CD3 mAb was reduced in 
several patients, although the overall mean response was not significantly different to 
that of the controls. It has been reported that T cell responses are dampened down in 
RA, with T cell-derived cytokines being undetectable at the protein level in the synovial 
fluid and synovium (reviewed by Brennan et al., 1991), reduced IL-2 production in 
response to PHA (Combe et al., 1985) and depressed responses in cell-mediated 
immune reactions (Emery et al., 1984). The latter abnormality could be reversed by the 
addition of IL-2 (Emery et al., 1984). In these experiments IL-2 was able to potentiate 
the response to anti-CD3 mAb in certain RA patients, but in others the response to anti- 
CD3 mAb and EL-2 was as low as with anti-CD3 mAb alone. These responses were 
thought to correlate with disease activity as there was no correlation between 
proliferation and sex or age. In the experiments reported in this thesis, neither 
oestrogen or testosterone had any effect on the response to any of the stimuli tested, 
van den Brink et al. (1992) also failed to demonstrate an effect with these two 
hormones.
FSH and LH have been found to increase the proliferation of peripheral blood 
lymphocytes (Costa et al., 1990). The effect was greater in elderly (59-90 years) than 
young (30-40 years) females, and there was a negative correlation between the effect of 
FSH and the plasma level of 17p-oestradiol alone, or both 17p-oestradiol and 
progesterone, in the younger subjects. Preliminary data using PBMC from 
premenopausal female controls failed to demonstrate any effect of FSH, at comparable 
concentrations to those used by Costa et al. (1990) (results not shown). According to 
the previous findings, this may relate to higher plasma oestrogen levels.
6 .2  OESTROGEN RECEPTOR
The negative results obtained, in terms of an effect of oestrogen on cytokine production 
or proliferation by PBMC, were supported by further investigation into the activity of 
the 17p-oestradiol utilised and the presence of ER on PBMC. Cell lines which were 
reported to be either ER-positive and hence oestrogen-responsive (ZR-75 and T-47D 
cells), or ER-negative and therefore unresponsive to oestrogen (Hs578T cells), were
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employed as a means of studying the efficacy of the batch of oestrogen used for 
previous experiments and also as positive and negative controls in studies of ER 
expression.
ZR-75 cells were shown to proliferate in response to 17p-oestradiol, demonstrating that 
the negative results obtained were not due to an inactivity of the oestrogen employed. 
However, the reportedly ER-positive cell line, T-47D, was unresponsive, with results 
identical to those seen with the ER-negative cell line, Hs578T. Details of an ER/PR- 
negative T-47D clone, obtained by maintaining the cells for one year in oestrogen-free 
medium, have been described (Murphy et al., 1990). This clone was refractory to both 
oestrogen and anti-oestrogen treatment,whereas another clone has been described 
which is oestrogen-insensitive but still retains ER expression (Dabre & Daly, 1990). 
Therefore it is possible that the T-47D cells used in these experiments, which were 
present in-house, may have been subjected to culture conditions previously which 
resulted in the loss of oestrogen responsiveness. As will be described, the cells were 
shown to express ER mRNA, although ER protein was not detectable.
The response of the ZR-75 cell line to 17p-oestradiol was inhibited by the anti- 
oestrogen, tamoxifen, illustrating that this was a specific oestrogen effect. When 
10‘9 M 17p-oestradiol was used to induce proliferation tamoxifen had a purely 
antagonistic effect. However, when a concentration of 10-10 M was employed, only 
concentrations of tamoxifen above 10-7 M were inhibitory, whereas lower 
concentrations potentiated the oestrogen effect. Tamoxifen is known to behave as a 
partial agonist which would explain this finding.
The ability of a cell to respond to a given ligand is governed by the degree of 
expression of the specific receptor. Receptors for the sex hormones are commonly 
present in very low amounts, although in some cells as few as 10000-80000 ER sites 
per cell is sufficient to mediate a response (Katzenellenbogen et al., 1987). By 
constructing transfectants expressing varying levels of ER, Webb et al. (1992) 
concluded that below 500000 sites per cell the response was limited, in terms of the 
number of EREs bound by ER, whereas at higher ER titres spare receptors existed and 
’squelching' occurred, whereby the availability of a molecule essential for receptor 
functioning became limited. These findings demonstrated that under normal conditions 
there is relatively little occupation of EREs, suggesting that occupancy of responsive 
elements is not the only parameter controlling the cellular capacity to mediate an 
oestrogen response.
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Previous studies into the presence of ER in the immune system have been carried out 
using radiolabelled ligand-binding assays. Binding assays require the presence of 
unoccupied receptor, therefore the low levels of ER reported may be partly due to the 
inability to detect ER with bound oestrogen, or to the presence of other steroid binding 
factors, such as SHBG, which would also cause an underestimation of the actual 
amount of receptor present. A more direct method of measuring receptor expression is 
by use of specific mAbs. Using the H222 mAb, directed against the ER, in an 
immunocytochemical assay system, ER protein was detected in ZR-75 cells but not in 
T-47D cells, Hs578T cells, PBMC, synovial fibroblasts or rheumatoid synovial tissue. 
ZR-75 cells maintained under normal culture conditions demonstrated a similar degree 
of ER expression to that achieved with the MCF-7 cell line which was used to prepare 
control slides for use with the detection kit. The nuclear staining seen was unevenly 
distributed across the cell population. When ZR-75 cells were cultured in the absence of 
oestrogen, ER expression could not be demonstrated. One possible explanation for this 
is that ligand-binding is required for tight nuclear association of the receptor prior to 
detecting with anti-ER mAbs. Therefore, the failure to detect ER in this situation is not 
necessarily indicative of a functional downregulation in receptor expression, although a 
reduction in ER under conditions of oestrogen-deprivation cannot be totally excluded.
The failure of the H222 mAb to detect ER on any cells except known ER-positive 
breast carcinoma cell lines reflects the limitation of immunocytochemical analysis where 
receptor levels are constitutively low. The ER-D5 mAb was employed as an alternative, 
as it has been reported to be a far more sensitive indicator of ER expression. This 
antibody was raised against a 29 kD cytoplasmic antigen (p29), reported to be related to 
the ER (Coffer et al., 1985a) and a strong predictor of ER expression (Coffer et al., 
1985b). However, the relevance of the antigen to ER has yet to be confirmed. ER-D5- 
binding was demonstrated for all cells and synovial sections tested. ZR-75 cells gave 
the strongest cytoplasmic staining, which is in accordance with the ability of H222 
mAb to detect ER protein in these cells alone. Synovial fibroblasts were also found to 
express considerable p29, whereas the staining for the purportedly ER-negative cell 
line, Hs578T, and for PBMC, was weak and diffuse. The level of p29 expression by 
cells was also examined by FACS analysis which produced comparable results to those 
seen histologically.
The p29 antigen has been reported to be present at approximately one thousand times 
the concentration of ER in oestrogen-responsive tissues. Results with the ER-D5 mAb 
in breast tumours have shown that all ER-rich samples stain strongly, and those with 
low or undetectable ER using standard detection methods also showed a certain degree
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of positivity with ER-D5 (Coffer et al., 1985b; Cano et al., 1986). Thus, the results 
with the Hs578T cell line are likely to be indicative of ER expression below the level of 
detection, and hence functionality. ER mRNA could not be detected in this cell line 
which further supports this conclusion. The level of p29 expression was also shown to 
be low in PBMC, although staining patterns using the APAAP procedure were more 
intense for PBMC obtained from a postmenopausal female RA patient than for a 
premenopausal female control. Higher levels of p29 have been recorded for breast 
cancer patients above the age of 50 than those under 50 years (Coffer et al., 1985b). 
Therefore the results obtained here may reflect the age of the subject, or menopausal 
status. Alternatively, the increase in p29 expression could be as a result of the RA. 
However, when a range of RA patients and age- and sex-matched controls were studied 
for ER-D5-binding by FACS analysis, binding sites were generally lower in the RA 
patients than the controls, although the difference was not significant. When grouping 
into age there was also no significant difference in p29 expression. FACS analysis is a 
qualitative and quantitative method of assessing the degree of expression of both cell 
surface and intracellular markers, whereas APAAP staining is largely qualitative. In 
addition, there is greater scope for inter-experimental error with the latter technique.
The low expression of p29 antigen in the ER-negative cell line, Hs578T, and the 
comparably low levels of p29 in PBMC, questions the previous reports of ER in 
immune cells, and, if present, its functionality. Cohen et al. (1983) were the first group 
to publish data which suggested that ER were expressed exclusively by the CD8+ T cell 
population. This was supported by Stimson in 1988 who also reported the CD8+ 
subset to be positive for ER, and the CD4+ cells negative. Therefore the failure to 
detect ER in the mixed PBMC population could be due to the low numbers of CD8+ T 
cells present. Additionally, if p29 antigen expression is also restricted to CD8+ T cells, 
this would also explain the minimal staining seen with ER-D5 mAb. However, 
monocytes have also been reported to possess ER (Gulshan et al., 1990), which would 
suggest that an imbalance of ER-negative and ER-positive cells within the PBMC 
population is not the reason for the lack of detection of the receptor. In theory the 
lower ER-D5 binding in RA PBMC may reflect an underlying deficiency in the ER- 
expressing cell population. A reduction in CD8+ cell numbers has been reported in RA 
(Veys et al., 1982). However, this is controversial, and if the CD8+ cell subset is 
depleted in the RA patients included in the experiments reported in Chapter Four, the 
levels are unlikely to be reduced to such an extent that p29 expression would be 
affected. In addition, if monocytes do indeed express ER, one would expect p29 
antigen to be expressed simultaneously, which would likely counteract any underlying 
CD8+ cell deficiency in terms of ER-D5 binding.
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Synovial tissue from a postmenopausal female RA patient was observed following 
incubation with ER-D5 mAb. Distinct areas of positive staining were seen and closer 
examination revealed the most intense staining to be localised to clusters of infiltrating 
cells. The majority of infiltrating cells were negative which suggests that the 
predominant CD4+ T cells occurring here do not express p29. Therefore, the cells 
which appeared to express significant levels of p29 antigen could be CD8+ T cells, or 
alternatively B cells or macrophages. To date there are no reports of ER on B cells, 
although there have been reports of oestrogen effects, in particular on the CD5+ subset 
( see Introduction, Section 1.6.3). If macrophages are responsible for the intense cell 
staining within the clusters, stronger staining might have been expected in the synovial 
lining layer. However, only weak, diffuse staining was observed in this area. 
Alternatively, the macrophages present within the cell clusters may be activated in some 
way, perhaps by other inflammatory cells present, which results in an upregulation of 
p29 expression. The weak staining of the lining layer was somewhat unexpected 
following the strong ER-D5 binding seen with synovial fibroblasts, although it is 
difficult to extrapolate from the results with a single cell type maintained in culture to 
those with a network of cells in an ex vivo situation. Further investigation by dual­
labelling sections with the ER-D5 mAb and mAbs directed against different cell 
markers, including CD8, is required before any firm conclusion can be made regarding 
the phenotype of cells expressing p29 antigen.
In a recent publication, Cutolo et al. (1993) also used the ER-D5 mAb to detect ER in 
rheumatoid synovium, and performed dual-labelling to assess its cellular distribution. 
They demonstrated p29 expression in macrophage-like synoviocytes and CD8+,
CD29+ T cells, which supports the previous findings of ER in CD8+ cells in peripheral 
blood (Cohen et al,, 1983; Stimson, 1988) and monocyte/macrophages (Gulshan et al,, 
1990), and provides further evidence for a direct correlation between nuclear ER 
protein and cytoplasmic p29. The location of p29 antigen, and presumably therefore 
ER, within RA synovium, and in particular its association with cells capable of 
contributing to the disease process, suggests that oestrogen may be of importance in the 
joint milieu.
The progression from studies of ER at the protein level to investigations of its 
transcriptional expression were necessitated by the failure to detect ER protein per se in 
PBMC using specific mAbs. Northern blot analysis of ZR-75 cell total RNA using a 
specific human ER cDNA probe appeared to demonstrate the expected 6.2 kb 
transcript, but neither T-47D cell, Hs578T cell or PBMC RNA hybridised to the ER 
cDNA Reverse transcription of total RNA and amplification of the cDNA product
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using Taq polymerase and specific oligonucleotide primers, designed to frame a region 
of the ER ligand-binding domain, provided a more sensitive method for the detection of 
ER mRNA. RNA from both the ZR-75 and T-47D breast carcinoma cell lines amplified 
to give the correct sized product. Sequencing of the PCR product for ZR-75 cells 
confirmed this to be identical to the oestrogen-binding domain of the human ER cDNA 
(Greene et al., 1986). Hs578T cells failed to demonstrate a PCR product, in support of 
this being an ER-negative cell line (Hackett et al., 1977). The expected DNA fragment 
was also obtained from synovial fibroblasts, which agrees with the relatively strong 
binding of ER-D5 mAb in these cells.
Reverse transcription of PBMC RNA and amplification by PCR with the ER-specific 
oligonucleotide primers resulted in a clear DNA product, illustrating that PBMC 
possess ER mRNA. The expression of ER mRNA was demonstrated consistently for 
female controls using this method, whereas in two of the three male control PBMC 
RNA samples the PCR product was present in only low amounts or was undetectable. 
The male control demonstrating the greatest level of ER mRNA expression, in terms of 
the amount of PCR product observed, was receiving steroid therapy which may have 
upregulated ER levels transcriptionally. Interestingly, PBMC obtained from two 
premenopausal female controls demonstrated a slower migrating species, in addition to 
the predicted fragment. This appeared to be between 320 and 350 bp, compared to the 
expected 287 bp product. It was initially considered that this may be related to 
endogenous hormone levels as it appeared to be limited to a subpopulation of the female 
controls and was not demonstrated with RNA from male donors. However, when the 
Taq polymerase was obtained from a different source, and a MgCl2 titration was carried 
out using ZR-75 cell cDNA, the same two bands were seen at concentrations of MgCl2  
above 1.5 mM. Hence, despite the fact that the concentration of MgCl2  used previously 
was 1.5 mM and that the two bands were only detected in certain RT-PCR reactions, it 
was concluded that the second PCR product was a PCR artefact. This was further 
substantiated when a band-stab method was employed to attempt to separate the two 
PCR products (Bjourson & Cooper, 1992) and a single PCR product was consistently 
recovered on re-amplification, indicating that the second band was an artefact of the 
original, perhaps due to differential splicing. The inability to separate the two products 
meant that they could not be sequenced and hence the exact identity of the second PCR 
fragment could not be verified.
Bellido et al. (1993) also used the RT-PCR method to detect ER mRNA and developed 
a pair of oligonucleotide primers to frame a 350 bp region of the DNA-binding domain 
of the murine uterine ER for this purpose. Using these primers with reverse transcribed
RNA from two bone marrow-derived stromal cell lines and an osteoblast-like line, as 
well as from the ER-positive breast carcinoma cell line, MCF-7, the 350 bp fragment 
was detected as was a second faster migrating product. The second PCR product 
appeared to be of similar size to that observed with PBMC RNA here, which may 
suggest that this is a genuine result and not a PCR artefact as originally thought. It is 
possible that the MgCl2  concentration determined the ability of the primers to bind to a 
different site, although the fact that primers described here, and those used by Bellido et 
al. (1993), were directed against two separate and both highly conserved domains of 
the receptor, makes it unlikely that the primers would have bound to regions other than 
these.
The results of these experiments demonstrate that PBMC express ER mRNA only at 
extremely low levels, and the translation of this into ER protein has yet to be 
confirmed, although the expression of the p29 antigen suggests that ER is present at the 
protein level. The recent development of a mAb directed against the DNA-binding 
domain of the ER may provide a sufficiently sensitive method to detect ER in PBMC 
immunohistochemically. The use of this antibody has provided the first convincing 
evidence of an immunohistochemical location of the ER in osteoblasts and osteoclasts 
(Mizuno et al., 1992; Ikegami et al., 1993), in situations where the H222 mAb has 
been unsuccessful (Colston et al., 1989). This could provide a useful tool in terms of 
allowing relatively small numbers of cells to be analysed for ER expression by flow 
cytometry, giving an accurate analysis of receptor sites per cell and expression by 
specific cell populations. Sumner et al. (1991) reported that the saponin- 
permeabilisation technique for the detection of intracellular antigens can be used for 
dual-labelling with antibodies directed against cell-surface markers added 
simultaneously, as permeabilisation did not significantly alter antibody binding to the 
cell surface. This would be useful with anti-ER mAbs and also the ER-D5 mAb.
6 .3  SEX HORMONE MODULATION OF INTEGRIN EXPRESSION
The ZR-75 cell line requires oestrogen to maintain anchorage-dependent growth in 
culture. Culturing the cells in oestrogen-depleted medium resulted in a significant 
reduction in cell growth and, unexpectedly, a change in morphology. This was 
observed after only three days of culture under these conditions, and appeared to be 
maximal after seven days. The change in ZR-75 cell morphology, including reduced 
cell adherence and colony formation, was associated with downregulation of the 
integrin subunit, <x6. a6 associates with the pi subunit to form VLA-6, a receptor for
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laminin. The other integrin subunits expressed on this cell line, a2, a3 and pi, were 
not altered following the period of oestrogen deprivation. a2pl (VLA-2) is a receptor 
for collagen and laminin and a3pl (VLA-3) forms a receptor for fibronectin, laminin 
and collagen.
Binding to laminin in the basement membrane is thought to be important in tumour 
metastasis, which is a complex process involving interactions between cancer cells and 
the basement membrane, which forms a natural barrier to be crossed when leaving the 
primary tumour, in intra- and extravasation and in the penetration of muscles and 
nerves (Liotta, 1986). Therefore it could be hypothesised that downregulation of a6 
expression would result in reduced metastasis due to reduced binding to laminin. A 
considerable proportion of carcinomas of the breast are oestrogen-dependent and can be 
controlled therapeutically with the anti-oestrogen, tamoxifen. According to these 
observations, continued oestrogen-stimulation of ER-positive breast carcinoma tissue 
would maintain high a6 levels and hence increase the likelihood of tumour metastasis. 
However, it is known that ER-negative tumours are less well differentiated and more 
invasive than their ER-positive counterparts and oestrogen-depletion of the ZR-75 cell 
line appeared to cause a downregulation of ER, in conjunction with the a6 integrin 
subunit.
The spectrum of integrin subunit expression on ZR-75 cells correlated with that defined 
for breast carcinoma tissues (D'Ardenne et al., 1991). In normal breast tissues a6
staining was shown to be weak in the epithelial cytoplasm, moderate in cell membrane
\
and most intense in the basement membrane. In contrast, carcinoma tissue 
demonstrated variable cytoplasmic/cell staining but there was a consistent loss of 
basement membrane staining for a6, which correlated with a reduction in the ligand, 
laminin. Gould et al. (1990) also demonstrated reduced a6 expression in all breast 
carcinomas, in conjunction with a reduction in pi levels. They concluded that the 
difference in a6 expression between carcinomas may explain their local invasiveness 
and metastatic behaviour. Oestrogen has been reported to increase the expression of the 
non-integrin 67 kD laminin receptor, thought to correlate directly with the metastatic 
phenotype of cancer cells (van den Brule et a l , 1992).
It has also been proposed that laminin is not involved in tumour cell migration 
(Coopman et a l , 1991), rather it may be that the loss of cell surface integrin expression 
is solely responsible for the morphological changes seen. Invasive breast carcinomas 
are characterised by a progressive loss of tissue organisation, including reduced 
differentiation, as was observed with the ZR-75 cell line in vitro. Pignatelli et al. (1992)
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reported a reduction in the expression of both a2pi and a6p4 receptors in invasive 
carcinomas. Therefore the reduction in a6 expression in ZR-75 cells may correlate with 
a reduction in the level of the a6p4 receptor, rather than a6pl, as the level of the pi 
subunit was unaltered. The expression of the fibronectin receptor subunit, a3, has also 
been proposed as an important factor in tumour cell metastasis (Gould et al., 1990).
The relevance of the downregulation of a6 expression in ZR-75 cells in vitro following 
a period of culture in oestrogen-depleted medium is only speculative. It would seem 
contradictory that the removal of oestrogen, considered to be detrimental in breast 
cancer, leads to the loss of integrin subunit expression, which has been proposed as 
being directly related to tumour cell differentiation and invasiveness. ot6 expression 
could be recovered after reculturing the cells in the presence of oestrogen. The effect of 
long-term oestrogen deprivation was not studied and the effects of this on a6 
expression at the mRNA level were also not examined. However, oestrogen has many 
effects, of which integrin expression may prove to be inconsequential. The effects of 
oestrogen in breast cancer are unlikely to be as defined as originally thought and a 
recent report demonstrating that, following transfection of ER into an ER-negative cell 
line, oestradiol could inhibit metastatic activity (Garcia et al., 1992), indicates that 
factors other than the ER appear to be involved.
Changes in integrin expression have also been reported to occur as a result of the 
inflammatory process, due to factors such as cytokines released at the inflammatory 
site, which may be important in conditions such as RA (reviewed by Panayi, 1993). 
FACS analysis of PBMC obtained from healthy controls demonstrated the expression 
of a4, a6, aL, aM, pi and p2 integrin subunits. aLp2 (LFA-1) and aMp2 (CR3 or 
Mac-1) are members of the leukocyte integrin family and are important in immune 
regulation. a4pl and a6pi perform interactions with the extracellular matrix which is 
also critical for immune surveillance (reviewed by Springer, 1990). Dual-labelling of 
cells confirmed that T cells express predominantly aL and p2, whereas aM and p2 were 
present in the highest levels on peripheral blood monocytes. All subunits found on 
PBMC were also found to be expressed on both T cells and monocytes. The aMp2 
receptor is not found on lymphocytes and therefore the demonstration of this subunit in 
the T cell population might have been a result of PMNL contamination. The high levels 
of aM expression found on monocytes could be due to inadvertent activation of the 
cells during the experimental procedure.
Results of experiments comparing integrin subunit expression on PBMC from controls 
and RA patients showed a general trend of reduced levels on RA cells. This was
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significant for pi in terms of the percentage of cells expressing the subunit and the 
number of sites per cell. The reduction in otL subunit was also significant, but only in 
terms of the percentage of positive cells. McCarthy et al. (1992) found a reduction in pi 
expression when examining RA peripheral blood leukocytes, and also reported an 
increase in aM. As the basal aM levels were thought to be modulated by cell 
preparation procedures, conclusions regarding the expression of this subunit in control 
and RA PBMC cannot be drawn. The VLA-4, -5 and -6 receptors are expressed on 
naive T cells, and memory T cells express three- to four-fold higher levels than resting 
cells (Shimizu et al., 1990). The initial investigation into PBMC integrin expression 
failed to demonstrate any appreciable anti-a5 mAb binding. However, subsequent 
studies showed low levels of this subunit. The expression of VLA-4, -5 and -6 was not 
significantly different on control and RA PBMC, whereas it might have been expected 
to see increased expression on RA cells as a result of activation in vivo. Binding of 
synovial fluid T cells to fibronectin was increased compared to the binding of peripheral 
blood T cells in RA, which appeared to be mediated by the VLA-5 (Garcia-Vicuna et 
al., 1992) and/or VLA-4 (Rodriguez et al., 1992) receptors. It is possible that any 
modulation of integrin expression in RA occurs exclusively at the inflammatory site, on 
synovial cells. It has also been found that the expression and function of integrins are 
not mutually exclusive, in that the increased cell adhesion can occur as a result of the 
activation of existing molecules, without the necessity for increased expression.
Incubation of control and RA PBMC with oestrogen did not alter basal levels of the 
various subunits. Cytokines such as IL-1 and TNF can modulate integrin expression 
(reviewed by Pober & Cotran, 1990) and may be important in enhancing cell adhesion 
in RA. It is possible that oestrogen may modulate the expression of adhesion molecules 
which are upregulated as a result of the inflammatory process. In this respect, 
oestrogen has been shown to potentiate TNF-induced upregulation of ICAM-1 and 
ELAM-1 on endothelial cells (Cid et al., 1992). ICAM-1 has been reported to be 
increased in RA synovial fluid macrophages compared with peripheral blood 
monocytes, and GM-CSF, IFN-y, TNF-a and IL-1 have the capacity to increase 
ICAM-1 expression on peripheral blood cells to a level comparable to that on synovial 
cells (Diaz-Gonzalez & Alvaro-Gracia, 1992). Therefore it would be of relevance to 
study the effect of oestrogen on ligands as well as receptors.
Integrin expression in rheumatoid synovial tissue was not studied. However, a recent 
report found that the a6 subunit was the only consistent subunit to be expressed by 
synovial lining cells, and that its expression appeared to correlate with disease activity 
in that weaker staining was observed in the strongly proliferative lining cell layers
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(Nikkari et al., 1993). A tenuous link can be made between loss of a6 expression in 
invasive breast carcinoma and reduced a6 expression in the proliferative rheumatoid 
synovium. The observation that withdrawal of oestrogen appeared to be the causal 
factor for downregulation of this subunit in the ZR-75 cell line, and the link between 
the menopause, and hence loss of sex hormones, and the onset of RA may implicate a 
role for oestrogen in the maintenance of a6 levels. There is no evidence for such an 
effect from the data presented in Chapter Five, although the modulation of stimulated 
a6 levels remains a possibility. This is obviously a very simplistic theory which is 
likely to incorporate many factors in vivo which are absent in the in vitro model.
6 .4  CONCLUDING REMARKS
RA is a chronic inflammatory disease characterised by a complex scenario of events 
which culminate in destruction of the joint architecture and a concomitant array of 
systemic effects. The role for sex hormones in these proceedings is substantiated by the 
preponderance of females developing the disease, the link between onset and the 
menopause, and the evidence provided from animal models of arthritis. As the immune 
system appears to be central to the pathogenesis of RA, and the relationship between 
the female sex and RA extends to include a range of autoimmune conditions, the 
obvious target for sex hormones would be that of immune regulation.
There is an ever-increasing body of information regarding the functioning of the 
immune system, and there are many parameters which could potentially be influenced 
by sex hormones. Two particular functions which are of direct relevance to the immune 
system in RA are that of cytokine production and adhesion molecule expression. These 
processes have the capacity to mediate cellular infiltration and perpetuation in the joint, 
and the inflammatory reaction and bone and cartilage destruction which ensues. The 
evidence presented here suggests that the sex hormones, in particular oestrogen, do not 
directly modulate cytokine or adhesion molecule (integrin) expression by rheumatoid 
peripheral blood cells or by cells taken from healthy controls.
There are many possible explanations for the failure to demonstrate a sex hormone 
effect on PBMC in in vitro models of immune function. The vast majority of sex 
hormone effects reported in the literature have resulted from in vivo models. PBMC 
derive from environments with differing hormonal levels which cannot be recreated in 
vitro. In addition, in the in vivo situation the coexistence of the different sex hormones, 
as well as their metabolites and other factors which control sex hormone production and
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effects, questions the relevance of in vitro models. Other hormones also appear to be 
important in immune regulation, and it is possible that oestrogen acts via modulating the 
expression of these proteins. Prolactin is perhaps the most important hormone in terms 
of immune regulation defined to date (see Introduction, Section 1.8.6). The immuno- 
potentiating actions of prolactin, and the production of poly amines as a result of 
prolactin-induced increases in ODC activity, are thought to be involved in the 
pathogenesis of autoimmune diseases such as SLE and RA. Oestrogen is known to act 
at the level of the pituitary to stimulate prolactin secretion (Franks, 1983). There is no 
evidence of an effect of oestrogen on lymphocyte prolactin mRNA expression from 
experiments reported in this thesis, although a direct effect of oestrogen on immune 
cells at the translational level cannot be ruled out. Nevertheless, a more likely theory is 
that oestrogen administered in vivo stimulates prolactin release from the pituitary which 
then modulates immune function directly.
The increasing evidence to suggest that ERs are present on CD8+ T cells, macrophage­
like synoviocytes and, as was demonstrated here at the mRNA level, on synovial 
fibroblasts, indicates that oestrogen has the potential to influence immune function and 
directly modulate the cells within the joint. The failure to demonstrate ER at the protein 
level and the detection of only very low levels of ER mRNA, could be due to the small 
percentage of ER-positive cells present within PBMC. Future investigations using 
purified cell types are required to provide the information necessary to determine 
whether this is so, or whether the receptor expression is constitutively low on all cells 
and hence unlikely to be functional. Distribution of ER on cells within a PBMC 
population obviously governs their ability to mediate oestrogen response. For example, 
if monocytes are found to be ER-negative this could explain the lack of effect of 
oestrogen on PBMC monokine expression, and if CD8+ cells are exclusively ER- 
positive then assays of immune function, such as cytotoxicity, directed at this cell type 
would be more applicable. Alternatively, receptors could be present in sufficient 
amounts to mediate a response, with the failure to elicit a response occurring at a 
transcriptional level. Thus, an underlying inability to form stable ER/ERE complexes, 
or a subsequent defect in the transcription of oestrogen-responsive genes, perhaps 
through the absence of a crucial transcription factor, could explain the hormone- 
unresponsiveness of immune cells in culture. Differences in EREs could also explain 
the tissue specificity in oestrogen responsiveness.
The synovial tissue could be considered the target tissue in RA. The gross proliferation 
of cells, seen within the synovial membrane, and the release of degradative enzymes, 
for example, are confined to the joint space. Therefore, it is possible that any potential
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modulatory effect of the sex hormones in the immune system is localised to the area of 
inflammatory activity. Indeed, much of the evidence to date demonstrates a direct effect 
of the sex hormones, especially oestrogen, on bone cells, which is thought to be of 
importance in the bone disorder, osteoporosis. A closer investigation of ER expression 
and integrin molecule distribution within the synovial membrane and an examination of 
the effects of the sex hormones on synovial cells in vitro, would provide an interesting 
successor to the studies carried out as part of this study. In addition, it has been 
reported that the upregulation of adhesion molecules on the endothelium could facilitate 
the accumulation of inflammatory cells within the joint. Hence, the endothelial cell 
provides another possible means of hormonal intervention which would have direct 
relevance to changes which occur in RA.
There remains a considerable scope for research into the area of immunoendocrinology, 
and much work is required to unravel the complexities of sex hormone modulation of 
the immune system. The research carried out as part of this project can only support an 
indirect role for oestrogen in the periphery, suggesting that this hormone alone is not 
responsible for the heightened immune response in females. However, immune 
regulation encompasses a vast spectrum of interactions between cells and mediators, 
therefore this study is only the tip of the iceberg. A final conclusion that sex hormones 
act purely indirectly would have important consequences regarding the general 
perception of sex and immunity. Alternatively, the discovery of a direct role for sex 
hormones in autoimmune diseases such as RA would clarify many of the complexities 
in this area and open the door to a host of new therapeutic approaches.
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